
<html lang="en"     class="pb-page"  data-request-id="e56779f7-2a0e-4902-9e54-bbe7b7b12b8a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.9b01736;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-6"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors" /></meta><meta name="dc.Creator" content="Ya’nan  Yu" /></meta><meta name="dc.Creator" content="Yuqiao  Han" /></meta><meta name="dc.Creator" content="Fupo  Zhang" /></meta><meta name="dc.Creator" content="Zhenmei  Gao" /></meta><meta name="dc.Creator" content="Tong  Zhu" /></meta><meta name="dc.Creator" content="Suzhen  Dong" /></meta><meta name="dc.Creator" content="Mingliang  Ma" /></meta><meta name="dc.Description" content="PI3K-Akt-mTOR signaling pathway has been validated as an effective targeting pathway for cancer therapy. However, no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is stil..." /></meta><meta name="Description" content="PI3K-Akt-mTOR signaling pathway has been validated as an effective targeting pathway for cancer therapy. However, no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is stil..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 18, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01736" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01736" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01736" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01736" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01736" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0019.jpeg" /></meta><meta property="og:description" content="PI3K-Akt-mTOR signaling pathway has been validated as an effective targeting pathway for cancer therapy. However, no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is still essential to discover a candidate with good efficacy and low toxicity. In our design, a series of imidazo[1,2-a]pyridine derivatives had been synthesized and subjected to activity assessment in vitro and in vivo. 15a was proved to be a potent PI3K/mTOR dual inhibitor with excellent kinase selectivity, modest plasma clearance, and acceptable oral bioavailability. Besides, 15a displayed significant inhibition of tumor growth in HCT116 and HT-29 xenografts without obvious effect on body weight." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01736"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01736">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01736&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01736&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01736&amp;href=/doi/10.1021/acs.jmedchem.9b01736" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 3028-3046</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01689" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01809" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ya’nan Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ya’nan Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ya%E2%80%99nan++Yu">Ya’nan Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuqiao Han</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuqiao Han</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuqiao++Han">Yuqiao Han</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fupo Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fupo Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fupo++Zhang">Fupo Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhenmei Gao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhenmei Gao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhenmei++Gao">Zhenmei Gao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tong Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tong Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tong++Zhu">Tong Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Suzhen Dong</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Suzhen Dong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>S.D.: phone, 86-21-62238763; fax, 86-21-62238763; email, <a href="/cdn-cgi/l/email-protection#8efdf4eae1e0e9ceecfcefe7e0a0ebede0fba0ebeafba0ede0"><span class="__cf_email__" data-cfemail="becdc4dad1d0d9fedcccdfd7d090dbddd0cb90dbdacb90ddd0">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Suzhen++Dong">Suzhen Dong</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Mingliang Ma</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingliang Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</div><div class="loa-info-affiliations-info">Key Laboratory of Brain Functional Genomics, Ministry of Education, East China Normal University, Shanghai 200062, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>M.M.: phone, 86-21-62233026; fax, 86-021-62233026; email, <a href="/cdn-cgi/l/email-protection#c2afaeafa382a0b0a3abaceca7a1acb7eca7a6b7eca1ac"><span class="__cf_email__" data-cfemail="7518191814351707141c1b5b10161b005b1011005b161b">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingliang++Ma">Mingliang Ma</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7591-6748" title="Orcid link">http://orcid.org/0000-0002-7591-6748</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01736&amp;href=/doi/10.1021%2Facs.jmedchem.9b01736" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 3028–3046</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 18, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 October 2019</li><li><span class="item_label"><b>Published</b> online</span>18 February 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 March 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01736" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01736</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3028%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYa%25E2%2580%2599nan%2BYu%252C%2BYuqiao%2BHan%252C%2BFupo%2BZhang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D6%26contentID%3Dacs.jmedchem.9b01736%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BImidazo%255B1%252C2-a%255Dpyridine%2BDerivatives%2Bas%2BNovel%2BPI3K%252FmTOR%2BDual%2BInhibitors%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3046%26publicationDate%3DMarch%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01736"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2235</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">11</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01736" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ya’nan&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Yuqiao&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Fupo&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Zhenmei&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Tong&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Suzhen&quot;,&quot;last_name&quot;:&quot;Dong&quot;},{&quot;first_name&quot;:&quot;Mingliang&quot;,&quot;last_name&quot;:&quot;Ma&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;3028-3046&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01736&quot;},&quot;abstract&quot;:&quot;PI3K-Akt-mTOR signaling pathway has been validated as an effective targeting pathway for cancer therapy. However, no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is still essential to discover a candidate with good efficacy and low toxicity. In our design, a series of imidazo[1,2-a]pyridine derivatives had been synthesized and subjected to activity assessment in vitro and in vivo. 15a was proved to be a potent PI3K/mTOR dual inhibitor with excellent kinase selectivity, modest plasma clearance, and acceptable oral bioavailability. Besides, 15a displayed significant inhibition of tumor growth in HCT116 and HT-29 xenografts without obvious effect on body weight.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01736&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01736" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01736&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01736" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01736&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01736" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01736&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01736&amp;href=/doi/10.1021/acs.jmedchem.9b01736" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01736" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01736" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01736%26sid%3Dliteratum%253Aachs%26pmid%3D32069401%26genre%3Darticle%26aulast%3DYu%26date%3D2020%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BImidazo%255B1%252C2-a%255Dpyridine%2BDerivatives%2Bas%2BNovel%2BPI3K%252FmTOR%2BDual%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D6%26spage%3D3028%26epage%3D3046%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/jmcmar.2020.63.issue-6/20200326/jmcmar.2020.63.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">PI3K-Akt-mTOR signaling pathway has been validated as an effective targeting pathway for cancer therapy. However, no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is still essential to discover a candidate with good efficacy and low toxicity. In our design, a series of imidazo[1,2-<i>a</i>]pyridine derivatives had been synthesized and subjected to activity assessment <i>in vitro</i> and <i>in vivo</i>. <b>15a</b> was proved to be a potent PI3K/mTOR dual inhibitor with excellent kinase selectivity, modest plasma clearance, and acceptable oral bioavailability. Besides, <b>15a</b> displayed significant inhibition of tumor growth in HCT116 and HT-29 xenografts without obvious effect on body weight.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07644" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07644" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Phosphoinositide 3-kinase (PI3K) is a family of lipid kinases playing central roles in regulation of cellular growth, proliferation, differentiation, migration, apoptosis, and autophagy. The family members catalyze the phosphorylation of phosphatidylinositol 4,5-diphosphate (PIP<sub>2</sub>) to produce phosphatidylinositol 3,4,5-triphosphate (PIP<sub>3</sub>), which transduces extracellular signals into cells to induce cellular response as a second messenger. There are three classes of PI3K members that have been identified, of which class I has been extensively studied. Class I PI3Ks are further divided into four isoforms: α, β, γ, and δ based on their different regulatory subunits. Dysregulation of PI3Kα, -β, -γ, and -δ has been demonstrated to be associated with many cancers by abnormal phosphorylation of their effector Akt (protein kinase B, PKB).<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> Mammalian target of rapamycin (mTOR) is an atypical serine/threonine kinase and regulates cell growth and metabolism in response to extracellular nutrient and energy factors. Overactivation of mTOR signaling can be caused by gain-of-function mutation of PI3K<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> or loss-of-function of tumor suppressor PTEN (phosphate and tension homology deleted on chromosome 10)<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> in many cancers. Thus, the PI3K-Akt-mTOR signaling has long been a therapeutic targeting pathway for development of cancer treatment.</div><div class="NLM_p">Although tumorigenesis is often related to abnormal activation of PI3K-Akt-mTOR signaling pathway, activation of the pathway is not vertical. A negative feedback has been found between mTOR and PI3K. For example, inhibition of mTOR complex 1 (mTORC1) by rapamycin induced insulin receptor substrate 1 (IRS-1) overexpression and induced Akt activation resulting in cancer cell survival, proliferation, and growth, thus compromising the antitumor effects of the inhibitor.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> On the other hand, mTOR signaling can also be activated in a PI3K-independent manner.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> These studies suggest that combination therapy of ablating mTOR function and preventing Akt activation may have improved antitumor activity. Until now, more than 40 inhibitors of this signaling pathway have reached different stages of clinical development for tumor therapies. But only six of them (the mTOR inhibitors temsirolimus and everolimus; the PI3K inhibitors idelalisib, copanlisib, alpelisib, and duvelisib) were approved by FDA for clinical use.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a></div><div class="NLM_p">Several class I PI3K/mTOR dual inhibitors have entered different clinical research stages, such as gedatolisib, PQR309, apitolisib, LY3023414, omipalisib, and so on<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Among these clinical candidates, omipalisib (PI3Kα <i>K</i><sub>i</sub> = 0.019 nM; PI3Kβ <i>K</i><sub>i</sub> = 0.13 nM; PI3Kγ <i>K</i><sub>i</sub> = 0.024 nM; PI3Kδ <i>K</i><sub>i</sub> = 0.06 nM; mTORC1 <i>K</i><sub>i</sub> = 0.18 nM; mTORC2 <i>K</i><sub>i</sub> = 0.3 nM), a potent PI3K/mTOR dual inhibitor, exhibits the best kinase inhibitory activity at picomolar concentrations.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> It is currently explored in clinical phase I study for treatment of idiopathic pulmonary fibrosis, solid tumors, and lymphoma. However, all these inhibitors have varying degrees of adverse events<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> and no PI3K/mTOR dual inhibitor has been successfully approved by FDA. Therefore, the development of PI3K/mTOR dual inhibitors with good clinical activity, few side effects, and low toxicity is extremely urgent.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of PI3K/mTOR dual inhibitors in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Hayakawa et al.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> reported a novel PI3Kα inhibitor containing an arylsulfonylhydrazide-substituted imidazo[1,2-<i>a</i>]pyridine structure exemplified by PIK-75 (in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a><b>)</b>, which showed significant kinase inhibitory activity with an IC<sub>50</sub> of 0.3 nM. In order to develop a new structural class of potent PI3K inhibitors, Kim et al.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> discovered HS-173 (in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, PI3Kα IC<sub>50</sub> = 0.8 nM) using fragment-growing strategy. They found HS-173 has maintained PI3Kα inhibitory activity. To avoid hydrolysis of the ester group of HS-173 in the phosphate buffer solution, Fan et al.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> designed <b>1i</b> by replacing the C-3 position of the imidazo[1,2-<i>a</i>]pyridine core with an amide bond. <b>1i</b> possesses comparable enzymatic inhibitory activity (in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, PI3Kα IC<sub>50</sub> = 0.5 nM) and good antiproliferative effects on HCT116 and SUN638 cells. Taken together, PI3K inhibitors containing the structure of imidazo[1,2-<i>a</i>]pyridine demonstrate good inhibitory effect on both kinase and cancer cell proliferation. In addition, this core still has a large number of sites that can be modified, which interested us a lot.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of PI3K inhibitors containing imidazo[1,2-<i>a</i>]pyridine core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In this communication, we describe our work on designing and synthesizing a series of imidazo[1,2-<i>a</i>]pyridine derivatives as potent PI3K/mTOR dual inhibitors and the discovery of <b>15a</b>, a drug candidate for cancer treatment.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Optimization Strategy</h3><div class="NLM_p">According to the docking model of <b>1i</b>,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> the nitrogen atom on the pyridyl ring forms a hydrogen bond interaction with Ser854 in the hinge region. On the basis of maintaining the interaction, a bioisosterism strategy is employed to replace the linker of <b>1i</b>. In addition, several sulfonamide methoxypyridine derivative side chains at the C-6 position and linkers with different substituents at the C-3 position of the core were brought in. Thus, the basic scaffold was constructed by three parts that target three active pockets: the affinity binding pocket, the hinge region, and the ribose binding pocket (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design strategy based on <b>1i</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Previous research<a onclick="showRef(event, 'ref13 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref13 ref18 ref19 ref20">(13,18−20)</a> indicated that the sulfonamide methoxypyridine structure is an essential group for maintaining PI3K inhibitory activity. It forms a hydrogen bond network with the Trp, Asp, and Lys residues in the affinity binding pocket. Generally, compounds with halogen-substituted benzenesulfonamides, for example, 2,4-difluorophenyl, 4-fluorophenyl, have better kinase-inhibitory activities than these with alkyl-substituted sulfonamides such as methyl and cyclopropyl. In addition, alkoxy group and the halogen on the C-2 position of the pyridine can increase kinase inhibitory activity compared to hydrogen or alkyl group. Therefore, we chose a phenyl or substituted phenyl group as a substituent for the side chain of the sulfonamide methoxypyridine.</div><div class="NLM_p last">Fan et al.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> used amide bond as a linker to improve bioavailability compared to HS-173 and proposed that the introduction of a hydrophilic group can effectively increase the kinase inhibitory activity. Furthermore, computational modeling showed that replacing an amide bond with 1,3,4-oxadiazole or 1,2,3-triazole will increase π–π interaction, which may lead to an increase in activity. Therefore, we tried to extend the hydrophilic group by attaching the amide bond to the triazole as a linker to solve the solubility problem, and 1,3,4-oxadiazole and 1,2,3-triazole were also introduced to the core as linkers. Hence, three series of compounds were synthesized.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">Compounds <b>5a</b>–<b>i</b> were synthesized according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Compound <b>1</b> was prepared starting with a cyclization reaction between 2-amino-5-iodopyridine and 2-chloro-3-oxopropionic acid ethyl ester.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Hydrolysis of ester <b>1</b> with NaOH resulted in carboxylic acid derivative <b>2</b>, and the corresponding intermediate <b>3</b> was obtained through amidation. Intermediate <b>4</b> was prepared by Suzuki reaction between <b>3</b> and 2,4-difluoro-<i>N</i>-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide which was synthesized according to the reported route,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> followed by a click reaction to produce <b>5a</b>–<b>i</b>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>5a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaOH, ethanol, H<sub>2</sub>O, 80 °C, 0.5 h, then HCl (2 mol/L), 78%; (b) prop-2-yn-1-amine, HATU, DIPEA, THF, 0 °C to rt, 12 h, 91%; (c) 2,4-difluoro-<i>N</i>-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 110 °C, 1.5 h, 80%; (d) N<sub>3</sub>-R<sub>2</sub>, CuTC, THF, rt, 12 h, 50–87%.</p></p></figure><div class="NLM_p">Compounds <b>9a</b>–<b>d</b> were synthesized as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Compound <b>6</b> was obtained through a cyclization reaction between 2-amino-5-bromopyridine and chloroacetaldehyde.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The new formed intermediate was treated with 2,4-difluoro-<i>N</i>-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide by Suzuki coupling to furnish compound <b>7</b>, followed by iodination. The TMS acetylenyl group was attached at the C3 position using Sonogashira coupling reaction to give compound <b>8</b>. And then, triazole analogues <b>9a</b>–<b>d</b> were generated by click reaction with various azide derivatives.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0011.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>9a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2,4-difluoro-<i>N</i>-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 110 °C, reflux, 1.5 h, 95%; (b) NIS, CH<sub>3</sub>CN, rt, 18 h, 80%; (c) trimethylsilylacetylene, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, PPh<sub>3</sub>, CuI, Et<sub>3</sub>N, THF, 45 °C, 14 h, 71%; (d) TBAF, THF, rt, 30 min, 66%; (e) N<sub>3</sub>-R<sub>1</sub>, CuTC, THF, rt, 12 h, 60–85%.</p></p></figure><div class="NLM_p">The synthetic routes of compounds <b>15a</b>–<b>r</b>, <b>18a</b>–<b>e</b>, <b>22</b>, and <b>26</b> were outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0012.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>15a</b>–<b>r</b> and <b>18a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) hydrazine hydrate, ethanol, 100 °C, reflux, 13 h, 86%; (b) acrolein, acetic acid, CHCl<sub>3</sub>, rt, 23 h; (c) IBD, DCM, rt, 14 h, 14–53% over two steps; (d) nucleophiles, DBU, DCM, rt, 12 h, 33–92%; (e) arylboronic ester, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 110 °C, reflux, 1.5 h, 33–87%; (f) methyl 3-formylbenzoate, acetic acid, CHCl<sub>3</sub>, 70 °C, reflux, 3 h; (g) hydrazine hydrate, ethanol, 50 °C, reflux, 13 h, 67%; (h) aldehydes, CHCl<sub>3</sub>, acetic acid, 70 °C, reflux, 12 h.</p></p></figure><div class="NLM_p">Ester <b>10</b> was synthesized via a cyclization reaction between 2-amino-5-bromopyridine and 2-chloro-3-oxopropionic acid ethyl ester.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Hydrazinolysis reaction between <b>10</b> and hydrazine hydrate yielded intermediate <b>11</b>. Hydrazide <b>11</b> was treated with several aldehydes to afford acyl imine derivatives, which was transformed to compounds <b>12</b> and <b>13</b> via cyclization. Compound <b>13</b> was subjected to electrophilic additions to provide intermediates <b>14a</b>–<b>f</b>. Then, compounds <b>12</b> and <b>14a</b>–<b>f</b> were engaged in Suzuki cross-couplings with corresponding boronic esters to afford final compounds <b>15a</b>–<b>r</b>, respectively.</div><div class="NLM_p">Compound <b>16</b> was generated from ester <b>10</b> via Suzuki cross-coupling. Hydrazinolysis of compound <b>16</b> resulted in intermediate <b>17</b>, which was converted to target compounds <b>18a</b>–<b>e</b> through condensation and cyclization.</div><div class="NLM_p">Compound <b>19</b> was prepared starting with ethyl bromopyruvate and 2-amino-5-bromopyridine,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> then functionalized to afford intermediate <b>21</b>. Suzuki coupling of intermediate <b>21</b> with boronic ester produced the desired product <b>22</b>.</div><div class="NLM_p">Compound <b>23</b>, which was synthesized from 2-chloro-3-oxopropionic acid ethyl ester and 2-amino-4-bromopyridine,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> was used as an intermediate in the preparation of compound <b>24</b>. Electrophilic addition of the resulting compound <b>24</b> generated intermediate <b>25</b>, which underwent Suzuki cross-coupling to get final compound <b>26</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0013.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>22</b> and <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) hydrazine hydrate, ethanol, 100 °C, reflux, 2 h, 44–87%; (b) acrolein, acetic acid, CHCl<sub>3</sub>, 70 °C, reflux, 3 h; (c) IBD, DCM, rt, 14 h, 27–31% over two steps; (d) nucleophiles, DBU, DCM, rt, 12 h, 34–64%; (e) arylboronic ester, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 110 °C, reflux, 1.5 h, 52–85%.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Structure–Activity Relationship (SAR)</h3><div class="NLM_p">The Kinase-Glo Plus luminescent assay was used for screening compounds with inhibitory activities against PI3Kα.</div><div class="NLM_p">First, the linkers were screened as shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. <b>5a</b>–<b>d</b> incorporated nitrogen-containing heterocycles using amide linkage triazole as a linker. And these four compounds exhibited improved inhibitory activities, compared to that of HS-173, <b>1i</b>, and PI103. When the substituent was changed to dimethylamino, the activity of <b>5e</b> (PI3Kα inhibition at 1 nM = 71%) decreased slightly, which identified a preference for bulky groups in R<sub>1</sub>. We further changed the heterocycles to hydrophobic groups. <b>5f</b>–<b>i</b> containing substituted benzene rings showed a significant increase in the kinase inhibition, with all the inhibition rates exceeding 85% at 1 nM. By contrast, the 1,2,3-triazole analogues <b>9a</b>–<b>c</b> exhibited a mild decrease in inhibitory activities, and dimethylamino substituted <b>9c</b> showed the weakest inhibition. Extending the substituent of <b>9b</b> by one carbon atom, <b>9d</b> (PI3Kα inhibition at 1 nM = 80%) showed an improved potency in inhibitory activity. When using 1,3,4-oxadiazole as a linker, we found that <b>15a</b> (PI3Kα inhibition at 1 nM = 80%) had the best activity. Then these compounds were subject to cytotoxicity assay in HCT116 cells, and it was found that <b>5a</b>, <b>5e</b>, and <b>5i</b> had poor cellular inhibitory activities, probably because of their polarity with poor permeability in cells. However, <b>9a</b>–<b>d</b> displayed promising inhibitory activities, whose IC<sub>50</sub> values were lower than 1 μM. Among these compounds, <b>15a</b> displayed the strongest inhibitory activity in HCT116 cells with an IC<sub>50</sub> value of 0.01 μM. It was more than 1000 times than those of <b>18a</b>, <b>22</b>, <b>26</b>, <b>15o</b>, <b>15p</b>, <b>15q</b>, and <b>15r</b>, which was consistent with the kinase data. Hence, <b>15a</b> was selected as a lead compound for further structural optimization.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Studies of the Linkers<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0014.gif" alt="" id="gr8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0015.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">– stands for “not detected”.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">The proliferation–inhibitory effects of compounds in HCT116 cells were measured after 72 h treatment using CCK-8 assay. The IC<sub>50</sub> values were done by 8-dose response in triplicate.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">clogP values were predicted by Chemdraw.</p></div></div><div></div></div><div class="NLM_p">Initially, hydrophilic groups in R<sub>1</sub>, such as substituted benzene rings, thiophene, and alkyl groups, were introduced while keeping R<sub>3</sub> and R<sub>4</sub> unchanged. It was found that <b>15a</b>, <b>15f</b>, and <b>15h</b> had remarkable inhibitory activities (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). When the pyrrolidine ring was introduced, the kinase inhibitory activity of <b>15b</b> distinctly decreased. Replacing the pyrrolidine of <b>15b</b> with six-membered piperidine afforded compound <b>15d</b> and resulted in enhanced inhibitory activity. By replacement of the nitrogen heterocycle by a dimethylamino group, the inhibition rate of <b>15e</b> had a slight decline. When the substituent was a methoxy group, the inhibition rate of <b>15f</b> was 79%, which was comparable to that of <b>15a</b>. It was found that the inhibitory activity was much better than <b>15a</b> when the meta position of the phenyl ring was a hydrophilic carboxylic acid function (<b>15h</b>), and the activity decreased significantly by 1.5 times when the carboxylic acid was esterified (<b>15g</b>). Replacement of substituents by the hydrophobic trifluoromethyl group and the methyl group resulted in a distinct loss in the inhibitory activity by 2.7 and 1.7 times compared with the carboxyl group substitution. Altering the phenyl group to thiophene (<b>18c</b>) resulted in the improved inhibitory potency of PI3Kα, and the inhibition rate was 89%. If the substituent was a hydrophilic ethyl group (<b>18d</b>) or a methyl group (<b>18e</b>), the inhibitory activities were significantly enhanced to 85% and 83%, which was better than <b>15a</b>. These results suggested that the introduction of a hydrophilic group such as 1-methyl-4-ethylpiperazine, meta-benzoic acid, ethyl and methyl as R<sub>1</sub> substituent could result in high PI3Kα kinase inhibition.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Studies of 1,3,4-Oxadiazole Analogues<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0016.gif" alt="" id="gr10" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0017.gif" alt="" id="gr11" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0018.gif" alt="" id="GRAPHIC-d7e1047-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">– stands for “not detected”.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">The proliferation–inhibitory effects of compounds in HCT116 cells were measured after 72 h treatment using CCK-8 assay. The IC<sub>50</sub> values were done by 8-dose response in triplicate.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">clogP values were predicted by Chemdraw.</p></div></div><div></div></div><div class="NLM_p">To further explore the SAR, we investigated the effects of R<sub>3</sub>, R<sub>4</sub> substituents on the imidazo[1,2-<i>a</i>]pyridine scaffold. <b>15i</b>–<b>o</b> were synthesized by changing R<sub>4</sub>. When replacing a fluorine on the benzene ring with chlorine, the inhibition rate of <b>15i</b> was slightly decreased to 71%. When the substituent on the phenyl ring was removed to para-trifluoromethyl or para-fluorine, the activity was greatly reduced. <b>15n</b>, which replaced 2,4-difluorophenyl with a methyl group, showed a 3.2-fold decrease in potency. When there was only an amino group at R<sub>4</sub>, <b>15o</b> totally lost its inhibitory effect on PI3Kα kinase. Then the effect of R<sub>3</sub> group was examined. Similar to the methoxy group, <b>15p</b>, whose R<sub>3</sub> group is chlorine-substituted, maintained the activity with an IC<sub>50</sub> of 0.23 nM. However, the removal of Cl gave the unsubstituted compound <b>15q</b>, which had a dramatic loss in potency. In addition, the compound <b>15r</b> inhibited the kinase by only 7% after removing the methoxy group and the substituents of the benzene ring, further indicating that the methoxy and 2,4-difluorophenyl were essential for inhibitory activity in these compounds.</div><div class="NLM_p">Finally, <b>22</b> and <b>26</b> were synthesized by changing the binding sites of the side chains of <b>15a</b>. The kinase activity data showed that when the substituent at the C-3 position was transferred to the C-2 position, the inhibition rate of <b>22</b> was only 5%. In addition, movement of the substituent from C-6 to C-7 (<b>26</b>) resulted in complete loss of inhibitory activity on the kinase. Therefore, it was indicated that the C-3 and C-6 positions were active sites of such compounds.</div><div class="NLM_p">Therefore, <b>15a</b> which has the best cellular inhibitory activity was selected to measure the inhibition of PI3K subtypes and mTOR kinase. The data showed that it had good effects on all PI3K subtypes and mTOR kinase (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The effects were comparable or better than the clinic drug copanlisib, which had been demonstrated to be a pan-PI3K/mTOR dual-target inhibitor and greatly inhibit the proliferation of many cancer cells.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a><b>15a</b> was also screened at a 1 μM to detect its kinase selectivity using DiscoverX’s kinomescan technology. Among 97 kinases tested, <b>15a</b> only exhibited good affinity for PIK3CA, PIK3CG, and PIK3C2B, suggesting excellent kinase selectivity (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.9b01736/suppl_file/jm9b01736_si_001.pdf" class="ext-link">Tables S1 and S2</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Activities of <b>15a</b> against Class I PI3Ks and mTOR</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="​" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kα</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kβ</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kγ</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kδ</th><th class="colsep0 rowsep0" align="center" char="​">mTOR</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">copanlisib</td><td class="colsep0 rowsep0" align="char" char=".">0.11</td><td class="colsep0 rowsep0" align="char" char=".">4.57</td><td class="colsep0 rowsep0" align="char" char=".">1.68</td><td class="colsep0 rowsep0" align="char" char=".">0.18</td><td class="colsep0 rowsep0" align="char" char="​">45<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15a</b></td><td class="colsep0 rowsep0" align="char" char=".">0.20</td><td class="colsep0 rowsep0" align="char" char=".">0.58</td><td class="colsep0 rowsep0" align="char" char=".">1.20</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char="​">21</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The IC<sub>50</sub> of copanlisib against mTOR was cited from ref <a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>.</p></div></div></div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinase-selectivity profiling of compound <b>15a</b> at a concentration of 1 μM (DiscoveRX). (A) TREEspot interaction maps for compound <b>15a</b> against 97 kinases. (B) Only PI3K isoforms were hits (mTOR is not included in the screening). Data for binding interaction are reported as % control, where low values stand for stronger hits. <i>S</i>-score is a quantitative indicator of compound selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">PI3K/Akt/mTOR signaling pathway is one of the most frequently mutant pathways occurring in many cancers.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> copanlisib has been shown to have more potent inhibitory activity in PIK3CA mutant and/or HER2 overexpression cells lines compared with HER2-negative and wild-type PIK3CA cancer cell lines.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Therefore, some cell lines with PIK3CA mutation (MCF-7, HT-29, HCT116), HER2 overexpression (LOVO), and PTEN loss (PC3) were chosen to detect the inhibitory effects of <b>15a</b> on cell proliferation using the CCK-8 assay. It was shown that <b>15a</b> performed well on all these cell lines with submicromolar IC<sub>50</sub> values. Besides, cytotoxicity of <b>15a</b> was also investigated in normal cells to detect its therapeutic window in cells. The results showed that <b>15a</b> displayed much lower cytotoxicity in HUVEC cells with an IC<sub>50</sub> of 15.53 μM, which is several hundreds or thousands times higher than that of the cancer cells detected (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). These suggested that <b>15a</b> could inhibit cancer cell proliferation at concentration without affecting normal cells. Hence, <b>15a</b> was chosen for further antitumor research.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferative Activities of Various Cell Lines<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">HCT116</th><th class="colsep0 rowsep0" align="center">HT-29</th><th class="colsep0 rowsep0" align="center">MCF-7</th><th class="colsep0 rowsep0" align="center">PC-3</th><th class="colsep0 rowsep0" align="center">LOVO</th><th class="colsep0 rowsep0" align="center">HUVEC</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15a</b></td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">0.052</td><td class="colsep0 rowsep0" align="left">0.04</td><td class="colsep0 rowsep0" align="left">0.071</td><td class="colsep0 rowsep0" align="left">0.0052</td><td class="colsep0 rowsep0" align="left">15.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">copanlisib</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.95</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">0.053</td><td class="colsep0 rowsep0" align="left">35.42</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">The proliferation–inhibitory effects of compounds in indicated cells were measured after 72 h treatment using CCK-8 assay. The IC<sub>50</sub> values were done by 8-dose response in triplicate. ND: not detected.</p></div></div></div><div class="NLM_p">Then the intracellular PI3K/mTOR pathway inhibitory activities of <b>15a</b> were evaluated by Western blot analysis. <b>15a</b> was observed to inhibit PI3K/Akt/mTOR pathway inside the cancer cells, as suggested by the dose-dependent decrease of phosphorylation of Akt and its downstream target p70S6K in HCT116 and HT-29 cell lines (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). There is a little difference of Akt vs p70S6K response between HCT116 and HT-29 cells. <b>15a</b> has more effects on Akt phosphorylation than p70S6K phosphorylation in HCT116 cells while the situation is contrary in HT-29 cells. The phenomena might be caused by different cell context of the two cells. They have different gene mutations. For example, HCT116 cells have KRAS mutation, while HT-29 cells have wild type KRAS. This kind of difference might have some effects on the sensitivity of the cells to the same compound. Of course, the accurate mechanism needs further investigation. Meanwhile, Akt protein level was observed to decrease at 1 μM. The reason might be that many cells underwent apoptosis and autophagy at that concentration, which led to degradation of proteins including Akt.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0005.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of <b>15a</b> on pAKT, AKT, p-p70S6K, and p70S6K in HCT116 and HT-29 cells. HCT116 cells and HT-29 cells were treated at the indicated concentrations of <b>15a</b> for 24 h. The expression levels of AKT, p70S6K, and their phosphorylated forms were analyzed by Western blotting. GAPDH was used as a loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Docking Modeling</h3><div class="NLM_p">Docking analysis were carried out to examine the binding modes of <b>15a</b> in the PI3Kα isoform and mTOR using the AutoDock software (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The docking results showed that compound <b>15a</b> and PI3Kα formed four conserved hydrogen bonds, one of which formed between the nitrogen atom on the imidazo[1,2-<i>a</i>]pyridine ring in the hinge region and Val851. More importantly, the other two were formed in the affinity pocket. The nitrogen atom on pyridine ring of the side chain, Asp810, Tyr836, and water formed a hydrogen bond. And the methoxy oxygen atom on the pyridine ring interacted with Lys802 by another hydrogen bond. Finally, the nitrogen atom on the <i>N</i>-methylpiperazine ring of compound <b>15a</b> formed a conserved hydrogen bond with Asn853 in the ribose binding pocket region. In addition to the hydrogen bond interaction, the linker 1,2,3-oxadiazole of the compound <b>15a</b> also formed a π–π interaction with Trp780. The analysis of <b>15a</b> docked into the mTOR model indicated that hydrogen bonds between the nitrogen atom on the core and Val2240, nitrogen atom on the <i>N</i>-methylpiperazine ring and Thr2245 were formed and it kept the π–π interaction of the oxadiazole ring. The proposed binding modes supported the observed inhibitory activity of <b>15a</b> to PI3Kα and mTOR kinases.</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0006.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Proposed binding modes between compound <b>15a</b> and the PI3Kα (left, PDB code for PI3Kα is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JPS">4JPS</a>) and mTOR (right, PDB code for mTOR is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>) models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Pharmacokinetic Analysis</h3><div class="NLM_p"><b>15a</b> was further progressed into <i>in vivo</i> pharmacokinetic studies at an intravenous dose of 1 mg/kg and at an oral dose of 5 mg/kg in rats. Moderate plasma clearance was found after intravenous administration with CL < 1000 mL h<sup>–1</sup> kg<sup>–1</sup> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Good oral plasma exposures (AUC<sub>0–∞</sub> > 3000 h·ng/mL) and acceptable oral bioavailability (26.8%) were achieved in this species (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). To investigate the distribution of <b>15a</b> in tumors, plasma and tumor concentration at 24 and 48 h after a single po administration of <b>15a</b> at 20 mg/kg in nude mice bearing HCT116 human colorectal cancer xenografts had been measured. The results showed that 373 ng/mL (about 0.6 μM) <b>15a</b> was reserved in tumor at 48 h after administration (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B).</div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0007.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Pharmacokinetic/pharmacodynamic evaluations of <b>15a</b> in SD rats and HCT116 human colorectal cancer xenografts in nude mice. (A) Mean plasma concentration versus time curves after a single intravenous and oral dosing of <b>15a</b> to male SD rats (<i>n</i> = 3). (B) Plasma and tumor concentrations of <b>15a</b> formulated in vehicle containing 5% DMSO, 45% PEG400 following a single po administration of 20 mg/kg (<i>n</i> = 2) in HCT116 xenografts in nude mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Data for Compound <b>15a</b> in Rats</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="4" align="center">iv (1 mg/kg)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="4" align="center">po (5 mg/kg)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><i>T</i><sub><i>1/2</i></sub> (h)</th><th class="colsep0 rowsep0" align="center">CL (mL h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (mL/kg)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–∞</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–∞</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4.71</td><td class="colsep0 rowsep0" align="left">339.6</td><td class="colsep0 rowsep0" align="left">690</td><td class="colsep0 rowsep0" align="left">2958</td><td class="colsep0 rowsep0" align="left">7.94</td><td class="colsep0 rowsep0" align="left">553</td><td class="colsep0 rowsep0" align="left">3965</td><td class="colsep0 rowsep0" align="left">26.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">iv formulation: 5% DMSO and 5% Solutol in saline; 3 rats for iv.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">po formulation: 0.5% CMC; 3 rats for po.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Antitumor Assay <i>in Vivo</i></h3><div class="NLM_p">On the basis of the promising biochemical, cellular, and pharmacokinetic properties, <b>15a</b> was subject to antitumor evaluation <i>in vivo</i>. HCT116 and HT-29 xenograft model of BALB/c nude mice were established and treated with vehicle or <b>15a</b> by po administration daily. Copanlisib (ip injection) was used as a positive control. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, both copanlisib and <b>15a</b> significantly decreased HCT116 tumor growth with tumor growth inhibition (TGI) of 57.89% and 65.77%, respectively. Meanwhile, copanlisib and <b>15a</b> had no obvious effects on body weight. To further confirm the effects of <b>15a</b> on PI3K <i>in vivo</i>, immunohistochemical analysis and HE staining of the HCT116 tumors collected at the end of the animal studies were performed. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>E, the staining of Ki-67, a cell proliferation maker, decreased obviously in tumor slices of <b>15a</b>- and copanlisib-treated mice. Meanwhile, down-regulation of p-AKT levels (indicated by the brown staining) was also observed. Besides, more massive patchy necrosis in tumors was found with even eosin-stained proteins in <b>15a</b>- and copanlisib-treated groups. Similarly, <b>15a</b> (20 mg/kg, po) and copanlisib (15 mg/kg, ip) also greatly suppressed HT-29 tumor growth compared with control, with TGIs of 68.26% and 60.67%, respectively (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A,C,D). Besides, <b>15a</b> hadn’t caused visible loss of body weight (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B). Although the <i>in vivo</i> antitumor effects are promising and no obvious decrease of body weight can be observed, liver injury was observed in our animal studies (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01736/suppl_file/jm9b01736_si_001.pdf" class="ext-link">Figure S1</a>). The type of liver toxicity, effects on liver enzymes levels, and the mechanism of inducing toxicity are still under investigation. Therefore, structure modification should be done to find some new compounds with reserved activity and reduced toxicity.</div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0008.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <b>15a</b> inhibited tumor growth of HCT116 xenograft in female BALB/c nude mice. (A) Tumor volume changes following the treatment of <b>15a</b> at a dose of 15 mg/kg (po, daily) and copanlisib (ip, every second day) at a dose of 15 mg/kg beginning on the fifth day after inoculation. (B) Average body weights for <b>15a</b>, copanlisib, and vehicle-treated mice groups. (C) Tumors removed from vehicle, copanlisib, and <b>15a</b>-treated mice groups. (D) Tumor weight of vehicle, copanlisib, and <b>15a</b>-treated mice groups. (E) Immunohistochemical staining of Ki67 and p-AKT(S473) and HE staining in tumor tissues from <b>15a</b>-treated mice and vehicle groups. Results are expressed as the mean ± SEM (<i>n</i> = 6 for each group) and analyzed by one-way ANOVA analysis: ****<i>P</i> < 0.0001 vs vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0009.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <b>15a</b> inhibited tumor growth of HT-29 xenograft in female BALB/c nude mice. (A) Tumor volume changes following the treatment of <b>15a</b> at doses of 10 mg/kg and 20 mg/kg (po, daily) and copanlisib (ip, every second day) at a dose of 15 mg/kg beginning on the eighth day after inoculation. (B) Average body weights for <b>15a</b>, copanlisib, and vehicle-treated mice groups. (C) Tumors removed from vehicle, copanlisib, and <b>15a</b>-treated mice groups. (D) Tumor weight of vehicle, copanlisib, and <b>15a</b>-treated mice groups. Results are expressed as the mean ± SEM (<i>n</i> = 7 for each group) and analyzed by one-way ANOVA analysis: ****<i>P</i> < 0.0001 vs vehicle, ***<i>P</i> < 0.001 vs vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70864" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70864" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A new series of imidazo[1,2-<i>a</i>]pyridine derivatives as potent PI3K/mTOR dual inhibitors was discovered and developed, which led to the discovery of <b>15a</b>. The tested results provided a lead compound <b>15a</b>, which showed a significant inhibitory effect on both PI3K and mTOR kinases. Furthermore, <b>15a</b> displayed excellent kinase selectivity, good PK properties, and satisfactory antitumor activity <i>in vitro</i> and <i>in vivo</i>, which might be a potential drug candidate for cancer research. However, <b>15a</b> also induced obvious liver injury. Hence, our future efforts will be on finding well-tolerated <b>15a</b> derivatives with good activities.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87432" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87432" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Chemistry</h3><div class="NLM_p last">All solvents and reagents were used from commercial sources without further purification. Flash column chromatography was performed using silica gel from Qingdao Haiyang. <sup>1</sup>H NMR and <sup>13</sup>C NMR data were recorded on a Bruker Ascend-400 spectrometer using solvent residual as an internal standard. Chemical shifts are performed in ppm (δ), and coupling constants (<i>J</i>) are in hertz (Hz). ESI-MS spectra were obtained on Bruker micrOTOF-II spectrometer. The purities of final compounds (>95%) were determined by HPLC using Thermo Scientific UltiMate 3000 HPLC or Waters e2695 (254 nm detection) with a 1.0 mL/min flow rate using a 5–95% gradient of acetonitrile/water with 0.1% HCOOH over 30 min.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Procedure A for Synthesizing 6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)-<i>N</i>-((1-(2-(4- methylpiperazin-1-yl)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)imidazo[1,2-α]pyridine-3-carboxamide (<b>5a</b>)</h3><div class="NLM_p">To a solution of 2-amino-5-iodopyridine (508 mg, 2.31 mmol) in 95% EtOH (10 mL), 2-chloro-3-oxopropionic acid ethyl ester (878 mg, 5.27 mmol) was added, followed by concentrated sulfuric acid (453 mg, 4.62 mmol) added dropwise. The solution was stirred at room temperature until it became white. Then, it was stirred at 100 °C for 24 h under reflux. After that, the white solid was removed by filtration, and the mixture was concentrated and diluted with dichloromethane (20 mL) and washed twice with H<sub>2</sub>O (30 mL). The organic phase was extracted and dried (Na<sub>2</sub>SO<sub>4</sub>). The reaction mixture gave a brown solid after concentration. Dichloromethane (5 mL) and petroleum ether (10 mL) were used to recrystallize to give a white solid <b>1</b> (461 mg, 63%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.57 (s, 1H), 8.21 (s, 1H), 7.58 (d, <i>J</i> = 9.4 Hz, 1H), 7.51 (d, <i>J</i> = 9.4 Hz, 1H), 4.42 (q, <i>J</i> = 7.1 Hz, 2H), 1.43 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 160.34, 146.89, 141.22, 135.46, 132.56, 118.74, 115.69 (2C), 60.72, 14.42.</div><div class="NLM_p">A solution of <b>1</b> (461 mg, 1.46 mmol), NaOH (584 mg, 14.6 mmol) in EtOH (10 mL), and H<sub>2</sub>O (10 mL) was stirred at 100 °C for 30 min. The reaction mixture was concentrated, and H<sub>2</sub>O (15 mL) was added. The solution was adjusted to pH 5–6 with 1 M hydrochloric acid. White solid was precipitated, which was filtered and dried to give a white solid (393 mg, 78%). Then the solid (393 mg, 1.14 mmol) was suspended in THF (15 mL). The mixture was stirred at 0 °C for 10 min after adding DIPEA (293 mg, 2.27 mmol). Then the mixture was stirred for another 20 min after adding HATU (474 mg, 1.25 mmol). After addition of propargylamine (75 mg, 1.36 mmol), the mixture was naturally warmed to room temperature and stirred for 13 h. Petroleum ether (15 mL) was added to the reaction mixture to give a solid, which was filtered to give a white solid. The solid was dissolved in H<sub>2</sub>O (15 mL) and stirred on a stirrer for 15 min, filtered, and dried to give white powder <b>3</b> (335 mg, 91%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.73 (s, 1H), 9.05 (t, <i>J</i> = 5.7 Hz, 1H, NH), 8.34 (s, 1H), 7.68 (d, <i>J</i> = 9.1 Hz, 1H), 7.59 (d, <i>J</i> = 9.3 Hz, 1H), 4.13 (d, <i>J</i> = 3.1 Hz, 1H), 3.21 (s, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.51, 145.43, 137.01, 134.39, 131.90, 118.50, 117.40, 81.01, 78.51, 73.15, 27.70.</div><div class="NLM_p">To a 50 mL reaction bottle, <b>3</b> (335 mg, 1.03 mmol), 2,4-difluoro-<i>N</i>-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide (483 mg, 1.13 mmol), potassium carbonate (426 mg, 3.09 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (60 mg, 0.05 mmol) in 1,4-dioxane (15 mL), and H<sub>2</sub>O (3 mL) were added. The mixture was stirred at 110 °C for 2 h under a nitrogen atmosphere. The mixture was filtered by using the diatomaceous earth, then concentrated in vacuum. The crude product was purified by silica gel column chromatography (DCM/MeOH = 50:1) to give <b>4</b> (298 mg, 58%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.59 (s, 1H), 8.28 (s, 1H), 8.09–7.98 (m, 2H), 7.92 (s, 1H), 7.75 (d, <i>J</i> = 9.3 Hz, 1H), 7.55 (t, <i>J</i> = 5.6 Hz, 1H, NH), 7.50 (d, <i>J</i> = 9.3 Hz, 1H), 7.11 (t, <i>J</i> = 8.4 Hz, 1H), 6.95 (t, <i>J</i> = 10.4 Hz, 1H), 5.31 (s, 1H), 4.29 (d, <i>J</i> = 3.0 Hz, 2H), 3.91 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.22 (dd, <i>J</i> = 258.7, 11.6 Hz), 160.34, 159.81 (dd, <i>J</i> = 259.2, 12.8 Hz), 154.44, 146.73, 140.17, 136.81, 132.99 (d, <i>J</i> = 10.6 Hz), 127.05, 126.74, 126.33, 125.27, 124.54, 123.12 (dd, <i>J</i> = 13.6, 3.7 Hz), 120.70, 118.30, 117.49, 112.35 (dd, <i>J</i> = 22.0, 3.5 Hz), 105.76 (t, <i>J</i> = 25.5 Hz), 79.85, 71.53, 54.12, 28.88.</div><div class="NLM_p">Compound <b>4</b> (298 mg, 0.60 mmol) dissolved in THF (15 mL), 1-(2-azidoethyl)-4-methylpiperazine (112 mg, 0.66 mmol), and CuTC (11 mg, 0.06 mmol) were added and stirred under nitrogen atmosphere for 12 h. The reaction mixture was concentrated and purified using silica gel column chromatography (DCM/MeOH = 30:1) to result in the white product <b>5a</b> (320 mg, 80%), mp = 110–112 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.69 (s, 1H, NH), 9.15 (s, 1H), 8.42 (s, 1H), 8.17 (s, 1H), 8.04 (s, 1H), 7.94–7.77 (m, 3H), 7.76–7.66 (m, 1H), 7.57–7.40 (m, 1H), 7.28–7.11 (m, 1H), 4.58 (d, <i>J</i> = 5.7 Hz, 2H), 4.45 (t, <i>J</i> = 6.4 Hz, 2H), 3.72 (s, 3H), 2.73 (t, <i>J</i> = 6.4 Hz, 2H), 2.48–2.32 (m, 8H), 2.15 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.44 (dd, <i>J</i> = 252.3, 11.0 Hz), 160.09, 159.16 (dd, <i>J</i> = 256.6, 13.6 Hz), 157.29, 145.94, 144.78, 138.81, 137.38, 131.82 (d, <i>J</i> = 10.6 Hz), 129.86, 126.44, 126.30, 125.99, 124.05, 123.96, 123.72, 123.46, 118.26, 117.40, 111.55 (dd, <i>J</i> = 21.9, 3.9 Hz), 105.56 (t, <i>J</i> = 26.0 Hz), 56.64, 53.97 (2C), 53.23, 51.41 (2C), 46.62, 44.50, 34.07. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>33</sub>N<sub>10</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 667.2375; found, 667.2335. Purity: 98.94%.</div><div class="NLM_p last">Compounds <b>5b</b>–<b>i</b> were prepared by a procedure similar to that described for the synthesis of <b>5a</b>.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)-<i>N</i>-((1-(2-(pyrrolidin-1-yl)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)imidazo[1,2-<i>a</i>]pyridine-3-carboxamide (<b>5b</b>)</h3><div class="NLM_p last">Mp = 207–210 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.59 (s, 1H, NH), 8.24 (s, 1H), 8.18 (t, <i>J</i> = 5.9 Hz, 1H), 8.07 (d, <i>J</i> = 2.3 Hz, 1H), 8.00 (q, <i>J</i> = 7.8 Hz, 1H), 7.92 (s, 1H), 7.84 (s, 1H), 7.69 (d, <i>J</i> = 9.3 Hz, 1H), 7.43 (d, <i>J</i> = 9.2 Hz, 1H), 7.05 (t, <i>J</i> = 8.5 Hz, 1H), 6.96 (t, <i>J</i> = 8.9 Hz, 1H), 4.76 (d, <i>J</i> = 5.6 Hz, 2H), 4.51 (t, <i>J</i> = 6.7 Hz, 2H), 3.91 (s, 3H), 2.99 (t, <i>J</i> = 6.7 Hz, 2H), 2.56 (s, 4H), 1.75 (s, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.16 (dd, <i>J</i> = 258.6, 11.7 Hz), 160.71, 159.82 (dd, <i>J</i> = 259.3, 12.9 Hz), 154.51, 146.69, 144.82, 140.29, 137.11, 132.89 (d, <i>J</i> = 10.8 Hz), 127.02, 126.71, 126.60, 125.23, 124.20, 123.36, 123.20, 120.70, 118.58, 117.59, 112.19 (dd, <i>J</i> = 20.2, 3.7 Hz), 105.72 (t, <i>J</i> = 25.4 Hz), 55.45, 54.06 (3C), 49.41, 34.52, 23.53 (2C). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>30</sub>N<sub>9</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 638.2110; found, 638.2067. Purity: 99.82%.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)-<i>N</i>-((1-(2-morpholinoethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)imidazo[1,2-<i>a</i>]pyridine-3-carboxamide (<b>5c</b>)</h3><div class="NLM_p last">Mp = 200–205 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.60 (s, 1H, NH), 8.40 (s, 1H), 8.28 (s, 1H), 8.07 (s, 1H), 8.03–7.95 (m, 1H), 7.91 (d, <i>J</i> = 15.9 Hz, 2H), 7.69 (d, <i>J</i> = 9.3 Hz, 1H), 7.45 (d, <i>J</i> = 9.3 Hz, 1H), 7.03 (t, <i>J</i> = 8.5 Hz, 1H), 6.96 (t, <i>J</i> = 9.4 Hz, 1H), 4.77 (d, <i>J</i> = 5.8 Hz, 2H), 4.49 (t, <i>J</i> = 6.7 Hz, 2H), 3.88 (s, 3H), 3.66 (s, 4H), 2.84 (t, <i>J</i> = 6.6 Hz, 2H), 2.50 (s, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.11 (dd, <i>J</i> = 258.5, 11.5 Hz), 160.79, 159.82 (dd, <i>J</i> = 259.1, 12.9 Hz), 154.68, 146.65, 144.98, 140.27, 137.15, 132.83 (d, <i>J</i> = 10.7 Hz), 126.98, 126.95, 126.62, 125.16, 124.21, 123.47, 123.34, 120.78, 118.57, 117.57, 112.11 (dd, <i>J</i> = 22.1, 3.8 Hz), 105.71 (t, <i>J</i> = 25.4 Hz), 66.79 (2C), 57.81, 53.99, 53.44 (2C), 47.49, 34.47. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>30</sub>N<sub>9</sub>O<sub>5</sub>SF<sub>2</sub> (M + H)<sup>+</sup> 654.2059; found, 654.2061. Purity: 98.96%.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)-<i>N</i>-((1-(2-(piperidin-1-yl)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)imidazo[1,2-<i>a</i>]pyridine-3-carboxamide (<b>5d</b>)</h3><div class="NLM_p last">Mp = 120–124 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.60 (s, 1H, NH), 8.30 (d, <i>J</i> = 15.5 Hz, 2H), 8.06 (s, 1H), 8.00 (q, <i>J</i> = 8.5 Hz, 1H), 7.92 (s, 1H), 7.89 (s, 1H), 7.71 (d, <i>J</i> = 9.2 Hz, 1H), 7.43 (d, <i>J</i> = 9.1 Hz, 1H), 7.05 (t, <i>J</i> = 9.2 Hz, 1H), 6.96 (t, <i>J</i> = 9.2 Hz, 1H), 4.76 (d, <i>J</i> = 5.7 Hz, 2H), 4.48 (t, <i>J</i> = 6.5 Hz, 2H), 3.90 (s, 3H), 2.79 (t, <i>J</i> = 6.6 Hz, 2H), 2.52–2.35 (m, 4H), 1.60–1.46 (m, 4H), 1.44–1.32 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.16 (dd, <i>J</i> = 258.5, 11.5 Hz), 160.70, 159.82 (dd, <i>J</i> = 258.9, 13.1 Hz), 154.49, 144.81, 140.28, 137.14, 132.90 (d, <i>J</i> = 10.5 Hz), 126.96, 126.66, 126.61, 125.20, 124.21, 123.46, 123.28 (dd, <i>J</i> = 13.8, 3.8 Hz), 120.65, 118.57, 117.60, 112.19 (dd, <i>J</i> = 22.0, 3.2 Hz), 105.72 (t, <i>J</i> = 25.5 Hz), 58.14, 54.48, 54.04 (2C), 47.88, 34.51, 25.84 (2C), 24.04. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>32</sub>N<sub>9</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 652.2266; found, 652.2269. Purity: 99.22%.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)-<i>N</i>-((1-(2- (dimethylamino)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)imidazo[1,2-<i>a</i>]pyridine-3-carboxamide (<b>5e</b>)</h3><div class="NLM_p last">Mp = 88–89 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.59 (s, 1H, NH), 8.35 (s, 1H), 8.27 (s, 1H), 8.06 (s, 1H), 8.00 (q, <i>J</i> = 7.8 Hz, 1H), 7.92 (s, 1H), 7.88 (s, 1H), 7.68 (d, <i>J</i> = 9.3 Hz, 1H), 7.43 (d, <i>J</i> = 9.1 Hz, 1H), 7.05 (t, <i>J</i> = 8.4 Hz, 1H), 6.96 (t, <i>J</i> = 9.3 Hz, 1H), 4.77 (d, <i>J</i> = 5.6 Hz, 2H), 4.48 (t, <i>J</i> = 6.5 Hz, 2H), 3.88 (s, 3H), 2.81 (t, <i>J</i> = 6.4 Hz, 2H), 2.28 (s, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 164.67 (dd, <i>J</i> = 253.8, 11.0 Hz), 160.75, 159.19 (dd, <i>J</i> = 254.3, 12.4 Hz), 156.57, 146.63, 145.11, 137.02, 136.20, 132.56, 132.46, 128.18, 126.99, 126.94, 126.87, 125.12, 124.87, 123.30, 118.50, 117.11, 111.11 (dd, <i>J</i> = 19.9, 4.0 Hz), 105.05 (t, <i>J</i> = 25.6 Hz), 58.61, 53.25, 48.15, 45.76 (2C), 45.28. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>28</sub>N<sub>9</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 612.1953; found, 612.1930. Purity: 99.62%.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)-<i>N</i>-((1-(2-methoxyphenyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)imidazo[1,2-<i>a</i>]pyridine-3-carboxamide (<b>5f</b>)</h3><div class="NLM_p last">Mp = 147–149 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.61 (s, 1H, NH), 8.35–8.18 (m, 2H), 8.07 (d, <i>J</i> = 2.1 Hz, 1H), 8.03–7.88 (m, 3H), 7.78–7.73 (m, 1H), 7.71 (d, <i>J</i> = 9.5 Hz, 1H), 7.49–7.36 (m, 2H), 7.12–7.00 (m, 3H), 6.98–6.88 (m, 1H), 4.87 (d, <i>J</i> = 5.6 Hz, 2H), 3.92 (s, 3H), 3.88 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.21 (dd, <i>J</i> = 258.8, 11.5 Hz), 160.69, 159.81 (dd, <i>J</i> = 259.0, 13.0 Hz), 154.31, 151.13, 144.16, 140.25, 137.05, 132.97, 132.86, 130.24, 127.04, 126.64, 126.30, 126.10, 125.44, 125.30, 124.79, 124.26, 123.15 (dd, <i>J</i> = 13.7, 3.7 Hz), 121.16, 120.65, 117.67, 112.25 (dd, <i>J</i> = 21.9, 3.5 Hz), 112.22, 105.75 (t, <i>J</i> = 25.4 Hz), 55.99, 54.11, 34.57. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>25</sub>N<sub>8</sub>O<sub>5</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 647.1637; found, 647.1661. Purity: 99.84%.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)-<i>N</i>-((1-(2-hydroxyphenyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)imidazo[1,2-<i>a</i>]pyridine-3-carboxamide (<b>5g</b>)</h3><div class="NLM_p last">Mp = 235–238 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.72 (s, 1H, NH), 9.20 (s, 1H), 8.46 (d, <i>J</i> = 8.4 Hz, 2H), 8.34 (s, 1H), 7.93–7.87 (m, 1H), 7.84 (d, <i>J</i> = 9.5 Hz, 2H), 7.76 (d, <i>J</i> = 9.3 Hz, 1H), 7.66–7.52 (m, 2H), 7.34 (t, <i>J</i> = 7.8 Hz, 1H), 7.24 (t, <i>J</i> = 8.6 Hz, 1H), 7.12 (d, <i>J</i> = 8.2 Hz, 1H), 6.99 (t, <i>J</i> = 7.7 Hz, 1H), 4.72 (d, <i>J</i> = 5.6 Hz, 2H), 3.70 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.59 (dd, <i>J</i> = 258.7, 11.6 Hz), 160.06, 159.26 (dd, <i>J</i> = 257.6, 13.7 Hz), 157.40, 149.48, 145.97, 144.63, 141.64, 137.50, 132.65, 131.94, 131.83, 129.95, 126.31, 126.21, 124.98, 124.53, 124.34, 123.17, 120.42, 119.45, 118.32, 117.44, 116.99, 111.88 (dd, <i>J</i> = 22.4, 3.4 Hz), 105.79 (t, <i>J</i> = 26.1 Hz), 53.42, 33.90. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>23</sub>N<sub>8</sub>O<sub>5</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 633.1480; found, 633.1453. Purity: 99.62%.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Methyl-2-(4-((6-(5-((2,4-difluorophenyl)sulfonamido)-6-methoxypyridin-3- yl)imidazo[1,2-<i>a</i>]pyridine-3-carboxamido)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)benzoate (<b>5h</b>)</h3><div class="NLM_p last">Mp = 119–124 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.62 (s, 1H, NH), 8.25 (s, 1H), 8.08 (s, 1H), 8.04–7.95 (m, 4H), 7.93 (s, 1H), 7.76–7.63 (m, 2H), 7.63–7.55 (m, 1H), 7.51 (d, <i>J</i> = 7.8 Hz, 1H), 7.46 (d, <i>J</i> = 9.3 Hz, 1H), 7.05 (t, <i>J</i> = 8.4 Hz, 1H), 6.94 (t, <i>J</i> = 8.9 Hz, 1H), 4.87 (d, <i>J</i> = 5.7 Hz, 2H), 3.92 (s, 3H), 3.71 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.21 (dd, <i>J</i> = 258.8, 11.6 Hz), 165.50, 160.74, 159.81 (dd, <i>J</i> = 259.0, 12.9 Hz), 154.35, 146.78, 144.78, 140.26, 137.05, 136.06, 132.89 (d, <i>J</i> = 11.0 Hz), 131.25, 129.99, 127.29, 127.00, 126.78 (d, <i>J</i> = 4.2 Hz), 126.37, 125.26, 124.61, 124.34, 123.14 (dd, <i>J</i> = 13.6, 3.9 Hz), 120.65, 118.51, 117.67, 112.25 (dd, <i>J</i> = 22.0, 3.7 Hz), 105.77 (t, <i>J</i> = 25.4 Hz), 54.12, 52.65, 34.56. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>25</sub>N<sub>8</sub>O<sub>6</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 675.1586; found, 675.1536. Purity: 97.83%.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-((1-(2-Carbamoylphenyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)-6-(5-((2,4-difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-<i>a</i>]pyridine-3-carboxamide (<b>5i</b>)</h3><div class="NLM_p last">Mp = 112–115 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 9.71 (s, 1H), 9.21 (s, 1H), 8.45 (s, 1H), 8.34 (d, <i>J</i> = 5.7 Hz, 2H), 7.90 (d, <i>J</i> = 10.6 Hz, 1H), 7.86–7.71 (m, 3H), 7.61 (s, 2H), 7.46 (s, 1H), 7.24 (t, <i>J</i> = 8.8 Hz, 1H), 4.69 (d, <i>J</i> = 5.7 Hz, 2H), 3.68 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.96, 165.06 (dd, <i>J</i> = 254.1, 11.5 Hz), 160.08, 159.27 (dd, <i>J</i> = 257.4, 13.5 Hz), 157.45, 145.97, 144.96, 142.02, 137.53, 133.86, 133.08 (d, <i>J</i> = 3.7 Hz), 131.88 (d, <i>J</i> = 10.7 Hz), 130.35, 129.25, 128.52, 126.33, 126.25, 125.43, 124.88 (dd, <i>J</i> = 14.4, 3.3 Hz), 124.39, 124.14, 123.11, 119.99, 118.35, 117.46, 111.93 (dd, <i>J</i> = 22.4, 3.0 Hz), 105.83 (t, <i>J</i> = 26.1 Hz), 53.46, 33.87. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>24</sub>N<sub>9</sub>O<sub>5</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 660.1589; found, 660.1614. Purity: 99.51%.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Procedure B for Synthesizing 2,4-difluoro-<i>N</i>-(2-methoxy-5-(3-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>9a</b>)</h3><div class="NLM_p">A solution of 2-amino-5-bromopyridine (434 mg, 2.51 mmol) in 95% EtOH (10 mL) was treated with sodium bicarbonate (422 mg, 5.02 mmol). To the solution was added chloroacetaldehyde (512 mg, 6.53 mmol), and the mixture was stirred at 80 °C overnight. The reaction mixture was concentrated and diluted with DCM (15 mL), then washed with H<sub>2</sub>O (15 mL). The organic layer was extracted and dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure to give the crude product. The crude product was purified by chromatography on silica gel (PE/EA = 2:1) to give <b>6</b> (232 mg, 47%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.28 (s, 1H), 7.63 (s, 1H), 7.55 (s, 1H), 7.52 (d, <i>J</i> = 9.7 Hz, 1H), 7.21 (d, <i>J</i> = 9.5 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 143.84, 134.33, 127.81, 125.79, 118.46, 112.61, 107.00.</div><div class="NLM_p">Compound <b>6</b> (232 mg, 1.18 mmol) was dissolved in 1,4-dioxane (15 mL) and H<sub>2</sub>O (3 mL). 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide (552 mg, 1.30 mmol), potassium carbonate (488 mg, 3.54 mmol), and Pd(dppf)Cl<sub>2</sub>·DCM (97 mg, 0.12 mmol) were purged by nitrogen three times and stirred under reflux at 110 °C for 3 h. The mixture was filtered by the diatomaceous earth and was concentrated and purified using silica gel column chromatography (DCM/MeOH = 50:1). A white solid <b>7</b> was obtained in a yield of 95%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.24 (s, 1H), 8.07 (s, 1H), 7.94 (s, 1H), 7.88 (q, <i>J</i> = 7.8 Hz, 1H), 7.75–7.58 (m, 3H), 7.29 (d, <i>J</i> = 9.0 Hz, 1H), 6.95 (t, <i>J</i> = 8.7 Hz, 2H), 3.95 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.18 (dd, <i>J</i> = 259.2, 11.6 Hz), 159.86 (dd, <i>J</i> = 259.2, 12.8 Hz), 154.54–152.73 (m), 144.61, 140.17, 134.31, 132.37 (d, <i>J</i> = 10.5 Hz), 127.19, 126.76, 124.41, 123.45 (dd, <i>J</i> = 13.8, 4.0 Hz), 122.95, 122.89, 120.66, 118.16, 112.96, 111.94 (dd, <i>J</i> = 21.9, 3.6 Hz), 105.78 (t, <i>J</i> = 25.4 Hz), 54.16.</div><div class="NLM_p">To <b>7</b> (465 mg, 1.12 mmol) and NIS (277 mg, 1.23 mmol) was added acetonitrile (15 mL). The mixture was stirred under nitrogen atmosphere for 14 h. The reaction mixture was concentrated and purified by silica gel chromatography (DCM/MeOH = 50:1). A white solid <b>7</b> (486 mg, 80%) was obtained. The compound (486 mg, 0.90 mmol), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (63 mg, 0.09 mmol), triethylamine (723 mg, 7.16 mmol), PPh<sub>3</sub> (35 mg, 0.14 mmol) were dissolved in freshly opened THF (10 mL). The reaction was stirred at room temperature for 30 min under the nitrogen protection. CuI (17 mg, 0.09 mmol) and trimethylsilylacetylene (263 mg, 2.69 mmol) were added. The reaction was purged with nitrogen and was stirred at 45 °C for 12 h. The mixture was filtered by diatomaceous earth and was concentrated and purified by silica gel column chromatography (DCM/MeOH = 150:1). A white solid <b>8</b> (327 mg) was obtained in a yield of 71%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.20 (s, 1H), 7.98 (s, 1H), 7.86 (s, 1H), 7.79–7.70 (m, 2H), 7.61 (d, <i>J</i> = 9.3 Hz, 1H), 7.25 (d, <i>J</i> = 9.3 Hz, 1H), 6.82 (t, <i>J</i> = 8.5 Hz, 2H), 3.84 (d, <i>J</i> = 1.8 Hz, 3H), 0.20 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.24 (dd, <i>J</i> = 258.9, 11.7 Hz), 159.90 (dd, <i>J</i> = 259.2, 13.1 Hz), 154.50, 144.63, 140.16, 139.25, 132.39 (d, <i>J</i> = 10.5 Hz), 127.08, 126.65, 125.76, 123.86, 123.53 (dd, <i>J</i> = 13.7, 3.9 Hz), 122.26, 120.84, 118.26, 112.01 (dd, <i>J</i> = 22.1, 3.6 Hz), 109.51, 106.29, 105.84 (d, <i>J</i> = 25.4 Hz), 91.38, 54.25, 0.00 (3C).</div><div class="NLM_p"><b>8</b> (327 mg, 0.64 mmol) was dissolved in THF (10 mL). TBAF (182 mg, 0.70 mmol) was added, and the mixture was stirred at room temperature for 20 min. The reaction mixture was concentrated and purified by silica gel column chromatography (DCM/MeOH = 150:1) to result in a white solid with a yield of 66%. The compound (185 mg, 0.42 mmol) was dissolved in THF (10 mL). 1-(2-Azidoethyl)-4-methylpiperazine (78 mg, 0.46 mmol) and CuTC (15 mg, 0.08 mmol) were added and stirred under nitrogen atmosphere for 10 h. The reaction mixture was concentrated and purified by silica gel column chromatography (DCM/MeOH = 40:1). A white solid <b>9a</b> (172 mg, 69%) was obtained. Mp = 201–204 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.50 (s, 1H), 8.15–8.05 (m, 3H), 7.97 (d, <i>J</i> = 2.2 Hz, 1H), 7.89 (s, 1H), 7.73 (d, <i>J</i> = 9.3 Hz, 1H), 7.42 (d, <i>J</i> = 7.5 Hz, 1H), 7.18 (t, <i>J</i> = 8.0 Hz, 1H), 6.95 (t, <i>J</i> = 8.5 Hz, 1H), 4.60 (t, <i>J</i> = 6.2 Hz, 2H), 3.95 (s, 3H), 2.94 (t, <i>J</i> = 6.2 Hz, 2H), 2.82–2.35 (m, 8H), 2.32 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.16 (dd, <i>J</i> = 258.2, 11.5 Hz), 159.75 (dd, <i>J</i> = 258.9, 13.0 Hz), 154.24, 145.30, 139.86, 138.71, 133.20 (d, <i>J</i> = 10.6 Hz), 132.63, 127.32, 125.94, 124.66, 124.04, 123.48, 123.18 (dd, <i>J</i> = 13.6, 3.8 Hz), 120.97, 120.93, 117.70, 116.69, 112.37 (dd, <i>J</i> = 22.0, 3.7 Hz), 105.69 (t, <i>J</i> = 25.4 Hz), 57.33, 54.95 (2C), 54.07, 52.86 (2C), 47.75, 45.82. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>30</sub>N<sub>9</sub>O<sub>3</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 610.2160; found, 610.2151. Purity: 99.89%.</div><div class="NLM_p last">Compounds <b>9b</b>–<b>d</b> were prepared by a procedure similar to that described for the synthesis of <b>9a</b>.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(3-(1-(2-morpholinoethyl)-1<i>H</i>-1,2,3-triazol-4-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>9b</b>)</h3><div class="NLM_p last">Mp = 142–143 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.50 (s, 1H), 8.15–8.06 (m, 3H), 7.97 (s, 1H), 7.90 (s, 1H), 7.73 (d, <i>J</i> = 9.3 Hz, 1H), 7.42 (d, <i>J</i> = 9.4 Hz, 1H), 7.18 (t, <i>J</i> = 7.9 Hz, 1H), 6.96 (t, <i>J</i> = 8.8 Hz, 1H), 4.62 (t, <i>J</i> = 6.2 Hz, 2H), 3.95 (s, 3H), 3.76–3.68 (m, 4H), 2.94 (t, <i>J</i> = 6.2 Hz, 2H), 2.64–2.49 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.19 (dd, <i>J</i> = 258.4, 11.5 Hz), 159.76 (dd, <i>J</i> = 259.0, 13.1 Hz), 154.17, 145.24, 139.92, 138.73, 133.17 (d, <i>J</i> = 10.9 Hz), 132.58, 127.22, 125.82, 124.68, 124.00, 123.48, 123.08 (dd, <i>J</i> = 13.6, 3.7 Hz), 120.89, 120.77, 117.65, 116.64, 112.39 (dd, J = 22.1, 3.5 Hz), 105.71 (t, <i>J</i> = 24.6 Hz), 66.82 (2C), 57.84, 54.08, 53.48 (2C), 47.53. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>27</sub>N<sub>8</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 597.1844; found, 597.1854. Purity: 99.84%.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(5-(3-(1-(2-(Dimethylamino)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide (<b>9c</b>)</h3><div class="NLM_p last">Mp = 164–166 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.51 (s, 1H), 8.16–8.06 (m, 3H), 7.96 (s, 1H),7.89 (s, 1H), 7.72 (d, <i>J</i> = 9.3 Hz, 1H), 7.40 (d, <i>J</i> = 7.4 Hz, 1H), 7.19 (t, <i>J</i> = 8.1 Hz, 1H),6.95 (t, <i>J</i> = 9.0 Hz, 1H), 4.60 (t, <i>J</i> = 6.3 Hz, 2H), 3.95 (s, 3H), 2.88 (t, <i>J</i> = 6.2 Hz, 2H),2.32 (s, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.21 (dd, <i>J</i> = 258.1, 11.5 Hz), 159.75 (dd, <i>J</i> = 258.7, 12.7 Hz), 154.13, 145.24, 139.89, 138.74, 133.24 (d, <i>J</i> = 10.9 Hz), 132.64, 127.29, 125.77, 124.61, 124.06, 123.41, 123.07 (dd, <i>J</i> = 13.5, 3.8 Hz), 120.99, 120.81, 117.65, 116.72, 112.43 (dd, <i>J</i> = 22.1, 3.4 Hz), 105.70 (t, <i>J</i> = 25.5 Hz), 58.69, 54.09, 48.31, 45.37 (2C). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>25</sub>N<sub>8</sub>O<sub>3</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 555.1738; found, 555.1721. Purity: 98.55%.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(3-(1-(3-morpholinopropyl)-1<i>H</i>-1,2,3-triazol-4-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>9d</b>)</h3><div class="NLM_p last">Mp = 166–167 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.52 (s, 1H), 8.15–8.05 (m, 2H), 8.02 (s, 1H),7.97 (s, 1H), 7.89 (s, 1H), 7.73 (d, <i>J</i> = 9.3 Hz, 1H), 7.42 (d, <i>J</i> = 8.9 Hz, 1H), 7.19 (t, <i>J</i> = 8.5 Hz, 1H), 6.97 (t, <i>J</i> = 8.3 Hz, 1H), 4.60 (t, <i>J</i> = 6.9 Hz, 2H), 3.94 (s, 3H), 3.76–3.69 (m, 4H), 3.48 (t, 2H), 2.50–2.44 (m, 4H), 2.21 (d, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.17 (dd, <i>J</i> = 258.3, 11.5 Hz), 159.75 (dd, <i>J</i> = 259.0, 13.0 Hz), 154.22, 139.94, 138.72, 133.19, 133.08, 132.52, 127.20, 125.95, 124.76, 124.03, 123.53, 123.10 (dd, <i>J</i> = 13.6, 3.8 Hz), 120.76, 120.64, 117.62, 116.62, 112.36 (dd, <i>J</i> = 22.0, 3.6 Hz), 105.70 (t, <i>J</i> = 25.4 Hz), 66.86 (2C), 55.00, 54.07, 53.52 (2C), 48.39, 26.96. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>29</sub>N<sub>8</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 611.2001; found, 611.2036. Purity: 99.94%.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Procedure C<sub>1</sub> for Synthesizing 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>15a</b>)</h3><div class="NLM_p">To a solution of 2-amino-5-bromopyridine (337 mg, 1.95 mmol) in 95% EtOH (10 mL) was added 2-chloro-3-oxopropionic acid ethyl ester (748 mg, 4.49 mmol), followed by concentrated sulfuric acid (382 mg, 3.90 mmol) added dropwise. The solution was stirred at room temperature until it became white. Then, it was stirred at 100 °C for 24 h under reflux. After that, the white solid was removed by filtration, and the mixture was concentrated and diluted with dichloromethane (20 mL) and washed twice with H<sub>2</sub>O (30 mL). The organic phase was extracted and dried (Na<sub>2</sub>SO<sub>4</sub>). The reaction mixture gave a brown solid after concentration. Dichloromethane (5 mL) and petroleum ether (10 mL) were used to recrystallize to give a white solid <b>10</b> (331 mg, 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.55 (s, 1H), 8.32 (s, 1H), 7.84 (d, <i>J</i> = 9.5 Hz, 1H), 7.64 (d, <i>J</i> = 9.4 Hz, 1H), 4.46 (q, <i>J</i> = 7.1 Hz, 2H), 1.44 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 159.81, 145.00, 138.32, 132.73, 128.02, 117.51, 116.21, 110.50, 61.32, 14.34.</div><div class="NLM_p"><b>10</b> (331 mg, 1.23 mmol) was dissolved in 95% EtOH (10 mL), and hydrazine hydrate (1.22 g, 24.6 mmol) was added. The mixture was stirred under reflux at 100 °C for 13 h. After cooling to room temperature, more crystals were precipitated. Then it was filtered, and the filter cake was rinsed with 95% EtOH (5 mL). The solid was dried to obtain white needle crystals <b>11</b> (270 mg, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.87 (s, 1H, NH), 9.62 (s, 1H), 8.31 (s, 1H), 7.72 (d, <i>J</i> = 9.5 Hz, 1H), 7.58 (d, <i>J</i> = 9.4 Hz, 1H), 4.55 (s, 2H, NH). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.98, 145.02, 136.37, 129.46, 126.99, 118.32, 117.28, 107.69.</div><div class="NLM_p">Compound <b>11</b> (270 mg, 1.06 mmol) was dissolved in chloroform (10 mL). Two drops of acetic acid and acrolein (154 mg, 2.76 mmol) were added, and the mixture was stirred at 70 °C for 10 h under reflux. The reaction mixture was concentrated to give a white solid. The compound was dissolved in dichloromethane (10 mL), and IBD (410 mg, 1.27 mmol) was added in an ice bath, and the mixture reacted at room temperature for 12 h. The reaction mixture was concentrated and separated by silica gel column chromatography. Yellow powder <b>13</b> (148 mg) was obtained in a yield of 48% by two steps. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.63 (s, 1H), 8.29 (s, 1H), 7.69 (d, <i>J</i> = 9.5 Hz, 1H), 7.53 (d, <i>J</i> = 9.5 Hz, 1H), 6.82 (dd, <i>J</i> = 17.7, 11.3 Hz, 1H), 6.40 (d, <i>J</i> = 17.7 Hz, 1H), 5.93 (d, <i>J</i> = 11.3 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 162.19, 156.64, 146.54, 137.67, 130.94, 128.00, 125.62, 119.44, 118.46, 111.02, 109.57.</div><div class="NLM_p">Compound <b>13</b> (148 mg, 0.51 mmol) was dissolved in dichloromethane (10 mL). <i>N</i>-Methylpiperazine (56 mg, 0.56 mmol) and DBU (85 mg, 0.56 mmol) were added, and the mixture was stirred at room temperature for 13 h. The reaction mixture was concentrated and purified by silica gel chromatography (DCM/MeOH = 50:1) to give <b>14a</b> (133 mg, 67%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.60 (s, 1H), 8.23 (s, 1H), 7.67 (d, <i>J</i> = 9.5 Hz, 1H), 7.51 (d, <i>J</i> = 9.5 Hz, 1H), 3.17 (t, <i>J</i> = 7.4 Hz, 2H), 2.92 (t, <i>J</i> = 7.4 Hz, 2H), 2.76–2.54 (m, 4H), 2.53–2.36 (m, 4H), 2.28 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 164.23, 157.21, 146.34, 137.20, 130.68, 127.92, 118.40, 111.24, 109.37, 54.97 (2C), 54.61, 52.79 (2C), 45.97, 23.42.</div><div class="NLM_p">Compound <b>14a</b> (133 mg, 0.34 mmol), 2,4-difluoro-<i>N</i>-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide (158 mg, 0.37 mmol), potassium carbonate (70 mg, 0.51 mmol), and Pd(dppf)Cl<sub>2</sub>·DCM (25 mg, 0.03 mmol) were dissolved in 1,4-dioxane (10 mL) and H<sub>2</sub>O (2 mL). The mixture was stirred under nitrogen and refluxed at 110 °C for 2.5 h. The mixture was filtered by diatomaceous earth, then it was concentrated and purified by silica gel column chromatography (DCM/MeOH = 50:1). A white solid <b>15a</b> (168 mg, 81%) was obtained. Mp = 96–98 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.48 (s, 1H), 8.28 (s, 1H), 8.19–8.09 (m, 2H), 7.98 (d, <i>J</i> = 2.3 Hz, 1H), 7.85 (d, <i>J</i> = 9.3 Hz, 1H), 7.59 (d, <i>J</i> = 9.3 Hz, 1H), 7.25 (t, <i>J</i> = 8.4 Hz, 1H), 6.96 (t, <i>J</i> = 8.3 Hz, 1H), 3.98 (s, 3H), 3.20 (t, <i>J</i> = 7.4 Hz, 2H), 2.96 (t, <i>J</i> = 7.4 Hz, 2H), 2.76–2.41 (m, 8H), 2.32 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.21 (dd, <i>J</i> = 258.3, 11.6 Hz), 164.01, 159.74 (dd, <i>J</i> = 258.7, 12.7 Hz), 157.57, 154.37, 146.97, 139.71, 137.32, 133.27 (d, <i>J</i> = 10.7 Hz), 126.88, 126.52, 125.43, 125.24, 124.94, 123.16 (dd, <i>J</i> = 12.7, 3.5 Hz), 121.38, 118.01, 112.47 (dd, <i>J</i> = 22.3, 3.4 Hz), 111.37, 105.72 (t, <i>J</i> = 25.4 Hz), 54.87 (2C), 54.57, 54.16, 52.54 (2C), 45.78, 23.41. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>29</sub>N<sub>8</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 611.2001; found, 611.2036. Purity: 99.47%.</div><div class="NLM_p last">Compounds <b>15b</b>–<b>f</b> were prepared by a procedure similar to that described for the synthesis of <b>15a</b>.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-(pyrrolidin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>15b</b>)</h3><div class="NLM_p last">Mp = 95–96 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.48 (s, 1H), 8.29 (s, 1H), 8.22–8.08 (m, 2H),7.98 (s, 1H), 7.85 (d, <i>J</i> = 9.2 Hz, 1H), 7.58 (d, <i>J</i> = 9.3 Hz, 1H), 7.27 (t, <i>J</i> = 7.5 Hz, 1H),6.96 (t, <i>J</i> = 8.8 Hz, 1H), 3.99 (s, 3H), 3.24 (t, <i>J</i> = 7.5 Hz, 2H), 3.06 (t, <i>J</i> = 7.5 Hz, 2H),2.77–2.59 (m, 4H), 1.91–1.75 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.29 (dd, <i>J</i> = 258.7, 11.6 Hz), 164.06, 159.74 (dd, <i>J</i> = 258.7, 12.9 Hz), 157.58, 154.15, 146.99, 139.68, 137.38, 133.34 (d, <i>J</i> = 10.9 Hz), 126.82, 126.54, 125.19, 125.00, 124.96, 123.00 (dd, <i>J</i> = 13.6, 3.7 Hz), 121.28, 118.04, 112.58 (dd, <i>J</i> = 22.3, 3.6 Hz), 111.41, 105.77 (t, <i>J</i> = 25.4 Hz), 54.21, 54.02 (2C), 52.62, 25.31, 23.52 (2C). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>26</sub>N<sub>7</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 582.1735; found, 582.1692. Purity: 99.71%.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-morpholinoethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>15c</b>)</h3><div class="NLM_p last">Mp = 78–81 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.47 (s, 1H), 8.29 (s, 1H), 8.19–8.09 (m, 2H),7.98 (d, <i>J</i> = 2.3 Hz, 1H), 7.85 (d, <i>J</i> = 9.3 Hz, 1H), 7.60 (d, <i>J</i> = 9.2 Hz, 1H), 7.26 (t, <i>J</i> = 8.4 Hz, 1H), 6.97 (t, <i>J</i> = 8.2 Hz, 1H), 3.98 (s, 3H), 3.73 (s, 4H), 3.21 (t, <i>J</i> = 7.3 Hz, 2H),2.95 (t, <i>J</i> = 7.3 Hz, 2H), 2.59 (s, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.27 (dd, <i>J</i> = 258.6, 11.5 Hz), 163.95, 159.75 (dd, <i>J</i> = 258.9, 12.8 Hz), 157.57, 154.23, 146.93, 139.83, 137.26, 133.26 (d, <i>J</i> = 10.8 Hz), 129.75 (dd, <i>J</i> = 297.2, 11.1 Hz), 126.94, 126.43, 125.24 (d, <i>J</i> = 3.1 Hz), 124.91, 122.97 (dd, <i>J</i> = 13.6, 3.7 Hz), 121.04, 117.98, 112.51 (dd, <i>J</i> = 22.2, 3.5 Hz), 111.34, 105.77 (t, <i>J</i> = 25.5 Hz), 66.80 (2C), 54.99, 54.20, 53.27 (2C), 23.21. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>26</sub>N<sub>7</sub>O<sub>5</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 598.1684; found, 598.1724. Purity: 99.05%.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-(piperidin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>15d</b>)</h3><div class="NLM_p last">Mp = 95–97 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.47 (s, 1H), 8.29 (s, 1H), 8.19–8.08 (m, 2H),7.98 (s, 1H), 7.85 (d, <i>J</i> = 9.3 Hz, 1H), 7.59 (d, <i>J</i> = 11.0 Hz, 1H), 7.27 (t, <i>J</i> = 9.6 Hz,1H), 6.96 (t, 1H), 3.98 (s, 3H), 3.23 (t, <i>J</i> = 7.5 Hz, 2H), 2.94 (t, <i>J</i> = 7.5 Hz, 2H), 2.65–2.44 (m, 4H), 1.72–1.55 (m, 4H), 1.52–1.41 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.25 (dd, <i>J</i> = 258.4, 11.5 Hz), 164.26, 159.73 (dd, <i>J</i> = 258.8, 12.8 Hz), 157.53, 154.24, 146.92, 139.69, 137.28, 133.35, 133.24, 126.84, 126.48, 125.18, 124.90, 123.03 (dd, <i>J</i> = 13.6, 3.8 Hz), 121.24, 117.98, 112.53 (dd, <i>J</i> = 22.2, 3.6 Hz), 111.37, 105.75 (t, <i>J</i> = 25.4 Hz), 55.35, 54.18 (3C), 25.77 (2C), 24.12, 23.27. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>28</sub>N<sub>7</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 596.1892; found, 596.1903. Purity: 99.73%.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N</i>-(5-(3-(5-(2-(dimethylamino)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide (<b>15e</b>)</h3><div class="NLM_p last">Mp = 173–175 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.47 (s, 1H), 8.29 (s, 1H), 8.18–8.09 (m, 2H),7.97 (d, <i>J</i> = 2.2 Hz, 1H), 7.84 (d, <i>J</i> = 9.3 Hz, 1H), 7.58 (d, <i>J</i> = 8.3 Hz, 1H), 7.26 (t, <i>J</i> = 7.7 Hz, 1H), 6.96 (t, <i>J</i> = 10.0 Hz, 1H), 3.99 (s, 3H), 3.19 (t, <i>J</i> = 7.4 Hz, 2H), 2.90 (t, <i>J</i> = 7.4 Hz, 2H), 2.36 (s, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.29 (dd, <i>J</i> = 258.6, 11.7 Hz), 164.06, 159.75 (dd, <i>J</i> = 258.9, 13.1 Hz), 157.58, 154.23, 146.95, 139.82, 137.34, 133.30 (d, <i>J</i> = 10.9 Hz), 126.84, 126.51, 125.27, 125.17, 124.92, 123.00 (dd, <i>J</i> = 13.5, 3.8 Hz), 121.10, 118.01, 112.55 (dd, <i>J</i> = 22.1, 3.5 Hz), 111.40, 105.75 (t, <i>J</i> = 25.5 Hz), 55.84, 54.20, 45.13 (2C), 23.93. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>24</sub>N<sub>7</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 556.1579; found, 556.1583. Purity: 99.83%.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-methoxyethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>15f</b>)</h3><div class="NLM_p last">Mp = 178–182 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.47 (s, 1H), 8.30 (s, 1H), 8.20–8.08 (m, 2H),7.98 (d, <i>J</i> = 2.2 Hz, 1H), 7.85 (d, <i>J</i> = 9.3 Hz, 1H), 7.59 (d, <i>J</i> = 9.3 Hz, 1H), 7.28 (t, <i>J</i> = 8.4 Hz, 1H), 6.96 (t, <i>J</i> = 8.3 Hz, 1H), 3.99 (s, 3H), 3.92 (t, <i>J</i> = 6.4 Hz, 2H), 3.44 (s, 3H),3.28 (t, <i>J</i> = 6.5 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.34 (dd, <i>J</i> = 258.6, 11.7 Hz), 163.26, 159.75 (dd, <i>J</i> = 258.8, 12.9 Hz), 157.68, 154.06, 146.99, 139.77, 137.42, 133.32 (d, <i>J</i> = 11.0 Hz), 126.88, 126.50, 125.21, 124.94, 124.89, 122.88 (dd, <i>J</i> = 13.5, 3.9 Hz), 121.06, 118.03, 112.61 (dd, <i>J</i> = 22.1, 3.6 Hz), 111.35, 105.80 (t, <i>J</i> = 25.6 Hz), 68.57, 58.87, 54.24, 26.25. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>21</sub>N<sub>6</sub>O<sub>5</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 543.1262; found, 543.1234. Purity: 99.33%.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Procedure C<sub>2</sub> for Synthesizing Methyl-2-(4-((6-(5-((2,4-difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-<i>a</i>]pyridine-3-carboxamido)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)benzoate (<b>15g</b>)</h3><div class="NLM_p">Compound <b>11</b> (433 mg, 1.70 mmol) was dissolved in chloroform (20 mL). Methyl 3-formylbenzoate (307 mg, 1.87 mmol) and 5 drops of acetic acid were added and stirred at 70 °C for 3 h under reflux. The reaction mixture was concentrated to give a white solid. The compound (480 mg, 1.24 mmol) was dissolved in dichloromethane (10 mL), IBD (439 mg, 1.36 mmol) was added, and air was removed three times with nitrogen, and the mixture was stirred at room temperature for 14 h under the protection. The reaction mixture was concentrated and washed twice with H<sub>2</sub>O (10 mL). Then the organic phase was extracted and dried over Na<sub>2</sub>SO<sub>4</sub>. DCM (4 mL) and PE (10 mL) were used to recrystallize. The yield was 53%. White solid <b>12</b> (385 mg) was obtained with a yield of 53% by two steps.</div><div class="NLM_p last">Compound <b>12</b> (385 mg, 0.90 mmol), 2,4-difluoro-<i>N</i>-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide (413 mg, 0.97 mmol), potassium carbonate (371 mg, 2.69 mmol), Pd(dppf)Cl<sub>2</sub>·DCM (73 mg, 0.09 mmol) were dissolved in 1,4-dioxane (15 mL) and H<sub>2</sub>O (3 mL). The mixture was stirred under nitrogen protection and refluxed at 110 °C for 2.5 h. The mixture was filtered by diatomaceous earth, and the filtrate was concentrated and purified using silica gel column chromatography (DCM/MeOH = 80:1). <b>15g</b> (457 mg, 82%) was obtained as a white solid. Mp = 236–238 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.54 (s, 1H, NH), 8.79 (s, 1H), 8.46 (s, 1H), 8.40(d, <i>J</i> = 7.9 Hz, 1H), 8.25 (d, <i>J</i> = 7.8 Hz, 1H), 8.23–8.16 (m, 1H), 8.14 (s, 1H), 8.05–7.97 (m, 1H), 7.88 (d, <i>J</i> = 9.3 Hz, 1H), 7.73–7.59 (m, 2H), 7.55 (s, 1H), 7.32 (t, <i>J</i> = 8.5 Hz, 1H), 6.98 (t, <i>J</i> = 9.3 Hz, 1H), 4.01 (s, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.42 (dd, <i>J</i> = 258.8, 11.8 Hz), 165.97, 162.33, 159.78 (dd, <i>J</i> = 257.9, 12.5 Hz), 157.67, 153.97, 147.29, 139.74, 138.00, 133.37 (d, <i>J</i> = 10.7 Hz), 132.79, 131.34, 131.14, 129.47, 127.96, 127.10, 126.48, 125.44, 125.08, 124.58, 123.83, 122.84 (dd, <i>J</i> = 13.3, 4.0 Hz), 121.13, 118.19, 112.70 (dd, <i>J</i> = 22.5, 3.7 Hz), 111.14, 105.88 (t, <i>J</i> = 25.4 Hz), 54.31, 52.60. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>21</sub>N<sub>6</sub>O<sub>6</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 619.1211; found, 619.1227. Purity: 99.57%.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Procedure C<sub>3</sub> for Synthesizing 3-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-<i>a</i>]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzoic Acid (<b>15h</b>)</h3><div class="NLM_p"><b>15g</b> (173 mg, 0.28 mmol) was dissolved in 95% EtOH (15 mL) and H<sub>2</sub>O (5 mL), and lithium hydroxide monohydrate (118 mg, 2.82 mmol) was added and reacted at 50 °C for 2 h. The reaction solution was concentrated and dissolved with water, and the pH was adjusted to 4–5 with 1 mol/L HCl to precipitate a large amount of solid. The white solid was filtered and purified using a solution of DCM/MeOH = 10:1 to slurry to yield white solid <b>15h</b> (75 mg, 44%). Mp = 211–216 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.51 (s, 1H, NH), 9.35 (s, 1H), 8.70 (s, 1H), 8.54 (s,1H), 8.35 (s, 1H), 8.30 (d, <i>J</i> = 7.7 Hz, 1H), 8.13 (d, <i>J</i> = 7.7 Hz, 1H), 8.03–7.87 (m,4H), 7.72 (t, <i>J</i> = 7.8 Hz, 1H), 7.64 (t, <i>J</i> = 10.0 Hz, 1H), 7.32 (t, <i>J</i> = 8.4 Hz, 1H), 3.73 (s,3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.14, 165.13 (dd, <i>J</i> = 253.8, 12.0 Hz), 161.79, 159.27 (dd, <i>J</i> = 254.3, 12.4 Hz), 157.42, 156.78, 145.21, 141.95, 135.96, 132.44, 132.34, 131.97 (d, <i>J</i> = 10.2 Hz), 131.83, 130.51, 129.81, 128.28, 126.95, 125.28, 124.82, 124.69, 124.03, 123.09, 120.15, 116.91, 111.98 (dd, <i>J</i> = 21.9, 3.3 Hz), 110.89, 105.90 (t, <i>J</i> = 25.9 Hz), 53.53. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>19</sub>N<sub>6</sub>O<sub>6</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 605.1055; found, 605.1036. Purity: 95.43%.</div><div class="NLM_p last">Compounds <b>15i</b>–<b>r</b> were prepared by a procedure similar to that described for the synthesis of <b>15a</b>.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 4-Chloro-2-fluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>15i</b>)</h3><div class="NLM_p last">Mp = 88–89 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.43 (s, 1H), 8.44–8.36 (m, 1H), 8.28 (s, 1H),8.08 (s, 1H), 7.96 (s, 1H), 7.83 (d, <i>J</i> = 9.3 Hz, 1H), 7.58 (d, <i>J</i> = 9.4 Hz, 1H), 7.47 (t, <i>J</i> = 7.8 Hz, 1H), 7.25 (d, <i>J</i> = 7.7 Hz, 1H), 4.00 (s, 3H), 3.21 (t, <i>J</i> = 7.0 Hz, 2H), 2.97 (t, <i>J</i> = 7.0 Hz, 2H), 2.82–2.40 (m, 8H), 2.31 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 164.95 (d, <i>J</i> = 258.9 Hz), 163.99, 157.50, 153.99, 146.85, 139.30, 137.21, 134.81 (d, <i>J</i> = 10.2 Hz), 133.53 (d, <i>J</i> = 11.4 Hz), 132.04 (d, <i>J</i> = 3.5 Hz), 126.76, 126.33, 125.18, 124.86, 124.35, 121.39, 119.47 (d, <i>J</i> = 25.7 Hz), 117.90, 115.18 (d, <i>J</i> = 21.9 Hz), 111.32, 54.85 (2C), 54.53, 54.16, 52.57 (2C), 45.82, 23.36. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>29</sub>N<sub>8</sub>O<sub>4</sub>FSCl (M + H)<sup>+</sup> 627.1705; found, 627.1663. Purity: 98.06%.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>N</i>-(2-Methoxy-5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)-4-(trifluoromethyl)benzenesulfonamide (<b>15j</b>)</h3><div class="NLM_p last">Mp = 204–206 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.58 (s, 1H, NH), 8.31 (s, 1H), 8.16 (s, 1H), 8.08 (d, <i>J</i> = 6.8 Hz, 3H), 7.88 (d, <i>J</i> = 6.9 Hz, 3H), 7.79 (s, 1H), 7.63 (d, <i>J</i> = 9.4 Hz, 1H), 3.87 (s, 3H), 3.20 (t, <i>J</i> = 7.3 Hz, 2H), 2.96 (t, <i>J</i> = 7.4 Hz, 2H), 2.82–2.39 (m, 8H), 2.32 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 164.05, 157.58, 154.77, 146.98, 142.70, 140.27, 137.33, 134.73 (q, <i>J</i> = 33.0 Hz), 127.90, 127.21, 126.93 (2C) (d, <i>J</i> = 5.0 Hz), 126.69, 126.47 (2C) (q, <i>J</i> = 3.7 Hz), 125.19, 125.02, 123.14 (d, <i>J</i> = 273.2 Hz), 121.32, 118.07, 111.41, 54.89 (2C), 54.58, 54.03, 52.62 (2C), 45.82, 23.41. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>30</sub>N<sub>8</sub>O<sub>4</sub>F<sub>3</sub>S (M + H)<sup>+</sup> 643.2063; found, 643.2043. Purity: 99.72%.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 4-Fluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>15k</b>)</h3><div class="NLM_p last">Mp = 185–186 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.56 (s, 1H), 8.30 (s, 1H), 8.16–8.11 (m, 1H), 8.06–8.02 (m, 1H), 8.02–7.95 (m, 2H), 7.87 (d, <i>J</i> = 9.3 Hz, 1H), 7.61 (d, <i>J</i> = 9.3 Hz, 1H), 7.34–7.27 (m, 2H), 3.93 (s, 3H), 3.19 (t, <i>J</i> = 7.3 Hz, 2H), 2.95 (t, <i>J</i> = 7.3 Hz, 2H), 2.81–2.37 (m, 8H), 2.31 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 165.38 (d, <i>J</i> = 255.6 Hz), 164.01, 157.55, 154.48, 146.93, 139.83, 137.28, 134.90 (d, <i>J</i> = 3.2 Hz), 130.23 (2C) (d, <i>J</i> = 9.5 Hz), 127.00, 126.50, 126.08, 125.27, 124.88, 121.50, 117.98, 116.60 (2C) (d, <i>J</i> = 22.8 Hz), 111.35, 54.80 (2C), 54.52, 54.06, 52.50 (2C), 45.74, 23.37. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>30</sub>N<sub>8</sub>O<sub>4</sub>FS (M + H)<sup>+</sup> 593.2095; found, 593.2101. Purity: 99.90%.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>N</i>-(2-Methoxy-5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)-4-nitrobenzenesulfonamide (<b>15l</b>)</h3><div class="NLM_p last">Mp = 163–166 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.57 (s, 1H), 8.49 (d, <i>J</i> = 8.4 Hz, 2H), 8.30 (s, 1H), 8.22–8.12 (m, 3H), 8.05 (s, 1H), 7.88 (d, <i>J</i> = 9.3 Hz, 1H), 7.63 (d, <i>J</i> = 9.3 Hz, 1H), 3.94 (s, 3H), 3.20 (t, <i>J</i> = 7.3 Hz, 2H), 2.97 (t, <i>J</i> = 7.3 Hz, 2H), 2.81–2.42 (m, 8H), 2.35 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 164.04, 157.64, 154.53, 150.43, 147.01, 144.91, 140.07, 137.39, 128.79 (2C), 126.82, 126.69, 126.06, 125.15, 125.08, 124.66 (2C), 121.47, 118.13, 111.40, 54.78 (2C), 54.47, 54.18, 52.26 (2C), 45.55, 23.45. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>30</sub>N<sub>9</sub>O<sub>6</sub>S (M + H)<sup>+</sup> 620.2040; found, 620.2007. Purity: 99.11%.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>N</i>-(2-Methoxy-5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>15m</b>)</h3><div class="NLM_p last">Mp = 209–213 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.55 (s, 1H), 8.29 (s, 1H), 8.12 (t, <i>J</i> = 1.7 Hz, 1H), 8.04 (t, <i>J</i> = 1.8 Hz, 1H), 7.96–7.90 (m, 2H), 7.87 (d, <i>J</i> = 9.2 Hz, 1H), 7.64–7.55 (m, 4H), 3.90 (s, 3H), 3.19 (t, <i>J</i> = 7.4 Hz, 2H), 2.95 (t, <i>J</i> = 7.3 Hz, 2H), 2.78–2.40 (m, 8H), 2.32 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 163.99, 154.41, 147.02, 139.84, 138.80, 137.37, 133.38, 129.28 (2C), 127.32 (2C), 127.12, 126.58, 126.11, 125.34, 124.91, 121.56, 118.04, 111.39, 54.88 (2C), 54.58, 54.05, 52.53 (2C), 45.80, 23.42. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>31</sub>N<sub>8</sub>O<sub>4</sub>S (M + H)<sup>+</sup> 575.2189; found, 575.2212. Purity: 99.55%.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>N</i>-(2-Methoxy-5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)methanesulfonamide (<b>15n</b>)</h3><div class="NLM_p last">Mp = 186–188 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.60 (s, 1H), 8.34–8.20 (m, 2H), 8.03 (d, <i>J</i> = 2.4 Hz, 1H), 7.87 (d, <i>J</i> = 9.3 Hz, 1H), 7.61 (d, <i>J</i> = 9.3 Hz, 1H), 4.10 (s, 3H), 3.17 (t, <i>J</i> = 7.4 Hz, 2H), 3.07 (s, 3H), 2.93 (t, <i>J</i> = 7.4 Hz, 2H), 2.79–2.35 (m, 8H), 2.31 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 164.02, 157.56, 154.57, 147.08, 140.42, 137.45, 127.36, 127.06, 126.82, 125.29, 125.00, 121.59, 118.09, 111.41, 54.90 (2C), 54.58, 54.37, 52.60 (2C), 45.84, 40.01, 23.41. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>29</sub>N<sub>8</sub>O<sub>4</sub>S (M + H)<sup>+</sup> 513.2032; found, 513.2018. Purity: 98.73%.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 2-Methoxy-5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-amine (<b>15o</b>)</h3><div class="NLM_p last">Mp = 115–119 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.54 (s, 1H), 8.25 (s, 1H), 7.88–7.77 (m, 2H), 7.64 (d, <i>J</i> = 9.3 Hz, 1H), 7.18 (s, 1H), 4.05 (s, 3H), 3.17 (t, <i>J</i> = 7.4 Hz, 2H), 2.94 (t, <i>J</i> = 7.4 Hz, 2H), 2.84–2.37 (m, 8H), 2.31 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 163.84, 157.57, 152.92, 146.96, 137.13, 132.78, 131.32, 127.12, 126.25, 126.18, 124.29, 117.94, 117.55, 111.13, 54.86 (2C), 54.52, 53.53, 52.58 (2C), 45.82, 23.34. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>27</sub>N<sub>8</sub>O<sub>2</sub> (M + H)<sup>+</sup> 435.2257; found, 435.2271. Purity: 97.10%.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-(2-Chloro-5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide (<b>15p</b>)</h3><div class="NLM_p last">Mp = 144–146 °C. <sup>1</sup>H NMR (400 MHz, 50% methanol-<i>d</i><sub>4</sub> + 50% CDCl<sub>3</sub>) δ 9.59 (s, 1H), 8.33 (d, <i>J</i> = 8.4 Hz, 2H), 8.21 (s, 1H), 8.05 (q, <i>J</i> = 7.9 Hz, 1H), 7.91 (d, <i>J</i> = 9.2 Hz, 1H), 7.76 (d, <i>J</i> = 9.2 Hz, 1H), 7.14 (t, <i>J</i> = 7.5 Hz, 1H), 7.02 (t, <i>J</i> = 9.2 Hz, 1H), 3.24 (t, <i>J</i> = 7.2 Hz, 2H), 2.99 (t, <i>J</i> = 7.2 Hz, 2H), 2.89–2.50 (m, 8H), 2.45 (s, 3H). <sup>13</sup>C NMR (101 MHz, 50% methanol-<i>d</i><sub>4</sub> + 50% CDCl<sub>3</sub>) δ 166.66 (dd, <i>J</i> = 256.8, 11.5 Hz), 165.65, 161.68 (dd, <i>J</i> = 258.7, 13.2 Hz), 158.85, 148.36, 145.47, 142.66, 138.31, 136.25, 133.77, 133.66, 131.34, 131.11 (d, <i>J</i> = 23.3 Hz), 129.01, 126.87, 126.28, 119.19, 113.28 (dd, <i>J</i> = 25.6, 3.5 Hz), 113.02, 107.05 (t, <i>J</i> = 26.3 Hz), 55.75 (2C), 55.54, 53.05 (2C), 46.26, 24.45. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>26</sub>N<sub>8</sub>O<sub>3</sub>F<sub>2</sub>SCl (M + H)<sup>+</sup> 615.1505; found, 615.1477. Purity: 97.66%.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 2,4-Difluoro-<i>N</i>-(5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>15q</b>)</h3><div class="NLM_p last">Mp = 225–228 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.40 (s, 1H), 8.47 (s, 1H), 8.40 (s, 1H), 8.28 (s, 1H), 8.09 (q, <i>J</i> = 8.2 Hz, 1H), 7.95 (d, <i>J</i> = 9.3 Hz, 1H), 7.85 (d, <i>J</i> = 9.3 Hz, 1H), 7.76 (s, 1H), 7.46 (t, <i>J</i> = 9.6 Hz, 1H), 7.33 (t, <i>J</i> = 8.3 Hz, 1H), 3.20 (t, <i>J</i> = 7.1 Hz, 2H), 2.87 (t, <i>J</i> = 7.1 Hz, 2H), 2.80–2.54 (m, 8H), 2.39 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.49 (dd, <i>J</i> = 253.0, 11.9 Hz), 164.09, 158.91 (dd, <i>J</i> = 256.2, 13.1 Hz), 156.94, 146.50, 141.58, 140.29, 138.79, 137.34, 132.27 (d, <i>J</i> = 10.3 Hz), 131.74, 126.87, 125.92 (d, <i>J</i> = 14.5 Hz), 124.80, 124.50, 123.09, 117.84, 111.92 (dd, <i>J</i> = 21.8, 2.9 Hz), 110.96, 105.86 (t, <i>J</i> = 26.1 Hz), 53.79 (2C), 53.62, 51.03 (2C), 44.26, 22.71. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>27</sub>N<sub>8</sub>O<sub>3</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 581.1895; found, 581.1868. Purity: 99.90%.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-(5-(3-(5-(2-(4-Methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>15r</b>)</h3><div class="NLM_p last">Mp = 217–220 °C. <sup>1</sup>H NMR (400 MHz, 50% methanol-<i>d</i><sub>4</sub> + 50% CDCl<sub>3</sub>) δ 9.57 (s, 1H,NH), 8.55 (s, 1H), 8.33 (d, <i>J</i> = 4.2 Hz, 2H), 8.01–7.87 (m, 4H), 7.77 (d, <i>J</i> = 9.3 Hz, 1H), 7.65–7.54 (m, 3H), 3.25 (t, <i>J</i> = 7.2 Hz, 2H), 2.98 (t, <i>J</i> = 7.2 Hz, 2H), 2.84–2.43 (m, 8H), 2.33 (s, 3H). <sup>13</sup>C NMR (101 MHz, 50% methanol-<i>d</i><sub>4</sub> + 50% CDCl<sub>3</sub>) δ 165.86, 158.85, 148.36, 143.92, 142.17, 140.56, 138.18, 137.26, 134.58, 134.53, 130.67 (2C), 129.07, 128.41 (2C), 127.11, 126.89, 126.78, 119.00, 113.09, 55.79 (2C), 55.57, 53.41 (2C), 46.38, 24.28. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>29</sub>N<sub>8</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 545.2083; found, 545.2124. Purity: 99.41%.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Procedure D for Synthesizing 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(3-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>18a</b>)</h3><div class="NLM_p"><b>10</b> (511 mg, 1.90 mmol), 2,4-difluoro-<i>N</i>-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide (1.01 g, 2.38 mmol), potassium carbonate (393 mg, 2.85 mmol), Pd(dppf)Cl<sub>2</sub>·DCM (77 mg, 0.10 mmol) were dissolved in 1,4-dioxane (10 mL) and H<sub>2</sub>O (2 mL). The reaction was purged by nitrogen three times and stirred under reflux at 110 °C for 2.5 h. The filtration was aided by diatomaceous earth, and the reaction liquid was concentrated and separated by silica gel column chromatography (PE/EA = 1:1). A white solid <b>16</b> (307 mg, 33%) was obtained. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.44 (s, 1H, NH), 9.32 (s, 1H), 8.37 (s, 1H), 8.30 (s, 1H), 7.93 (s, 1H), 7.91–7.79 (m, 3H), 7.59 (s, 1H), 7.25 (s, 1H), 4.41 (q, <i>J</i> = 7.2 Hz, 2H), 3.73 (s, 3H), 1.39 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.08 (dd, <i>J</i> = 254.3, 11.7 Hz), 159.76, 159.29 (dd, <i>J</i> = 257.5, 13.6 Hz), 157.53, 146.88, 142.12, 141.32, 133.12, 131.82 (d, <i>J</i> = 10.7 Hz), 127.37, 125.84, 124.89 (dd, <i>J</i> = 14.4, 3.7 Hz), 123.96, 119.96, 117.67, 115.60, 111.91 (dd, <i>J</i> = 14.7, 3.8 Hz), 105.80 (t, <i>J</i> = 26.1 Hz), 60.25, 54.84, 14.19.</div><div class="NLM_p"><b>16</b> (307 mg, 0.63 mmol) was dissolved in 95% EtOH (8 mL), and hydrazine hydrate (315 mg, 6.3 mmol) was added. The mixture was stirred under reflux at 50 °C for 13 h. After cooling to room temperature, more crystals were precipitated. Then it was filtered and the filter cake was rinsed with 95% EtOH (3 mL). The solid was dried to obtain white needle crystals <b>17</b> (200 mg, 67%). <b>17</b> (200 mg, 0.42 mmol) was dissolved in chloroform (10 mL). Six drops of acetic acid and 3-(trifluoromethyl)benzaldehyde (191 mg, 1.10 mmol) were added, and the mixture was stirred at 70 °C for 10 h under reflux. The reaction mixture was concentrated to give a white solid. The compound was dissolved in DCM (10 mL), and IBD (0.51 mmol) was added in an ice bath and allowed to react at room temperature for 12 h. The mixture was concentrated and purified by silica gel column chromatography (DCM/MeOH = 60:1). The white solid <b>18a</b> (61 mg) was obtained in a two-step yield of 23%. Mp = 134–135 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.47 (s, 1H, NH), 9.27 (s, 1H), 8.54 (s, 1H), 8.39–8.24 (m, 3H), 8.06–7.90 (m, 3H), 7.89–7.76 (m, 3H), 7.61 (t, <i>J</i> = 9.5 Hz, 1H), 7.30(t, <i>J</i> = 9.6 Hz, 1H), 3.73 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.14 (dd, <i>J</i> = 254.4, 11.8 Hz), 161.07, 159.30 (dd, <i>J</i> = 257.9, 13.5 Hz), 157.31 (d, <i>J</i> = 1.8 Hz), 146.52, 141.84, 138.32, 132.30, 131.99 (d, <i>J</i> = 10.7 Hz), 130.67, 130.36, 130.22, 129.89, 128.37, 126.98, 125.58, 124.79 (dd, <i>J</i> = 14.9, 4.0 Hz), 124.16, 123.91, 123.75, 122.80 (d, <i>J</i> = 3.7 Hz), 122.18, 120.13, 117.74, 111.96 (dd, <i>J</i> = 22.4, 3.4 Hz), 110.50, 105.89 (t, <i>J</i> = 26.3 Hz), 53.49. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>18</sub>N<sub>6</sub>O<sub>4</sub>F<sub>5</sub>S (M + H)<sup>+</sup> 629.1030; found, 629.1071. Purity: 97.53%.</div><div class="NLM_p last">Compounds <b>18b</b>–<b>e</b> were prepared by a procedure similar to that described for the synthesis of <b>18a</b>.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(<i>m</i>-tolyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>18b</b>)</h3><div class="NLM_p last">Mp = 229–231 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.49 (s, 1H, NH), 9.26 (s, 1H), 8.46 (s, 1H), 8.33 (s,1H), 7.97–7.85 (m, 3H), 7.85–7.77 (m, 3H), 7.61 (t, <i>J</i> = 9.6 Hz, 1H), 7.42 (t, <i>J</i> = 7.6 Hz, 1H), 7.37 (d, <i>J</i> = 7.3 Hz, 1H), 7.31 (t, <i>J</i> = 8.3 Hz, 1H), 3.73 (s, 3H), 2.36 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.14 (dd, <i>J</i> = 254.0, 11.4 Hz), 162.19, 159.30 (dd, <i>J</i> = 257.7, 13.5 Hz), 157.28, 156.78, 146.37, 141.82, 138.71, 137.75, 132.54, 132.26, 132.01 (d, <i>J</i> = 11.0 Hz), 129.08, 126.79, 126.67, 125.66, 124.78 (dd, <i>J</i> = 14.3, 3.5 Hz), 124.01, 123.78, 123.63, 122.65, 120.12, 117.67, 111.98 (dd, <i>J</i> = 22.3, 3.4 Hz), 110.71, 105.90 (t, <i>J</i> = 26.0 Hz), 53.50, 20.76. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>21</sub>N<sub>6</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 575.1313; found, 575.1332. Purity: 96.66%.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(thiophen-2-yl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>18c</b>)</h3><div class="NLM_p last">Mp = 224–228 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.26 (s, 1H), 8.39 (s, 1H), 8.32 (s, 1H), 7.98–7.91(m, 3H), 7.89–7.83 (m, 2H), 7.80 (d, <i>J</i> = 9.3 Hz, 1H), 7.61 (t, <i>J</i> = 9.7 Hz, 1H), 7.35–7.25 (m, 2H), 3.74 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.10 (dd, <i>J</i> = 254.6, 12.0 Hz), 159.29 (dd, <i>J</i> = 257.6, 13.5 Hz), 158.53, 157.28, 156.24, 146.38, 141.66, 137.64, 132.16, 132.04, 131.94, 131.59, 130.38, 128.56, 126.81, 125.60, 124.85 (dd, <i>J</i> = 14.3, 3.8 Hz), 124.07, 123.71 (d, <i>J</i> = 2.6 Hz), 120.27, 117.65, 111.92 (dd, <i>J</i> = 22.4, 3.4 Hz), 110.47, 105.85 (t, <i>J</i> = 26.2 Hz), 53.47. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>17</sub>N<sub>6</sub>O<sub>4</sub>F<sub>2</sub>S<sub>2</sub> (M + H)<sup>+</sup> 567.0721; found, 567.0732. Purity: 95.80%.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-(5-(3-(5-Ethyl-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide (<b>18d</b>)</h3><div class="NLM_p last">Mp = 205–208 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.49 (s, 1H), 8.29 (s, 1H), 8.20–8.09 (m, 2H), 7.85 (d, <i>J</i> = 9.3 Hz, 1H), 7.59 (d, <i>J</i> = 9.3 Hz, 1H), 7.29 (d, <i>J</i> = 8.2 Hz, 2H), 6.96 (t, <i>J</i> = 9.1 Hz, 1H), 4.00 (s, 3H), 3.03 (q, <i>J</i> = 7.6 Hz, 2H), 1.50 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.37 (dd, <i>J</i> = 258.9, 11.6 Hz), 166.31, 159.76 (dd, <i>J</i> = 258.7, 13.0 Hz), 157.53, 154.01, 146.99, 139.78, 137.28, 133.33 (d, <i>J</i> = 11.0 Hz), 126.84, 126.57, 125.20, 124.99, 124.83, 122.85 (dd, <i>J</i> = 13.6, 4.0 Hz), 121.07, 118.05, 112.63 (dd, <i>J</i> = 22.3, 3.7 Hz), 111.46, 105.82 (t, <i>J</i> = 26.8 Hz), 54.26, 19.00, 10.93. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>19</sub>N<sub>6</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 513.1157; found, 513.1187. Purity: 96.48%.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(3-(5-methyl-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>18e</b>)</h3><div class="NLM_p last">Mp = 228–231 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.47 (s, 1H), 8.28 (s, 1H), 8.21–8.07 (m, 2H), 7.98 (s, 1H), 7.85 (d, <i>J</i> = 9.3 Hz, 1H), 7.58 (d, <i>J</i> = 9.3 Hz, 1H), 7.28 (t, <i>J</i> = 8.5 Hz, 1H), 6.96 (t, <i>J</i> = 8.8 Hz, 1H), 4.00 (s, 3H), 2.69 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.39 (dd, <i>J</i> = 258.9, 11.5 Hz), 162.15, 159.76 (dd, <i>J</i> = 258.8, 13.0 Hz), 157.69, 153.95, 147.03, 139.76, 137.33, 133.33 (d, <i>J</i> = 11.0 Hz), 126.88, 126.57, 125.25, 125.01, 124.70, 122.81 (dd, <i>J</i> = 13.6, 3.7 Hz), 121.07, 118.08, 112.64 (dd, <i>J</i> = 22.2, 3.7 Hz), 111.37, 105.83 (t, <i>J</i> = 26.5 Hz), 54.28, 10.92. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>17</sub>N<sub>6</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 499.1000; found, 499.0999. Purity: 96.98%.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Procedure E for Synthesizing 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(2-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>22</b>)</h3><div class="NLM_p">2-Amino-5-bromopyridine (401 mg, 2.32 mmol) was dissolved in 20 mL of 95% EtOH, and ethyl 3-bromopyruvate (1.81 g, 4.64 mmol) was added. The reaction was stirred under reflux at 80 °C for 14 h. The reaction mixture was concentrated, diluted with DCM (20 mL), and washed by H<sub>2</sub>O (20 mL) twice. The organic phase was extracted and dried over Na<sub>2</sub>SO<sub>4</sub> to give a yellow solid <b>19</b> (331 mg, 53%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.33 (s, 1H), 8.17 (s, 1H), 7.58 (d, <i>J</i> = 9.6 Hz, 1H), 7.30 (d, <i>J</i> = 9.6 Hz, 1H), 4.46 (q, <i>J</i> = 7.1 Hz, 2H), 1.44 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 162.84, 143.60, 137.52, 129.78, 126.14, 119.62, 116.85, 108.74, 61.30, 14.38.</div><div class="NLM_p"><b>19</b> (331 mg, 1.23 mmol) was dissolved in 95% EtOH (10 mL), and hydrazine hydrate (1.22 g, 24.6 mmol) was added. The mixture was stirred under reflux at 100 °C for 13 h. After cooling to room temperature, more crystals were precipitated. Then it was filtered, and the filter cake was rinsed with 95% EtOH (5 mL). The solid was dried to obtain white needle crystals (257 mg, 82%). The compound (257 mg, 1.06 mmol) was dissolved in chloroform (10 mL). Two drops of acetic acid and acrolein (154 mg, 2.76 mmol) were added, and the mixture was stirred at 70 °C for 10 h under reflux. The reaction mixture was concentrated to give a white solid. The compound was dissolved in DCM (10 mL), and IBD (410 mg, 1.27 mmol) was added in an ice bath and reacted at room temperature for 10 h. The reaction mixture was concentrated and separated by silica gel column chromatography. Compound <b>20</b> (139 mg) was obtained in a yield of 45% by two steps. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (s, 1H), 8.33 (s, 1H), 7.62 (d, <i>J</i> = 9.6 Hz, 1H), 7.36 (d, <i>J</i> = 9.6 Hz, 1H), 6.81 (dd, <i>J</i> = 17.7, 11.3 Hz, 1H), 6.48 (d, <i>J</i> = 17.7 Hz, 1H), 5.89 (d, <i>J</i> = 11.3 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 163.78, 160.13, 144.37, 131.37, 130.05, 126.10, 125.72, 119.61, 119.03, 113.66, 108.90.</div><div class="NLM_p">Compound <b>20</b> (139 mg, 0.48 mmol) was dissolved in DCM (10 mL). <i>N</i>-Methylpiperazine (53 mg, 0.53 mmol) and DBU (81 mg, 0.53 mmol) were added, and the mixture was stirred at room temperature for 12 h. The reaction mixture was concentrated and purified by silica gel chromatography (DCM/MeOH = 50:1) to give <b>21</b> (129 mg, 69%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (s, 1H), 8.29 (s, 1H), 7.60 (d, <i>J</i> = 9.6 Hz, 1H), 7.36 (d, <i>J</i> = 9.6 Hz, 1H), 3.17 (t, <i>J</i> = 7.6 Hz, 2H), 2.94 (t, <i>J</i> = 7.6 Hz, 2H), 2.59 (s, 4H), 2.45 (s, 4H), 2.28 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 165.71, 160.66, 144.24, 131.56, 129.94, 126.10, 118.97, 113.21, 108.78, 54.95 (2C), 54.60, 52.73 (2C), 45.96, 23.51.</div><div class="NLM_p last">Compound <b>21</b> (129 mg, 0.33 mmol), 2,4-difluoro-<i>N</i>-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide (176 mg, 0.41 mmol), potassium carbonate (68 mg, 0.50 mmol), Pd(dppf)Cl<sub>2</sub>·DCM (25 mg, 0.03 mmol) were dissolved in 1,4-dioxane (10 mL) and H<sub>2</sub>O (2 mL). The mixture was stirred under nitrogen and refluxed at 110 °C for 3 h. The mixture was filtered by diatomaceous earth, then it was concentrated and purified by silica gel column chromatography (DCM/MeOH = 50:1). A white solid <b>22</b> (151 mg, 75%) was obtained. Mp = 255–260 °C. <sup>1</sup>H NMR (400 MHz, 50% methanol-<i>d</i><sub>4</sub> + 50% CDCl<sub>3</sub>) δ 8.62 (s, 1H), 8.53 (s, 1H), 8.17 (s, 1H), 8.01 (s, 1H), 7.94–7.83 (m, 1H), 7.76 (d, <i>J</i> = 9.3 Hz, 1H), 7.58 (d, <i>J</i> = 9.1 Hz, 1H), 7.12–6.96 (m, 2H), 3.90 (s, 3H), 3.23 (t, <i>J</i> = 7.3 Hz, 2H), 2.98 (t, <i>J</i> = 7.3 Hz, 2H), 2.86–2.40 (m, 8H), 2.32 (s, 3H). <sup>13</sup>C NMR (101 MHz, 50% methanol-<i>d</i><sub>4</sub> + 50% CDCl<sub>3</sub>) δ 167.44 (dd, <i>J</i> = 257.4, 11.5 Hz), 167.11, 162.40, 161.38 (dd, <i>J</i> = 259.7, 11.6 Hz), 157.74, 146.55, 142.07, 133.59 (d, <i>J</i> = 10.7 Hz), 131.54, 131.12, 128.76, 127.60, 126.25, 125.58 (dd, <i>J</i> = 14.1, 3.6 Hz), 125.15, 122.52, 119.07, 115.94, 113.00 (dd, <i>J</i> = 22.3, 3.5 Hz), 106.87 (t, <i>J</i> = 25.7 Hz), 55.83 (2C), 55.58, 55.08, 53.49 (2C), 46.58, 24.54. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>29</sub>N<sub>8</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 611.2001; found, 611.2036. Purity: 99.40%.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Procedure F for Synthesizing 2,4-Difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-7-yl)pyridin-3-yl)benzenesulfonamide (<b>26</b>)</h3><div class="NLM_p">2-Amino-4-bromopyridine (332 mg, 1.92 mmol) was dissolved in 20 mL of 95% EtOH, and 2-chloro-3-oxopropionic acid ethyl ester (732 mg, 3.84 mmol) was added. The reaction was stirred under reflux at 90 °C for 12 h. The reaction mixture was concentrated, diluted with DCM (20 mL), and washed by H<sub>2</sub>O (20 mL) twice. The organic phase was extracted and dried over Na<sub>2</sub>SO<sub>4</sub> to give <b>23</b> (284 mg, 55%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.30 (d, <i>J</i> = 7.3 Hz, 1H), 8.27 (s, 1H), 7.97 (s, 1H), 7.22 (d, <i>J</i> = 7.2 Hz, 1H), 6.81 (dd, <i>J</i> = 17.7, 11.3 Hz, 1H), 6.39 (d, <i>J</i> = 17.7 Hz, 1H), 5.92 (d, <i>J</i> = 11.3 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 162.14, 156.72, 148.17, 137.96, 128.05, 125.58, 121.65, 120.31, 119.40, 118.42, 111.07.</div><div class="NLM_p"><b>23</b> (284 mg, 1.06 mmol) was dissolved in 95% EtOH (10 mL), and hydrazine hydrate (528 mg, 10.6 mmol) was added. The mixture was stirred under reflux at 100 °C for 12 h. After cooling to room temperature, more crystals were precipitated. Then it was filtered, and the filter cake was rinsed with 95% EtOH (5 mL). The solid was dried to obtain white needle crystals (257 mg, 76%). The compound (207 mg, 0.81 mmol) was dissolved in chloroform (10 mL). Two drops of acetic acid and acrolein (91 mg, 1.62 mmol) were added, and the mixture was stirred at 70 °C for 10 h under reflux. The reaction mixture was concentrated to give a white solid. The compound was dissolved in DCM (10 mL), and IBD (287 mg, 0.89 mmol) was added in an ice bath and reacted at room temperature for 10 h. The reaction mixture was concentrated and separated by silica gel column chromatography. The solid <b>24</b> (120 mg) was obtained in a yield of 51% by two steps. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.30 (d, <i>J</i> = 7.3 Hz, 1H), 8.27 (s, 1H), 7.97 (s, 1H), 7.22 (d, <i>J</i> = 7.2 Hz, 1H), 6.81 (dd, <i>J</i> = 17.7, 11.3 Hz, 1H), 6.39 (d, <i>J</i> = 17.7 Hz, 1H), 5.92 (d, <i>J</i> = 11.3 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 162.14, 156.72, 148.17, 137.96, 128.05, 125.58, 121.65, 120.31, 119.40, 118.42, 111.07.</div><div class="NLM_p">Compound <b>24</b> (120 mg, 0.41 mmol) was dissolved in DCM (10 mL). <i>N</i>-Methylpiperazine (45 mg, 0.45 mmol) and DBU (68 mg 0.45 mmol) were added, and the mixture was stirred at room temperature for 12 h. The reaction mixture was concentrated and purified by silica gel chromatography (DCM/MeOH = 50:1) to give <b>25</b> (115 mg, 72%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.28 (d, <i>J</i> = 7.3 Hz, 1H), 8.21 (s, 1H), 7.96 (s, 1H), 7.21 (d, <i>J</i> = 7.2 Hz, 1H), 3.16 (t, <i>J</i> = 7.4 Hz, 2H), 2.92 (t, <i>J</i> = 7.4 Hz, 2H), 2.80–2.33 (m, 8H), 2.28 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 164.16, 157.29, 147.95, 137.44, 127.98, 121.36, 120.22, 118.24, 111.29, 54.96 (2C), 54.61, 52.79 (2C), 45.99, 23.38.</div><div class="NLM_p last">Compound <b>25</b> (115 mg, 0.30 mmol), 2,4-difluoro-<i>N</i>-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide (160 mg, 0.38 mmol), potassium carbonate (62 mg, 0.45 mmol), Pd(dppf)Cl<sub>2</sub>·DCM (25 mg, 0.03 mmol) were dissolved in 1,4-dioxane (10 mL) and H<sub>2</sub>O (2 mL). The mixture was stirred under nitrogen and refluxed at 110 °C for 3 h. The mixture was filtered by diatomaceous earth, then it was concentrated and purified by silica gel column chromatography (DCM/MeOH = 50:1). A white solid <b>26</b> (119 mg, 75%) was obtained. Mp = 209–210 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.45 (d, <i>J</i> = 7.2 Hz, 1H), 8.29 (s, 1H), 8.22 (d, <i>J</i> = 2.3 Hz, 1H), 8.06 (d, <i>J</i> = 2.2 Hz, 1H), 7.97–7.89 (m, 1H), 7.87 (s, 1H), 7.30–7.25 (m, 1H), 7.01–6.92 (m, 2H), 3.98 (s, 3H), 3.18 (t, <i>J</i> = 7.4 Hz, 2H), 2.94 (t, <i>J</i> = 7.4 Hz,2H), 2.81–2.37 (m, 8H), 2.33 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.16 (dd, <i>J</i> = 258.8, 11.7 Hz), 164.04, 159.83 (dd, <i>J</i> = 258.9, 12.9 Hz), 157.54, 154.95, 148.16, 140.32, 137.75, 136.29, 132.47 (d, <i>J</i> = 10.5 Hz), 128.06, 127.86, 126.15, 123.53 (dd, <i>J</i> = 13.7, 3.8 Hz), 121.10, 114.30, 113.43, 111.97 (dd, <i>J</i> = 22.0, 3.7 Hz), 110.93, 105.79 (d, <i>J</i> = 25.3 Hz), 54.92 (2C), 54.59, 54.27, 52.57 (2C), 45.84, 23.41. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>29</sub>N<sub>8</sub>O<sub>4</sub>F<sub>2</sub>S (M + H)<sup>+</sup> 611.2001; found, 611.2036. Purity: 98.69%.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Enzymatic Inhibitory Activity Assay</h3><div class="NLM_p">The <i>in vitro</i> inhibition assays of all final compounds against PI3K and mTOR were performed by Shanghai ChemPartner Co., Ltd. (China). The inhibitory activity assay of PI3Kα was performed with the Kinase-Glo assay (Promega, catalog no. V3771), while those of PI3Kβ, -γ, and -δ were performed with the ADP-Glo assay (Promega, catalog no. V9102/3). Briefly, compounds were serially diluted to certain concentrations. Then, the compound solution, PI3K enzymes (purchased from Invitrogen), PIP<sub>2</sub> substrate, and ATP were diluted in the kinase buffer, which was then added to a 384-well plate. The plate was incubated in a dark place at room temperature for 1 h. After that, Kinase-Glo or ADP-Glo reagents were added to stop the kinase reaction. After the addition of the kinase detection reagent, the data were collected in a PerkinElmer Envision plate reader.</div><div class="NLM_p last">The measurement of inhibitory activities of compound <b>15a</b> against mTOR was conducted with the LANCE Ultra assay. Briefly, the compound solution, the mTOR protein (Millipore, catalog no. 14-770), the ULight-4E-BP1 (Thr37/46) peptide substrate (PE, catalog no. TRF0128-M), and ATP were diluted in the kinase buffer. Then the solution was transferred to a 384-well plate and incubated at room temperature for 30 min. Following the addition of the LANCE detection buffer containing EDTA and Eu-antiphospho-4E-BP1 (Thr37/46) antibody (PE, catalog no. TRF0216-M), the plate was allowed to equilibrate for 1 h at room temperature. Then the signal was detected in a PerkinElmer Envision plate reader.</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Cell Viability Assay</h3><div class="NLM_p last">HCT116, HT-29, MCF-7, PC-3, and LOVO cell lines were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured at 37 °C with 5% CO<sub>2</sub>, using DMEM or McCoy’s 5A media (Basal Media Technologies Co., Ltd., Shanghai) with 10% (v/v) fetal bovine serum (BIOIND) and 1% (v/v) penicillin–streptomycin (Basal Media Technologies Co., Ltd., Shanghai). The <i>in vitro</i> inhibitory effect was measured using CCK-8 assay. Briefly, different kinds of cells were seeded in a 96-well plate at 2500 cells per well. After 24 h culture, 100 μLof medium containing one tested compound at certain concentration was added into each well. Seventy-two hours later, the old medium was replaced with fresh medium containing 10% CCK-8, and the cells were incubated (37 °C, 5% CO<sub>2</sub>) for another 2–4 h. The optical density at 450 nm of each well was read using a microplate reader (Molecular Devices). IC<sub>50</sub> values were calculated using GraphPad Prism 7.0 software.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Western Blot Analysis</h3><div class="NLM_p last">Cells were treated with <b>15a</b> at the indicated concentrations in 60 mm dishes for 24 h at 37 °C. Then the cells were collected in 1.5 mL centrifuge tubes and lysed with RIPA buffer (CWBIO) containing PMSF (1 mM) and protease inhibitor Cocktail (Roche). Protein concentration was determined by the BCA protein assay kit (Kingmorn). The protein samples (20 μg) were subjected to SDS–PAGE electrophoresis and then were transferred to 0.45 μm PVDF membranes (Millipore). The membranes were blocked with 5% nonfat milk in TBST and incubated with primary antibody overnight at 4 °C. After washing 3 times, the membrane was treated with secondary antibody (MULTI SCIENCES) at room temperature for 2 h. The target bands were visualized using an enhanced ECL detection kit with AI600 (GE, America) chemiluminescence system. The primary antibodies used are anti-AKT (1/2000 dilution, CST no. 4691T), anti-p-AKT ser<sup>473</sup> (1/2000 dilution, CST no. 4060T), anti-p70S6K (1/2000 dilution, Affinity no. AF6226), anti-p-p70S6K Thr<sup>389/412</sup> (1/2000 dilution, Affinity no. AF3228), anti-GAPDH (1/5000, Proteintech no. 60004-1-lg ), and anti-β-actin (1/5000 dilution, Proteintech no. 66009-1-lg).</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Molecular Docking</h3><div class="NLM_p last">The crystal structures of PI3Kα (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JPS">4JPS</a>) and mTOR kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>) were obtained from the Protein Data Bank. Molecular docking was performed by the AutoDock 4.2 software. All receptors and ligands were prepared by using the AutoDockTools module. For receptors, all water molecules except those that bridge the ligand and the residues were abandoned, and polar hydrogen atoms and partial charges were added. For ligands, the torsion tree was set to produce low-energy 3D structures. The center of the grid box was confined in the AutoGrid. The Lamarck genetic algorithm was used to search conformation using default parameters in Docking menu. The binding mode with the highest binding score was used in the analysis.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Pharmacokinetic Assay</h3><div class="NLM_p last">Male SD rats (about 220 g, <i>N</i> = 3 per group, JOINN Suzhou) were used in the PK study of compound <b>15a</b>. The formulation for oral administration was 0.5% sodium carboxymethyl cellulose (CMC) suspension (5 mg/kg) and that for intravenous administration was in saline containing 5% DMSO and 5% Solutol (1 mg/kg). The time points for blood sample collection were 0.25, 0.5, 1, 2, 4, 8, and 24 h after dosing for oral administration and 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h for intravenous injection. Plasma was collected by centrifugation at 5000 rpm for 10 min at 4 °C and analyzed by LC–MS/MS (AB SCIEX; API 4000 QTrap). The pharmacokinetic parameters were analyzed by noncompartmental methods using WinNonlin Professional version 6.3 (Pharsight, USA).</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> <i>In Vivo</i> Antitumor Assay</h3><div class="NLM_p last">HCT116 or HT-29 cells were cultured, collected during the logarithmic phase, and washed once with cold PBS. Female BALB/c nude mice (6–8 weeks old, JIHUI, Shanghai, China) were injected subcutaneously with 4 × 10<sup>6</sup> HCT116 cells or 5 × 10<sup>6</sup> HT-29 cells suspended in 0.1 mL of PBS. When the tumor grew to about 100 mm<sup>3</sup>, the mice were randomly divided into 3 groups (6 mice for each group) for the HCT116 xenograft model and 4 groups for the HT-29 xenograft model (7 mice for each group). For the vehicle group, mice were orally administered 5% DMSO/45% PEG400/50% ddH<sub>2</sub>O. For the positive control group, mice were ip injected with 15 mg/kg copanlisib suspended in 5% mannitol. For the <b>15a</b> group, the mice were treated orally with 15 mg/kg <b>15a</b> dissolved in the same solvent as vehicle group for the HCT116 xenograft model. As for HT-29 xenograft model, mice in the <b>15a</b> group were orally treated at the dose of 10 mg/kg and 20 mg/kg <b>15a</b>, respectively. The body weight and tumor volume were measured every 2 days. The tumor volume was determined with vernier calipers and calculated as this formula: <i>A</i><i>B</i><sup>2</sup>/2 (<i>A</i>, long diameter; <i>B</i>, short diameter). When the mice were sacrificed, the tumors were stripped and weighted. The tumor growth inhibition (TGI) was calculated as TGI = (1 – TW<sub>treatment</sub>/TW<sub>vehicle</sub>) × 100%, in which TW<sub>treatment</sub> is tumor weight of the treatment groups, while TW<sub>vehicle</sub> is the tumor weight of the vehicle group when the mice were sacrificed. The statistical analysis was performed with GraphPad Prism 8.0 software, and the significance level was evaluated with one-way ANOVA model.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Immunohistochemistry</h3><div class="NLM_p last">The removed tumors of vehicle, <b>15a</b>, and copanlisib-treated HCT116 xenograft mice were subject to paraffin-sectioning. Then the sections were stained using HE staining solution (G1003, ServiceBio, China) or immunostained with p-AKT473 antibody (CST no. 4060T) and Ki-67 antibody (CST no. 9449) according to the manufacturer’s protocol.</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Ethical Statement</h3><div class="NLM_p last">We state that all experiments with live subjects were performed in compliance with the Laboratory Animal Management Regulation of the People’s Republic of China and the three Rs (replacement, reduction, and refinement) strategy of William Russell and Rex Burch. East China Normal University has approved the experiments.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01736" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20320" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20320" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01736?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01736</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Specific data of kinase profiling of compound <b>15a</b> (Tables S1 and S2); liver injury in animal studies (Figure S1); NMR spectra and HPLC chromatograms of synthesized compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01736/suppl_file/jm9b01736_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01736/suppl_file/jm9b01736_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01736/suppl_file/jm9b01736_si_001.pdf">jm9b01736_si_001.pdf (7.86 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01736/suppl_file/jm9b01736_si_002.csv">jm9b01736_si_002.csv (4.54 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">We will release the atomic coordinates for <b>15a</b>/PI3Kα and <b>15a</b>/mTOR and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b01736" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31704" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31704" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suzhen Dong</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a7d4ddc3c8c9c0e7c5d5c6cec989c2c4c9d289c2c3d289c4c9"><span class="__cf_email__" data-cfemail="621118060d0c05220010030b0c4c07010c174c0706174c010c">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingliang Ma</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Key
Laboratory of Brain Functional Genomics, Ministry of Education, East China Normal University, Shanghai 200062, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7591-6748" title="Orcid link">http://orcid.org/0000-0002-7591-6748</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a1cccdccc0e1c3d3c0c8cf8fc4c2cfd48fc4c5d48fc2cf"><span class="__cf_email__" data-cfemail="026f6e6f63426070636b6c2c67616c772c6766772c616c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ya’nan Yu</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuqiao Han</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fupo Zhang</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenmei Gao</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tong Zhu</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.Y. and Y.H. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26323" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26323" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The work was supported by the National Natural Science Foundation of China (Grant 21572067).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-kinase</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">PIP<sub>2</sub></td><td class="NLM_def"><p class="first last">phosphatidylinositol 4,5-diphosphate</p></td></tr><tr><td class="NLM_term">PIP<sub>3</sub></td><td class="NLM_def"><p class="first last">phosphatidylinositol 3,4,5-triphosphate</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B (PKB)</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">nM</td><td class="NLM_def"><p class="first last">nanomolar</p></td></tr><tr><td class="NLM_term">μM</td><td class="NLM_def"><p class="first last">micromolar</p></td></tr><tr><td class="NLM_term">mL</td><td class="NLM_def"><p class="first last">milliliter</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">CuTC</td><td class="NLM_def"><p class="first last">copper(I) thiophene-2-carboxylate</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetrabutylammonium fluoride</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">IBD</td><td class="NLM_def"><p class="first last">iodosobenzenediacetate</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicyclo[5.4.0]undec-7-ene</p></td></tr><tr><td class="NLM_term">CCK-8</td><td class="NLM_def"><p class="first last">cell counting kit 8</p></td></tr><tr><td class="NLM_term">Val</td><td class="NLM_def"><p class="first last">valine</p></td></tr><tr><td class="NLM_term">Tyr</td><td class="NLM_def"><p class="first last">tyrosine</p></td></tr><tr><td class="NLM_term">Asp</td><td class="NLM_def"><p class="first last">aspartic acid</p></td></tr><tr><td class="NLM_term">Lys</td><td class="NLM_def"><p class="first last">lysine</p></td></tr><tr><td class="NLM_term">Asn</td><td class="NLM_def"><p class="first last">asparagine</p></td></tr><tr><td class="NLM_term">Trp</td><td class="NLM_def"><p class="first last">tryptophan</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">PE</td><td class="NLM_def"><p class="first last">petroleum ether</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i73">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11052" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11052" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 23 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span> <span> </span><span class="NLM_article-title">PI3K and Cancer: Lessons, Challenges and Opportunities</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&author=D.+A.+Frumanauthor=C.+Rommel&title=PI3K+and+Cancer%3A+Lessons%2C+Challenges+and+Opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0lgB9ZKgl_J0BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520Cancer%253A%2520Lessons%252C%2520Challenges%2520and%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+Regulation+of+Akt%2FPKB+by+the+Rictor-mTOR+Complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0ljMvf3DzxbSog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520Regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520Rictor-mTOR%2520Complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vivanco, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">The Phosphatidylinositol 3-kinase AKT Pathway in Human Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1038/nrc839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+Phosphatidylinositol+3-kinase+AKT+Pathway+in+Human+Cancer&doi=10.1038%2Fnrc839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0ljMvf3DzxbSog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520Phosphatidylinositol%25203-kinase%2520AKT%2520Pathway%2520in%2520Human%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D489%26epage%3D501%26doi%3D10.1038%2Fnrc839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span> <span> </span><span class="NLM_article-title">PI3K-Akt Pathway: Its Functions and Alterations in Human Cancer</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1023/B:APPT.0000045801.15585.dd</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1023%2FB%3AAPPT.0000045801.15585.dd" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=15505410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVKqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=667-676&author=M.+Osakiauthor=M.+Oshimuraauthor=H.+Ito&title=PI3K-Akt+Pathway%3A+Its+Functions+and+Alterations+in+Human+Cancer&doi=10.1023%2FB%3AAPPT.0000045801.15585.dd"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K-Akt pathway: Its functions and alterations in human cancer</span></div><div class="casAuthors">Osaki, M.; Oshimura, M.; Ito, H.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">667-676</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol-3-kinase (PI3K) is a lipid kinase and generates phosphatidylinositol-3,4,5-trisphosphate (PI(3, 4, 5)P3).  PI(3, 4, 5)P3 is a second messenger essential for the translocation of Akt to the plasma membrane where it is phosphorylated and activated by phosphoinositide-dependent kinase (PDK) 1 and PDK2.  Activation of Akt plays a pivotal role in fundamental cellular functions such as cell proliferation and survival by phosphorylating a variety of substrates.  In recent years, it was reported that alterations to the PI3K-Akt signaling pathway are frequent in human cancer.  Constitutive activation of the PI3K-Akt pathway occurs due to amplification of the PIK3C gene encoding PI3K or the Akt gene, or as a result of mutations in components of the pathway, for example PTEN (phosphatase and tensin homolog deleted on chromosome 10), which inhibit the activation of Akt.  Several small mols. designed to specifically target PI3K-Akt were developed, and induced cell cycle arrest or apoptosis in human cancer cells in vitro and in vivo.  Moreover, the combination of an inhibitor with various cytotoxic agents enhances the anti-tumor efficacy.  Therefore, specific inhibition of the activation of Akt may be a valid approach to treating human malignancies and overcoming the resistance of cancer cells to radiation or chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpetriT7oBnUrVg90H21EOLACvtfcHk0ljMvf3DzxbSog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVKqu70%253D&md5=9bb169ad851d289623247a49b3e63ffd</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1023%2FB%3AAPPT.0000045801.15585.dd&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253AAPPT.0000045801.15585.dd%26sid%3Dliteratum%253Aachs%26aulast%3DOsaki%26aufirst%3DM.%26aulast%3DOshimura%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DH.%26atitle%3DPI3K-Akt%2520Pathway%253A%2520Its%2520Functions%2520and%2520Alterations%2520in%2520Human%2520Cancer%26jtitle%3DApoptosis%26date%3D2004%26volume%3D9%26spage%3D667%26epage%3D676%26doi%3D10.1023%2FB%3AAPPT.0000045801.15585.dd" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuzugullu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">PI3K in Cancer: Divergent Roles of Isoforms, Modes of Activation and Therapeutic Targeting</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1038/nrc3860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1038%2Fnrc3860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=25533673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=7-24&author=L.+M.+Thorpeauthor=H.+Yuzugulluauthor=J.+J.+Zhao&title=PI3K+in+Cancer%3A+Divergent+Roles+of+Isoforms%2C+Modes+of+Activation+and+Therapeutic+Targeting&doi=10.1038%2Fnrc3860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting</span></div><div class="casAuthors">Thorpe, Lauren M.; Yuzugullu, Haluk; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-24</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular signalling in response to extracellular stimuli.  Hyperactivation of PI3K signalling cascades is one of the most common events in human cancers.  In this Review, we discuss recent advances in our knowledge of the roles of specific PI3K isoforms in normal and oncogenic signalling, the different ways in which PI3K can be upregulated, and the current state and future potential of targeting this pathway in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxh6fOPe86x7Vg90H21EOLACvtfcHk0ljMvf3DzxbSog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKltb3N&md5=0b609a62c2ec9fcc6efae437d2ed7a24</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc3860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3860%26sid%3Dliteratum%253Aachs%26aulast%3DThorpe%26aufirst%3DL.%2BM.%26aulast%3DYuzugullu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DPI3K%2520in%2520Cancer%253A%2520Divergent%2520Roles%2520of%2520Isoforms%252C%2520Modes%2520of%2520Activation%2520and%2520Therapeutic%2520Targeting%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D7%26epage%3D24%26doi%3D10.1038%2Fnrc3860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucherlapati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadjipanayis, A.</span></span> <span> </span><span class="NLM_article-title">A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">820</span>– <span class="NLM_lpage">832</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2017.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1016%2Fj.ccell.2017.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=28528867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVCntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=820-832&author=Y.+Zhangauthor=K.+S.+Ngauthor=M.+Kucherlapatiauthor=F.+Chenauthor=Y.+Liuauthor=Y.+H.+Tsangauthor=G.+D.+Velascoauthor=J.+J.+Kangauthor=R.+Akbaniauthor=A.+Hadjipanayis&title=A+Pan-Cancer+Proteogenomic+Atlas+of+PI3K%2FAKT%2FmTOR+Pathway+Alterations&doi=10.1016%2Fj.ccell.2017.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations</span></div><div class="casAuthors">Zhang, Yiqun; Kwok-Shing Ng, Patrick; Kucherlapati, Melanie; Chen, Fengju; Liu, Yuexin; Tsang, Yiu Huen; de Velasco, Guillermo; Jeong, Kang Jin; Akbani, Rehan; Hadjipanayis, Angela; Pantazi, Angeliki; Bristow, Christopher A.; Lee, Eunjung; Mahadeshwar, Harshad S.; Tang, Jiabin; Zhang, Jianhua; Yang, Lixing; Seth, Sahil; Lee, Semin; Ren, Xiaojia; Song, Xingzhi; Sun, Huandong; Seidman, Jonathan; Luquette, Lovelace J.; Xi, Ruibin; Chin, Lynda; Protopopov, Alexei; Westbrook, Thomas F.; Shelley, Carl Simon; Choueiri, Toni K.; Ittmann, Michael; Van Waes, Carter; Weinstein, John N.; Liang, Han; Henske, Elizabeth P.; Godwin, Andrew K.; Park, Peter J.; Kucherlapati, Raju; Scott, Kenneth L.; Mills, Gordon B.; Kwiatkowski, David J.; Creighton, Chad J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">820-832.e3</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Mol. alterations involving the PI3K/AKT/mTOR pathway (including mutation, copy no., protein, or RNA) were examd. across 11,219 human cancers representing 32 major types.  Within specific mutated genes, frequency, mutation hotspot residues, in silico predictions, and functional assays were all informative in distinguishing the subset of genetic variants more likely to have functional relevance.  Multiple oncogenic pathways including PI3K/AKT/mTOR converged on similar sets of downstream transcriptional targets.  In addn. to mutation, structural variations and partial copy losses involving PTEN and STK11 showed evidence for having functional relevance.  A substantial fraction of cancers showed high mTOR pathway activity without an assocd. canonical genetic or genomic alteration, including cancers harboring IDH1 or VHL mutations, suggesting multiple mechanisms for pathway activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9-7y_MBe6ErVg90H21EOLACvtfcHk0ljvyr18rIkygw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVCntLw%253D&md5=9e1d33679611a9ad57a7c3a815901d96</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2017.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2017.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DNg%26aufirst%3DK.%2BS.%26aulast%3DKucherlapati%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTsang%26aufirst%3DY.%2BH.%26aulast%3DVelasco%26aufirst%3DG.%2BD.%26aulast%3DKang%26aufirst%3DJ.%2BJ.%26aulast%3DAkbani%26aufirst%3DR.%26aulast%3DHadjipanayis%26aufirst%3DA.%26atitle%3DA%2520Pan-Cancer%2520Proteogenomic%2520Atlas%2520of%2520PI3K%252FAKT%252FmTOR%2520Pathway%2520Alterations%26jtitle%3DCancer%2520Cell%26date%3D2017%26volume%3D31%26spage%3D820%26epage%3D832%26doi%3D10.1016%2Fj.ccell.2017.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Q.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1500</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1158%2F0008-5472.CAN-05-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=16452206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1500-1508&author=K.+E.+O%E2%80%99Reillyauthor=F.+Rojoauthor=Q.-B.+Sheauthor=D.+Solitauthor=G.+B.+Millsauthor=D.+Smithauthor=H.+Laneauthor=F.+Hofmannauthor=D.+J.+Hicklinauthor=D.+L.+Ludwigauthor=J.+Baselgaauthor=N.+Rosen&title=mTOR+Inhibition+Induces+Upstream+Receptor+Tyrosine+Kinase+Signaling+and+Activates+Akt&doi=10.1158%2F0008-5472.CAN-05-2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span></div><div class="casAuthors">O'Reilly, Kathryn E.; Rojo, Fredi; She, Qing-Bai; Solit, David; Mills, Gordon B.; Smith, Debra; Lane, Heidi; Hofmann, Francesco; Hicklin, Daniel J.; Ludwig, Dale L.; Baselga, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1500-1508</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway.  In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.  Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity.  We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin deriv., RAD001.  IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR.  In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium.  The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation.  Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIDQUdQ-jbi7Vg90H21EOLACvtfcHk0ljvyr18rIkygw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D&md5=758cd9999dc156bf498edf32174fc2e7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2925%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DK.%2BE.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DShe%26aufirst%3DQ.-B.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DmTOR%2520Inhibition%2520Induces%2520Upstream%2520Receptor%2520Tyrosine%2520Kinase%2520Signaling%2520and%2520Activates%2520Akt%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1500%26epage%3D1508%26doi%3D10.1158%2F0008-5472.CAN-05-2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gulati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, G.</span></span> <span> </span><span class="NLM_article-title">Nutrient Sensing in the mTOR/S6K1 Signalling Pathway</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1042/BST0350236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1042%2FBST0350236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=17371247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1WrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=236-238&author=P.+Gulatiauthor=G.+Thomas&title=Nutrient+Sensing+in+the+mTOR%2FS6K1+Signalling+Pathway&doi=10.1042%2FBST0350236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Nutrient sensing in the mTOR/S6K1 signalling pathway</span></div><div class="casAuthors">Gulati, P.; Thomas, G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-238</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Nutrient overload induces constitutive S6K1 (S6 kinase 1) activation, which leads to insulin resistance by suppressing insulin-induced class I PI3K (phosphoinositide 3-kinase) signaling.  This finding gave rise to the question of the mechanism by which nutrients, such as AAs (amino acids), enter the mTOR (mammalian target of rapamycin)/S6K1 signaling pathway.  Counter to the prevailing view, our recent studies have shown that the AA input into the mTOR/S6K1 signaling pathway is not mediated by the tumor suppressor TSC1 (tuberous sclerosis complex 1)/TSC2 or its target, the proto-oncogene Rheb (Ras homolog enriched in brain).  Instead, we found that the AA input was mediated by class 3 PI3K, or hVps34 (human vacuolar protein sorting 34).  In brief, ectopic expression of hVps34 drives S6K1 activation, but only in the presence of AAs, and this effect is blocked by small interfering RNAs directed against hVps34.  Moreover, stimulation of cells with AAs increases hVps34 activity, as indicated by the prodn. of PI3P (phosphatidylinositol 3-phosphate).  PI3P mediates the recruitment of proteins contg. FYVE (Fab1p, YOTB, Vac1p, and EEA1) or PX (Phox homol.) domains to endosomal membranes, with PI3P-rich micro-domains acting as signaling platforms.  Addnl. evidence indicating hVps34 as the mediator of AA input to S6K1 came from expts. in which S6K1 activation was attenuated by ectopic expression of a cDNA contg. 2 FYVE domains, which bind to PI3P, preventing binding of proteins contg. either FYVE or PX domains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3zjUVa7vmuLVg90H21EOLACvtfcHk0ljvyr18rIkygw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1WrsLk%253D&md5=153eb4e66bcc0d6047d8a63c3602ff11</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1042%2FBST0350236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0350236%26sid%3Dliteratum%253Aachs%26aulast%3DGulati%26aufirst%3DP.%26aulast%3DThomas%26aufirst%3DG.%26atitle%3DNutrient%2520Sensing%2520in%2520the%2520mTOR%252FS6K1%2520Signalling%2520Pathway%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2007%26volume%3D35%26spage%3D236%26epage%3D238%26doi%3D10.1042%2FBST0350236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">M Nicole, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipovsky, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Feedback Inhibition of Akt Signaling Limits the Growth of Tumors Lacking Tsc2</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1773</span>– <span class="NLM_lpage">1778</span>, <span class="refDoi"> DOI: 10.1101/gad.1314605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1101%2Fgad.1314605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=16027169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD2MXotFahtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1773-1778&author=B.+D.+Manningauthor=L.+M+Nicoleauthor=A.+I.+Lipovskyauthor=A.+Derekauthor=D.+J.+Kwiatkowskiauthor=L.+C.+Cantley&title=Feedback+Inhibition+of+Akt+Signaling+Limits+the+Growth+of+Tumors+Lacking+Tsc2&doi=10.1101%2Fgad.1314605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2</span></div><div class="casAuthors">Manning, Brendan D.; Logsdon, M. Nicole; Lipovsky, Alex I.; Abbott, Derek; Kwiatkowski, David J.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1773-1778</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The PTEN and TSC2 tumor suppressors inhibit mammalian target of rapamycin (mTOR) signaling and are defective in distinct hamartoma syndromes.  Using mouse genetics, we find that Pten and Tsc2 act synergistically to suppress the severity of a subset of tumors specific to loss of each of these genes.  Interestingly, we find that the slow-growing tumors specific to Tsc2+/- mice exhibit defects in signaling downstream of Akt.  However, Pten haploinsufficiency restores Akt signaling in these tumors and dramatically enhances their severity.  This study demonstrates that attenuation of the PI3K-Akt pathway in tumors lacking TSC2 contributes to their benign nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKGLsPscfT7Vg90H21EOLACvtfcHk0ljoVpHennu_Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXotFahtrk%253D&md5=a6715a7e1831d6c0d63b6d3fefc192b9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1101%2Fgad.1314605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1314605%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DM%2BNicole%26aufirst%3DL.%26aulast%3DLipovsky%26aufirst%3DA.%2BI.%26aulast%3DDerek%26aufirst%3DA.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DFeedback%2520Inhibition%2520of%2520Akt%2520Signaling%2520Limits%2520the%2520Growth%2520of%2520Tumors%2520Lacking%2520Tsc2%26jtitle%3DGenes%2520Dev.%26date%3D2005%26volume%3D19%26spage%3D1773%26epage%3D1778%26doi%3D10.1101%2Fgad.1314605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mericbernstam, F.</span></span> <span> </span><span class="NLM_article-title">Targeting the PI3K Pathway in Cancer: Are We Making Headway?</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2018.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1038%2Fnrclinonc.2018.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=29508857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVyjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=273-291&author=F.+Jankuauthor=T.+A.+Yapauthor=F.+Mericbernstam&title=Targeting+the+PI3K+Pathway+in+Cancer%3A+Are+We+Making+Headway%3F&doi=10.1038%2Fnrclinonc.2018.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the PI3K pathway in cancer: are we making headway?</span></div><div class="casAuthors">Janku, Filip; Yap, Timothy A.; Meric-Bernstam, Funda</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">273-291</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The PI3K-AKT-mTOR pathway is one of the most frequently dysregulated pathways in cancer and, consequently, more than 40 compds. that target key components of this signalling network have been tested in clin. trials involving patients with a range of different cancers.  The clin. development of many of these agents, however, has not advanced to late-phase randomized trials, and the antitumor activity of those that have been evaluated in comparative prospective studies has typically been limited, or toxicities were found to be prohibitive.  Nevertheless, the mTOR inhibitors temsirolimus and everolimus and the PI3K inhibitors idelalisib and copanlisib have been approved by the FDA for clin. use in the treatment of a no. of different cancers.  Novel compds. with greater potency and selectivity, as well as improved therapeutic indexes owing to reduced risks of toxicity, are clearly required.  In addn., biomarkers that are predictive of a response, such as PIK3CA mutations for inhibitors of the PI3K catalytic subunit α isoform, must be identified and anal. and clin. validated.  Finally, considering that oncogenic activation of the PI3K-AKT-mTOR pathway often occurs alongside pro-tumorigenic aberrations in other signalling networks, rational combinations are also needed to optimize the effectiveness of treatment.  Herein, we review the current experience with anticancer therapies that target the PI3K-AKT-mTOR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbPxYBT6FMIbVg90H21EOLACvtfcHk0ljoVpHennu_Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVyjsLY%253D&md5=73e00e3137c598e3a88ecf6a3d180b8c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2018.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2018.28%26sid%3Dliteratum%253Aachs%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DMericbernstam%26aufirst%3DF.%26atitle%3DTargeting%2520the%2520PI3K%2520Pathway%2520in%2520Cancer%253A%2520Are%2520We%2520Making%2520Headway%253F%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26spage%3D273%26epage%3D291%26doi%3D10.1038%2Fnrclinonc.2018.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faia, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brophy, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lussier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillotson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDougall, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutok, J. L.</span></span> <span> </span><span class="NLM_article-title">PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1364</span>– <span class="NLM_lpage">1374</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1016%2Fj.chembiol.2013.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=24211136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslClsrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1364-1374&author=D.+G.+Winklerauthor=K.+L.+Faiaauthor=J.+P.+DiNittoauthor=J.+A.+Aliauthor=K.+F.+Whiteauthor=E.+E.+Brophyauthor=M.+M.+Pinkauthor=J.+L.+Proctorauthor=J.+Lussierauthor=C.+M.+Martinauthor=J.+G.+Hoytauthor=B.+Tillotsonauthor=E.+L.+Murphyauthor=A.+R.+Limauthor=B.+D.+Thomasauthor=J.+R.+MacDougallauthor=P.+Renauthor=Y.+Liuauthor=L.-S.+Liauthor=K.+A.+Jessenauthor=C.+C.+Fritzauthor=J.+L.+Dunbarauthor=J.+R.+Porterauthor=C.+Rommelauthor=V.+J.+Palombellaauthor=P.+S.+Changelianauthor=J.+L.+Kutok&title=PI3K-%CE%B4+and+PI3K-%CE%B3+Inhibition+by+IPI-145+Abrogates+Immune+Responses+and+Suppresses+Activity+in+Autoimmune+and+Inflammatory+Disease+Models&doi=10.1016%2Fj.chembiol.2013.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models</span></div><div class="casAuthors">Winkler, David G.; Faia, Kerrie L.; DiNitto, Jonathan P.; Ali, Janid A.; White, Kerry F.; Brophy, Erin E.; Pink, Melissa M.; Proctor, Jennifer L.; Lussier, Jennifer; Martin, Christian M.; Hoyt, Jennifer G.; Tillotson, Bonnie; Murphy, Erin L.; Lim, Alice R.; Thomas, Brian D.; MacDougall, John R.; Ren, Pingda; Liu, Yi; Li, Lian-Sheng; Jessen, Katti A.; Fritz, Christian C.; Dunbar, Joi L.; Porter, James R.; Rommel, Christian; Palombella, Vito J.; Changelian, Paul S.; Kutok, Jeffery L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1364-1374</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Phosphoinositide-3 kinase (PI3K)-δ and PI3K-γ are preferentially expressed in immune cells, and inhibitors targeting these isoforms are hypothesized to have anti-inflammatory activity by affecting the adaptive and innate immune response.  We report on a potent oral PI3K-δ and PI3K-γ inhibitor (IPI-145) and characterize this compd. in biochem., cellular, and in vivo assays.  These studies demonstrate that IPI-145 exerts profound effects on adaptive and innate immunity by inhibiting B and T cell proliferation, blocking neutrophil migration, and inhibiting basophil activation.  We explored the therapeutic value of combined PI3K-δ and PI3K-γ blockade, and IPI-145 showed potent activity in collagen-induced arthritis, ovalbumin-induced asthma, and systemic lupus erythematosus rodent models.  These findings support the hypothesis that inhibition of immune function can be achieved through PI3K-δ and PI3K-γ blockade, potentially leading to significant therapeutic effects in multiple inflammatory, autoimmune, and hematol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHLymau7LdZrVg90H21EOLACvtfcHk0ljoVpHennu_Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslClsrvN&md5=b9fdfd9444ac255430ff6c8a0fb71ab9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DWinkler%26aufirst%3DD.%2BG.%26aulast%3DFaia%26aufirst%3DK.%2BL.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DWhite%26aufirst%3DK.%2BF.%26aulast%3DBrophy%26aufirst%3DE.%2BE.%26aulast%3DPink%26aufirst%3DM.%2BM.%26aulast%3DProctor%26aufirst%3DJ.%2BL.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DC.%2BM.%26aulast%3DHoyt%26aufirst%3DJ.%2BG.%26aulast%3DTillotson%26aufirst%3DB.%26aulast%3DMurphy%26aufirst%3DE.%2BL.%26aulast%3DLim%26aufirst%3DA.%2BR.%26aulast%3DThomas%26aufirst%3DB.%2BD.%26aulast%3DMacDougall%26aufirst%3DJ.%2BR.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DFritz%26aufirst%3DC.%2BC.%26aulast%3DDunbar%26aufirst%3DJ.%2BL.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DKutok%26aufirst%3DJ.%2BL.%26atitle%3DPI3K-%25CE%25B4%2520and%2520PI3K-%25CE%25B3%2520Inhibition%2520by%2520IPI-145%2520Abrogates%2520Immune%2520Responses%2520and%2520Suppresses%2520Activity%2520in%2520Autoimmune%2520and%2520Inflammatory%2520Disease%2520Models%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1364%26epage%3D1374%26doi%3D10.1016%2Fj.chembiol.2013.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garces, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span> <span> </span><span class="NLM_article-title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: a Medicinal Chemistry Perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4815</span>– <span class="NLM_lpage">4850</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01492</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01492" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFOku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4815-4850&author=A.+E.+Garcesauthor=M.+J.+Stocks&title=Class+1+PI3K+Clinical+Candidates+and+Recent+Inhibitor+Design+Strategies%3A+a+Medicinal+Chemistry+Perspective&doi=10.1021%2Facs.jmedchem.8b01492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Garces, Aimie E.; Stocks, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4815-4850</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate the 3-OH of the inositol ring of phosphoinositides, and deregulation of this pathway has implications in many diseases.  The search for novel PI3K inhibitors has been at the forefront of academic and industrial medicinal chem. with over 600 medicinal chem.-based publications and patents appearing to date, leading to 38 clin. candidates and the launch of two drugs, idelalisib in 2014 and copanlisib in 2017.  This Perspective will discuss medicinal chem. design approaches to novel isoform-selective inhibitors through consideration of brief case histories of compds. that have progressed into clin. development or that have revealed new structural motifs in this highly competitive area of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUu2mgndklHbVg90H21EOLACvtfcHk0ljpEZuoAbMCIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFOku7bK&md5=907395a39ed6fb683464ee92c6a2537f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26aulast%3DGarces%26aufirst%3DA.%2BE.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26atitle%3DClass%25201%2520PI3K%2520Clinical%2520Candidates%2520and%2520Recent%2520Inhibitor%2520Design%2520Strategies%253A%2520a%2520Medicinal%2520Chemistry%2520Perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4815%26epage%3D4850%26doi%3D10.1021%2Facs.jmedchem.8b01492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhari, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donatelli, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newlander, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridgers, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarpong, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aller, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garver, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gontarek, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kershner, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherk, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegrzyn, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1021/ml900028r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml900028r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvF2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=39-43&author=S.+D.+Knightauthor=N.+D.+Adamsauthor=J.+L.+Burgessauthor=A.+M.+Chaudhariauthor=M.+G.+Darcyauthor=C.+A.+Donatelliauthor=J.+I.+Luengoauthor=K.+A.+Newlanderauthor=C.+A.+Parrishauthor=L.+H.+Ridgersauthor=M.+A.+Sarpongauthor=S.+J.+Schmidtauthor=G.+S.+Van+Allerauthor=J.+D.+Carsonauthor=M.+A.+Diamondauthor=P.+A.+Elkinsauthor=C.+M.+Gardinerauthor=E.+Garverauthor=S.+A.+Gilbertauthor=R.+R.+Gontarekauthor=J.+R.+Jacksonauthor=K.+L.+Kershnerauthor=L.+Luoauthor=K.+Rahaauthor=C.+S.+Sherkauthor=C.-M.+Sungauthor=D.+Suttonauthor=P.+J.+Tumminoauthor=R.+J.+Wegrzynauthor=K.+R.+Augerauthor=D.+Dhanak&title=Discovery+of+GSK2126458%2C+a+Highly+Potent+Inhibitor+of+PI3K+and+the+Mammalian+Target+of+Rapamycin&doi=10.1021%2Fml900028r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin</span></div><div class="casAuthors">Knight, Steven D.; Adams, Nicholas D.; Burgess, Joelle L.; Chaudhari, Amita M.; Darcy, Michael G.; Donatelli, Carla A.; Luengo, Juan I.; Newlander, Ken A.; Parrish, Cynthia A.; Ridgers, Lance H.; Sarpong, Martha A.; Schmidt, Stanley J.; Van Aller, Glenn S.; Carson, Jeffrey D.; Diamond, Melody A.; Elkins, Patricia A.; Gardiner, Christine M.; Garver, Eric; Gilbert, Seth A.; Gontarek, Richard R.; Jackson, Jeffrey R.; Kershner, Kevin L.; Luo, Lusong; Raha, Kaushik; Sherk, Christian S.; Sung, Chiu-Mei; Sutton, David; Tummino, Peter J.; Wegrzyn, Ronald J.; Auger, Kurt R.; Dhanak, Dashyant</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-43</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase α (PI3Kα) is a crit. regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers.  The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition. 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458, 1 (I)) has been identified as a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.  Compd. 1 is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBH6_ywCnjCrVg90H21EOLACvtfcHk0ljpEZuoAbMCIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvF2qtw%253D%253D&md5=72fcca85702dba95529ac03281e0bdbc</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fml900028r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml900028r%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DS.%2BD.%26aulast%3DAdams%26aufirst%3DN.%2BD.%26aulast%3DBurgess%26aufirst%3DJ.%2BL.%26aulast%3DChaudhari%26aufirst%3DA.%2BM.%26aulast%3DDarcy%26aufirst%3DM.%2BG.%26aulast%3DDonatelli%26aufirst%3DC.%2BA.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26aulast%3DNewlander%26aufirst%3DK.%2BA.%26aulast%3DParrish%26aufirst%3DC.%2BA.%26aulast%3DRidgers%26aufirst%3DL.%2BH.%26aulast%3DSarpong%26aufirst%3DM.%2BA.%26aulast%3DSchmidt%26aufirst%3DS.%2BJ.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DCarson%26aufirst%3DJ.%2BD.%26aulast%3DDiamond%26aufirst%3DM.%2BA.%26aulast%3DElkins%26aufirst%3DP.%2BA.%26aulast%3DGardiner%26aufirst%3DC.%2BM.%26aulast%3DGarver%26aufirst%3DE.%26aulast%3DGilbert%26aufirst%3DS.%2BA.%26aulast%3DGontarek%26aufirst%3DR.%2BR.%26aulast%3DJackson%26aufirst%3DJ.%2BR.%26aulast%3DKershner%26aufirst%3DK.%2BL.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DRaha%26aufirst%3DK.%26aulast%3DSherk%26aufirst%3DC.%2BS.%26aulast%3DSung%26aufirst%3DC.-M.%26aulast%3DSutton%26aufirst%3DD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DWegrzyn%26aufirst%3DR.%2BJ.%26aulast%3DAuger%26aufirst%3DK.%2BR.%26aulast%3DDhanak%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520GSK2126458%252C%2520a%2520Highly%2520Potent%2520Inhibitor%2520of%2520PI3K%2520and%2520the%2520Mammalian%2520Target%2520of%2520Rapamycin%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D39%26epage%3D43%26doi%3D10.1021%2Fml900028r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melendez Cuero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutvoet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anak, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Oral Phosphatidylinositol-3-kinase and mTOR Inhibitor BGT226 in Patients with Advanced Solid Tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2399</span>– <span class="NLM_lpage">2408</span>, <span class="refDoi"> DOI: 10.1093/annonc/mds011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1093%2Fannonc%2Fmds011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=22357447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A280%3ADC%252BC38vjvFemsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=2399-2408&author=B.+Markmanauthor=J.+Taberneroauthor=I.+Kropauthor=G.+I.+Shapiroauthor=L.+Siuauthor=L.+C.+Chenauthor=M.+Mitaauthor=M.+Melendez+Cueroauthor=S.+Stutvoetauthor=D.+Birleauthor=O.+Anakauthor=W.+Hacklauthor=J.+Baselga&title=Phase+I+Safety%2C+Pharmacokinetic%2C+and+Pharmacodynamic+Study+of+the+Oral+Phosphatidylinositol-3-kinase+and+mTOR+Inhibitor+BGT226+in+Patients+with+Advanced+Solid+Tumors&doi=10.1093%2Fannonc%2Fmds011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors</span></div><div class="casAuthors">Markman B; Tabernero J; Krop I; Shapiro G I; Siu L; Chen L C; Mita M; Melendez Cuero M; Stutvoet S; Birle D; Anak O; Hackl W; Baselga J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2399-408</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This phase I dose-escalation study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics (PDs), and preliminary antitumor activity of BGT226, a potent, oral dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin inhibitor.  PATIENTS AND METHODS:  Fifty-seven patients with advanced solid tumors received BGT226 2.5-125 mg/day three times weekly (TIW).  Dose escalation was guided by an adaptive Bayesian logistic regression model with overdose control.  Assessments included response per RECIST, [18F]-fluorodeoxyglucose uptake, and phosphorylated-S6 in skin and paired tumor samples.  RESULTS:  Three patients (125 mg cohort) had dose-limiting toxic effects (grade 3 nausea/vomiting, diarrhea).  BGT226-related adverse events included nausea (68%), diarrhea (61%), vomiting (49%), and fatigue (19%).  BGT226 demonstrated rapid absorption, variable systemic exposure, and a median half-life of 6-9 h.  Seventeen patients (30%) had stable disease (SD) as best response.  Nine patients had SD for ≥16 weeks.  Thirty patients (53%) achieved stable metabolic disease as assessed by [18F]-fluorodeoxyglucose-positron emission tomography; however, no correlation between metabolic response and tumor shrinkage according to computed tomography was observed.  PD changes suggested PI3K pathway inhibition but were inconsistent.  CONCLUSIONS:  The MTD of BGT226 was 125 mg/day TIW, and the clinically recommended dose was 100 mg/day TIW.  Limited preliminary antitumor activity and inconsistent target inhibition were observed, potentially due to low systemic exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHz9m4_rnszwpJitSxOdIlfW6udTcc2eYINvW2abTj3bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vjvFemsQ%253D%253D&md5=c9bab106af9fb7fea93049bc77587b9a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds011%26sid%3Dliteratum%253Aachs%26aulast%3DMarkman%26aufirst%3DB.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DKrop%26aufirst%3DI.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DSiu%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DMelendez%2BCuero%26aufirst%3DM.%26aulast%3DStutvoet%26aufirst%3DS.%26aulast%3DBirle%26aufirst%3DD.%26aulast%3DAnak%26aufirst%3DO.%26aulast%3DHackl%26aufirst%3DW.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520Safety%252C%2520Pharmacokinetic%252C%2520and%2520Pharmacodynamic%2520Study%2520of%2520the%2520Oral%2520Phosphatidylinositol-3-kinase%2520and%2520mTOR%2520Inhibitor%2520BGT226%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3D2399%26epage%3D2408%26doi%3D10.1093%2Fannonc%2Fmds011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gravis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machiels, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellado, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csonka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravartty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fizazi, K.</span></span> <span> </span><span class="NLM_article-title">Phase Ib Dose-finding Study of Abiraterone Acetate Plus Buparlisib (BKM120) or Dactolisib (BEZ235) in Patients with Castration-resistant Prostate Cancer</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2017.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1016%2Fj.ejca.2017.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=28282611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtFeltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=36-44&author=C.+Massardauthor=K.+N.+Chiauthor=D.+Castellanoauthor=J.+de+Bonoauthor=G.+Gravisauthor=L.+Dirixauthor=J.-P.+Machielsauthor=A.+Mitaauthor=B.+Melladoauthor=S.+Turriauthor=J.+Maierauthor=D.+Csonkaauthor=A.+Chakravarttyauthor=K.+Fizazi&title=Phase+Ib+Dose-finding+Study+of+Abiraterone+Acetate+Plus+Buparlisib+%28BKM120%29+or+Dactolisib+%28BEZ235%29+in+Patients+with+Castration-resistant+Prostate+Cancer&doi=10.1016%2Fj.ejca.2017.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer</span></div><div class="casAuthors">Massard, Christophe; Chi, Kim Nguyen; Castellano, Daniel; de Bono, Johann; Gravis, Gwenaelle; Dirix, Luc; Machiels, Jean-Pascal; Mita, Alain; Gonzalez, Begona Mellado; Turri, Sabine; Maier, Joan; Csonka, Denes; Chakravartty, Arunava; Fizazi, Karim</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) signalling axis and androgen receptor (AR) pathways exhibit reciprocal feedback regulation in phosphatase and tensin homolog (PTEN)-deficient metastatic castration-resistant prostate cancer (CRPC) in preclin. models.  This phase Ib study evaluated the pan-PI3K inhibitor buparlisib (BKM120) and the dual pan-PI3K/ mammalian target of rapamycin (mTOR) inhibitor dactolisib (BEZ235) in combination with abiraterone acetate (AA) in patients with CRPC.  Patients with CRPC who had progressed on AA therapy received escalating doses of either buparlisib or dactolisib, along with fixed doses of AA (1000 mg once daily (qd)) and prednisone (5 mg twice daily (bid)).  The primary objective was to define the max. tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of either buparlisib or dactolisib in combination with AA.  Secondary objectives included safety, antitumor activity (Prostate Cancer Working Group 2 (PCWG2) criteria; 30% of prostate-specific antigen (PSA) decline at ≥week 12) and pharmacokinetic (PK) profile.  In buparlisib + AA arm, 25 patients received buparlisib + AA (median age, 67 years; Eastern Cooperative Oncol. Group performance status (ECOG PS) of 0/1/2 for 7/17/1 patients, resp.).  At 100 mg qd; two patients experienced dose-limiting toxicities (DLTs) (grade 3 hyperglycemia; grade 2 asthenia), and this was the max. buparlisib dose explored.  Buparlisib + AA showed a 26% lower median area under the curve from time zero to 24°h (AUC0-24) and 48% lower median max. serum concn. (Cmax) vs. the single-agent buparlisib assessed in first-in-human study.  No objective response and few PSA decreases were reported.  In dactolisib + AA arm, 18 patients (median age, 71 years; ECOG PS of 0/1 for 6/12 patients, resp.) received dactolisib + AA at the first dose level (200 mg bid).  Five patients had 9 DLTs (grades 2&3 stomatitis; grade 3 hyperglycemia; grades 2& 3 diarrhea; grades 1& 2 pyrexia, grade 2 vomiting, and grade 2 chills).Based on the assessment of available pharmacokinetics, safety, and efficacy data, no further study is planned for either buparlisib or dactolisib in combination with AA in CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5ivzHQTJ0i7Vg90H21EOLACvtfcHk0lgW-CDyF-vLjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtFeltrY%253D&md5=4a92c856180ca246e3a44ae8dab0ac94</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2017.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2017.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DMassard%26aufirst%3DC.%26aulast%3DChi%26aufirst%3DK.%2BN.%26aulast%3DCastellano%26aufirst%3DD.%26aulast%3Dde%2BBono%26aufirst%3DJ.%26aulast%3DGravis%26aufirst%3DG.%26aulast%3DDirix%26aufirst%3DL.%26aulast%3DMachiels%26aufirst%3DJ.-P.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DMellado%26aufirst%3DB.%26aulast%3DTurri%26aufirst%3DS.%26aulast%3DMaier%26aufirst%3DJ.%26aulast%3DCsonka%26aufirst%3DD.%26aulast%3DChakravartty%26aufirst%3DA.%26aulast%3DFizazi%26aufirst%3DK.%26atitle%3DPhase%2520Ib%2520Dose-finding%2520Study%2520of%2520Abiraterone%2520Acetate%2520Plus%2520Buparlisib%2520%2528BKM120%2529%2520or%2520Dactolisib%2520%2528BEZ235%2529%2520in%2520Patients%2520with%2520Castration-resistant%2520Prostate%2520Cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2017%26volume%3D76%26spage%3D36%26epage%3D44%26doi%3D10.1016%2Fj.ejca.2017.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Britten, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houk, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P. M.</span></span> <span> </span><span class="NLM_article-title">Phase I Study of PF-04691502, a Small-molecule, Oral, Dual Inhibitor of PI3K and mTOR, in Patients with Advanced Cancer</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.1007/s10637-013-0062-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1007%2Fs10637-013-0062-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=24395457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVant70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=510-517&author=C.+D.+Brittenauthor=A.+A.+Adjeiauthor=R.+Millhamauthor=B.+E.+Houkauthor=G.+Borzilloauthor=K.+Pierceauthor=Z.+A.+Wainbergauthor=P.+M.+LoRusso&title=Phase+I+Study+of+PF-04691502%2C+a+Small-molecule%2C+Oral%2C+Dual+Inhibitor+of+PI3K+and+mTOR%2C+in+Patients+with+Advanced+Cancer&doi=10.1007%2Fs10637-013-0062-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer</span></div><div class="casAuthors">Britten, Carolyn D.; Adjei, Alex A.; Millham, Robert; Houk, Brett E.; Borzillo, Gary; Pierce, Kristen; Wainberg, Zev A.; LoRusso, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">510-517</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose To det. the max. tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, and preliminary evidence of antitumor activity of the PI3K/mTOR inhibitor PF-04691502, administered orally once daily.  Methods Escalating doses of PF-04691502 were administered to 23 patients with advanced solid tumors in sequential cohorts across the following dose levels: 2 mg, 4 mg, 8 mg, and 11 mg. 14 addnl. patients were enrolled in an expansion cohort at the MTD to ensure at least five matched pre- and post-treatment biopsies for biomarkers of PI3K activity.  Results The MTD of PF-04691502 was 8 mg orally once daily.  There were three dose-limiting toxicities: one grade 3 fatigue at 8 mg, one grade 3 rash at 11 mg, and one intolerable grade 2 fatigue at 11 mg.  Among 37 patients enrolled, treatment-related adverse events included fatigue, decreased appetite, nausea, hyperglycemia, rash, and vomiting.  Across all dose levels, av. steady-state plasma PF-04691502 concns. approximated or exceeded the target concn. of 16.2 ng/mL required for ≥75 % tumor growth inhibition in preclin. models.  PF-04691502 resulted in increased mean fasting serum glucose, insulin, and c-peptide levels, and produced partial blockade of PI3K signalling in five paired tumor biopsies, as demonstrated by redns. in phosphorylated Akt, FKHR/FKHRL1, and STAT3.  No objective anti-tumor responses were obsd.  Conclusions Daily oral administration of PF-04691502 was tolerable at 8 mg orally once daily, with a safety profile similar to other PI3K/mTOR inhibitors.  PF-04691502 demonstrated PI3K pathway inhibition by changing glucose homeostasis, and by decreasing phosphorylation of downstream mols. in tumor tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-Gyl-ccubnrVg90H21EOLACvtfcHk0ljlxelC86dOIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVant70%253D&md5=dbf09eb4421930dccf1dbeb0360d032f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs10637-013-0062-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-013-0062-5%26sid%3Dliteratum%253Aachs%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DMillham%26aufirst%3DR.%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DBorzillo%26aufirst%3DG.%26aulast%3DPierce%26aufirst%3DK.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DPhase%2520I%2520Study%2520of%2520PF-04691502%252C%2520a%2520Small-molecule%252C%2520Oral%252C%2520Dual%2520Inhibitor%2520of%2520PI3K%2520and%2520mTOR%252C%2520in%2520Patients%2520with%2520Advanced%2520Cancer%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2014%26volume%3D32%26spage%3D510%26epage%3D517%26doi%3D10.1007%2Fs10637-013-0062-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koizumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Sulfonylhydrazone-substituted Imidazo[1,2-a]pyridines as Novel PI3 Kinase p110α Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5837</span>– <span class="NLM_lpage">5844</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.05.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1016%2Fj.bmc.2007.05.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=17601739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=5837-5844&author=M.+Hayakawaauthor=K.+I.+Kawaguchiauthor=H.+Kaizawaauthor=T.+Koizumiauthor=T.+Ohishiauthor=M.+Yamanoauthor=M.+Okadaauthor=M.+Ohtaauthor=S.+I.+Tsukamotoauthor=F.+I.+Raynaud&title=Synthesis+and+Biological+Evaluation+of+Sulfonylhydrazone-substituted+Imidazo%5B1%2C2-a%5Dpyridines+as+Novel+PI3+Kinase+p110%CE%B1+Inhibitors&doi=10.1016%2Fj.bmc.2007.05.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110α inhibitors</span></div><div class="casAuthors">Hayakawa, Masahiko; Kawaguchi, Ken-ichi; Kaizawa, Hiroyuki; Koizumi, Tomonobu; Ohishi, Takahide; Yamano, Mayumi; Okada, Minoru; Ohta, Mitsuaki; Tsukamoto, Shin-ichi; Raynaud, Florence I.; Parker, Peter; Workman, Paul; Waterfield, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5837-5844</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The authors have previously reported the imidazo[1,2-a]pyridine deriv. 4 as a novel p110α inhibitor; however, although 4 is a potent inhibitor of p110α enzymic activity and tumor cell proliferation in vitro, it is unstable in soln. and ineffective in vivo.  To increase stability the pyrazole of 4 was replaced with a hydrazone and a moderately potent p110α inhibitor 7a was obtained.  Subsequent optimization of 7a afforded exceptionally potent p110α inhibitors, including compds. (I and II), with IC50 values of 0.30 nM and 0.26 nM.  Compd. I was also stable in soln. and exhibited significant antitumor effectiveness in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLaUeSvcQQULVg90H21EOLACvtfcHk0ljlxelC86dOIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWjsbg%253D&md5=e24268693f0022fd955d2d06ceb151ba</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.05.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.05.070%26sid%3Dliteratum%253Aachs%26aulast%3DHayakawa%26aufirst%3DM.%26aulast%3DKawaguchi%26aufirst%3DK.%2BI.%26aulast%3DKaizawa%26aufirst%3DH.%26aulast%3DKoizumi%26aufirst%3DT.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DYamano%26aufirst%3DM.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DTsukamoto%26aufirst%3DS.%2BI.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Sulfonylhydrazone-substituted%2520Imidazo%255B1%252C2-a%255Dpyridines%2520as%2520Novel%2520PI3%2520Kinase%2520p110%25CE%25B1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D5837%26epage%3D5844%26doi%3D10.1016%2Fj.bmc.2007.05.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Imidazopyridine Analogues as Inhibitors of Phosphoinositide 3-Kinase Signaling and Angiogenesis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2455</span>– <span class="NLM_lpage">2466</span>, <span class="refDoi"> DOI: 10.1021/jm101582z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101582z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivFyjt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2455-2466&author=O.+Kimauthor=Y.+Jeongauthor=H.+Leeauthor=S.-S.+Hongauthor=S.+Hong&title=Design+and+Synthesis+of+Imidazopyridine+Analogues+as+Inhibitors+of+Phosphoinositide+3-Kinase+Signaling+and+Angiogenesis&doi=10.1021%2Fjm101582z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Imidazopyridine Analogues as Inhibitors of Phosphoinositide 3-Kinase Signaling and Angiogenesis</span></div><div class="casAuthors">Kim, Okseon; Jeong, Yujeong; Lee, Hyunseung; Hong, Sun-Sun; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2455-2466</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinase α (PI3Kα) is an important regulator of intracellular signaling pathways, controlling remarkably diverse arrays of physiol. processes.  Because the PI3K pathway is frequently up-regulated in human cancers, the inhibition of PI3Kα can be a promising approach to cancer therapy.  In this study, we have designed and synthesized a new series of imidazo[1,2-a]pyridine derivs. as PI3Kα inhibitors through the fragment-growing strategy.  By varying groups at the 3- and 6-positions of imidazo[1,2-a]pyridines, we studied the SAR profiles and identified a series of potent PI3Kα inhibitors.  Representative derivs. showed good activity in cellular proliferation and apoptosis assays.  Moreover, these inhibitors exhibited noteworthy antiangiogenic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTcM2h9dxy2LVg90H21EOLACvtfcHk0ljlxelC86dOIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivFyjt70%253D&md5=f95faefaa020858642e959f424aeaba1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm101582z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101582z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DO.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DHong%26aufirst%3DS.-S.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Imidazopyridine%2520Analogues%2520as%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520Signaling%2520and%2520Angiogenesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2455%26epage%3D2466%26doi%3D10.1021%2Fjm101582z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. W.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Novel 3-Substituted Imidazo[1,2-a]pyridine and Quinazolin-4(3H)-one Derivatives as PI3Kα Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1016%2Fj.ejmech.2017.07.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=28800461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSls7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=95-106&author=Y.+H.+Fanauthor=W.+Liauthor=D.+D.+Liuauthor=M.+X.+Baiauthor=H.+R.+Songauthor=Y.+N.+Xuauthor=S.+K.+Leeauthor=Z.+P.+Zhouauthor=J.+Wangauthor=H.+W.+Ding&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Novel+3-Substituted+Imidazo%5B1%2C2-a%5Dpyridine+and+Quinazolin-4%283H%29-one+Derivatives+as+PI3K%CE%B1+Inhibitors&doi=10.1016%2Fj.ejmech.2017.07.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors</span></div><div class="casAuthors">Fan, Yan-Hua; Li, Wei; Liu, Dan-Dan; Bai, Meng-Xuan; Song, Hong-Rui; Xu, Yong-Nan; Lee, SangKook; Zhou, Zhi-Peng; Wang, Jian; Ding, Huai-Wei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95-106</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinase (PI3K) is a pivotal regulator of intracellular signaling pathways and considered as a promising target in the development of a therapeutic treatment of cancer.  Among the different PI3K subtypes, the PIK3CA gene encoding PI3K p110α is frequently mutated and overexpressed in majority of human cancers.  Therefore, the inhibition of PI3Kα has been considered to be an efficient approach for the treatment of cancer.  In this study, two series compds. contg. hydrophilic group in imidazo[1,2-a]pyridine and quinazolin-4(3H)-one were synthesized and their antiproliferative activities against five cancer cell lines, including HCT-116, SK-HEP-1, MDA-MB-231, SNU638 and A549, were evaluated.  Compd. I with most potent antiproliferative activity was selected for further biol. evaluation.  PI3K kinase assay showed that I has selectivity for PI3Kα distinguished from other isoforms.  The western blot assay indicated that I is more effective than HS-173, an imidazopyridine-based PI3Ka inhibitor, in reducing the levels of phospho-Akt.  All these results suggested that I is a potent PI3Kα inhibitor and could be considered as a potential candidate for the development of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolVgFNIFP22LVg90H21EOLACvtfcHk0liDcLNo_lW49Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSls7fI&md5=948df88b378b90d43ee4c71988dd4d16</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.074%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DY.%2BH.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DD.%2BD.%26aulast%3DBai%26aufirst%3DM.%2BX.%26aulast%3DSong%26aufirst%3DH.%2BR.%26aulast%3DXu%26aufirst%3DY.%2BN.%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DZhou%26aufirst%3DZ.%2BP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DH.%2BW.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Novel%25203-Substituted%2520Imidazo%255B1%252C2-a%255Dpyridine%2520and%2520Quinazolin-4%25283H%2529-one%2520Derivatives%2520as%2520PI3K%25CE%25B1%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D95%26epage%3D106%26doi%3D10.1016%2Fj.ejmech.2017.07.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-kinase Inhibitors for Cancer Treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6087</span>– <span class="NLM_lpage">6109</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00416</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00416" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyjs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6087-6109&author=S.+Linauthor=C.+Wangauthor=M.+Jiauthor=D.+Wuauthor=Y.+Lvauthor=K.+Zhangauthor=Y.+Dongauthor=J.+Jinauthor=J.+Chenauthor=J.+Zhangauthor=L.+Shengauthor=Y.+Liauthor=X.+Chenauthor=H.+Xu&title=Discovery+and+Optimization+of+2-Amino-4-methylquinazoline+Derivatives+as+Highly+Potent+Phosphatidylinositol+3-kinase+Inhibitors+for+Cancer+Treatment&doi=10.1021%2Facs.jmedchem.8b00416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment</span></div><div class="casAuthors">Lin, Songwen; Wang, Chunyang; Ji, Ming; Wu, Deyu; Lv, Yuanhao; Zhang, Kehui; Dong, Yi; Jin, Jing; Chen, Jiajing; Zhang, Jingbo; Sheng, Li; Li, Yan; Chen, Xiaoguang; Xu, Heng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6087-6109</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Increased phosphatidylinositol 3-kinase (PI3K) signaling is among the most common alterations in cancer, spurring intensive efforts to develop new cancer therapeutics that target this pathway.  In this work, we discovered a series of novel 2-amino-4-methylquinazoline derivs. through a hybridization and subsequent scaffold hopping approach that were highly potent class I PI3K inhibitors.  Lead optimization resulted in several promising compds. (e.g., 19, 20, 37, and 43) with nanomolar PI3K potencies, prominent antiproliferative activities, favorable PK profiles, and robust in vivo antitumor efficacies.  More interestingly, compared with 19 and 20, 37 and 43 demonstrated improved brain penetration and in vivo efficacy in an orthotopic glioblastoma xenograft model.  Furthermore, preliminary safety assessments including hERG channel inhibition, AMES, CYP450 inhibition, and single-dose toxicity were performed to characterize their toxicol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_AIT1xHicq7Vg90H21EOLACvtfcHk0liDcLNo_lW49Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyjs7bF&md5=3d9e6f2f1d8028cad66b3c14f8be353d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00416%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DLv%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%25202-Amino-4-methylquinazoline%2520Derivatives%2520as%2520Highly%2520Potent%2520Phosphatidylinositol%25203-kinase%2520Inhibitors%2520for%2520Cancer%2520Treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6087%26epage%3D6109%26doi%3D10.1021%2Facs.jmedchem.8b00416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulloora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabaraya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, A. V.</span></span> <span> </span><span class="NLM_article-title">New 6-Bromoimidazo[1,2-a]pyridine-2-carbohydrazide Derivatives: Synthesis and Anticonvulsant Studies</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3019</span>– <span class="NLM_lpage">3028</span>, <span class="refDoi"> DOI: 10.1007/s00044-013-0887-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1007%2Fs00044-013-0887-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeksrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=3019-3028&author=S.+Ullooraauthor=R.+Shabarayaauthor=A.+V.+Adhikari&title=New+6-Bromoimidazo%5B1%2C2-a%5Dpyridine-2-carbohydrazide+Derivatives%3A+Synthesis+and+Anticonvulsant+Studies&doi=10.1007%2Fs00044-013-0887-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">New 6-bromoimidazo[1,2-a]pyridine-2-carbohydrazide derivatives: synthesis and anticonvulsant studies</span></div><div class="casAuthors">Ulloora, Shrikanth; Shabaraya, Ramakrishna; Adhikari, Airody Vasudeva</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3019-3028</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Boston</span>)
        </div><div class="casAbstract">The facile synthesis and anticonvulsant study of new imidazo[1,2-a]pyridines carrying biol. active hydrazone functionality and suitably substituted 1,2,4-triazole moieties were reported.  The in-vivo anticonvulsant activity of the target compds. studied using maximal electroshock seizure and s.c. pentylenetetrazole, while their toxicity study was detd. by rotarod at 20, 40, and 100 mg/kg.  Most of the new compds. displayed remarkable anticonvulsant properties at these doses.  Particularly, hydrazide I and triazole II carrying H-bond donor groups, viz. OH and amine moieties, resp., exhibited complete protection against seizure comparable to std. diazepam.  All the compds. are non-toxic ≤100 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjDqOpZ0Ao_LVg90H21EOLACvtfcHk0liDcLNo_lW49Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeksrvM&md5=05d2ce5f998d86810fda347d338c2da1</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs00044-013-0887-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-013-0887-7%26sid%3Dliteratum%253Aachs%26aulast%3DUlloora%26aufirst%3DS.%26aulast%3DShabaraya%26aufirst%3DR.%26aulast%3DAdhikari%26aufirst%3DA.%2BV.%26atitle%3DNew%25206-Bromoimidazo%255B1%252C2-a%255Dpyridine-2-carbohydrazide%2520Derivatives%253A%2520Synthesis%2520and%2520Anticonvulsant%2520Studies%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2014%26volume%3D23%26spage%3D3019%26epage%3D3028%26doi%3D10.1007%2Fs00044-013-0887-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haegebarth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fracasso, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkie, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">BAY 80-6946 is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2319</span>– <span class="NLM_lpage">2330</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0993-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1158%2F1535-7163.MCT-12-0993-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=24170767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=2319-2330&author=N.+Liuauthor=B.+R.+Rowleyauthor=C.+O.+Bullauthor=C.+Schneiderauthor=A.+Haegebarthauthor=C.+A.+Schatzauthor=P.+R.+Fracassoauthor=D.+P.+Wilkieauthor=M.+Hentemannauthor=S.+M.+Wilhelmauthor=W.+J.+Scottauthor=D.+Mumbergauthor=K.+Ziegelbauer&title=BAY+80-6946+is+a+Highly+Selective+Intravenous+PI3K+Inhibitor+with+Potent+p110%CE%B1+and+p110%CE%B4+Activities+in+Tumor+Cell+Lines+and+Xenograft+Models&doi=10.1158%2F1535-7163.MCT-12-0993-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models</span></div><div class="casAuthors">Liu, Ningshu; Rowley, Bruce R.; Bull, Cathy O.; Schneider, Claudia; Haegebarth, Andrea; Schatz, Christoph A.; Fracasso, Paul R.; Wilkie, Dean P.; Hentemann, Martin; Wilhelm, Scott M.; Scott, William J.; Mumberg, Dominik; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2319-2330</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Because of the complexity derived from the existence of various phosphoinositide 3-kinase (PI3K) isoforms and their differential roles in cancers, development of PI3K inhibitors with differential pharmacol. and pharmacokinetic profiles would allow best exploration in different indications, combinations, and dosing regimens.  Here, we report BAY 80-6946, a highly selective and potent pan-class I PI3K inhibitor with sub-nanomolar IC50s against PI3Kα and PI3Kδ.  BAY 80-6946 exhibited preferential inhibition (about 10-fold) of AKT phosphorylation by PI3Kα compared with PI3Kβ in cells.  BAY 80-6946 showed superior antitumor activity (>40-fold) in PIK3CA mutant and/or HER2 overexpression as compared with HER2-neg. and wild-type PIK3CA breast cancer cell lines.  In addn., BAY 80-6946 revealed potent activity to induce apoptosis in a subset of tumor cells with aberrant activation of PI3K as a single agent.  In vivo, single i.v. administration of BAY 80-6946 exhibited higher exposure and prolonged inhibition of pAKT levels in tumors vs. plasma.  BAY 80-6946 is efficacious in tumors with activated PI3K when dosed either continuously or intermittently.  Thus, BAY 80-6946 induced 100% complete tumor regression when dosed as a single agent every second day in rats bearing HER2-amplified and PIK3CA-mutated KPL4 breast tumors.  In combination with paclitaxel, weekly dosing of BAY 80-6946 is sufficient to reach sustained response in all animals bearing patient-derived non-small cell lung cancer xenografts, despite a short plasma elimination half-life (1 h) in mice.  Thus, BAY 80-6946 is a promising agent with differential pharmacol. and pharmacokinetic properties for the treatment of PI3K-dependent human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxfdGLDML1MrVg90H21EOLACvtfcHk0lgpBPnsm0JK7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarsrrM&md5=344a497d4e4638f3b37900a417054510</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0993-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0993-T%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DRowley%26aufirst%3DB.%2BR.%26aulast%3DBull%26aufirst%3DC.%2BO.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DHaegebarth%26aufirst%3DA.%26aulast%3DSchatz%26aufirst%3DC.%2BA.%26aulast%3DFracasso%26aufirst%3DP.%2BR.%26aulast%3DWilkie%26aufirst%3DD.%2BP.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DScott%26aufirst%3DW.%2BJ.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DBAY%252080-6946%2520is%2520a%2520Highly%2520Selective%2520Intravenous%2520PI3K%2520Inhibitor%2520with%2520Potent%2520p110%25CE%25B1%2520and%2520p110%25CE%25B4%2520Activities%2520in%2520Tumor%2520Cell%2520Lines%2520and%2520Xenograft%2520Models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D2319%26epage%3D2330%26doi%3D10.1158%2F1535-7163.MCT-12-0993-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBiasi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winckler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFramboise, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zander, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacConaill, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoletti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majmudar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziaugra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beroukhim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barretina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emery, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellinghoff, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischel, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloughesy, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liau, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalona, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signoretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span> <span> </span><span class="NLM_article-title">High-throughput Oncogene Mutation Profiling in Human Cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1038/ng1975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1038%2Fng1975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=17293865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVOktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2007&pages=347-351&author=R.+K+Thomasauthor=A.+C.+Bakerauthor=R.+M.+DeBiasiauthor=W.+Wincklerauthor=T.+LaFramboiseauthor=W.+M.+Linauthor=M.+Wangauthor=W.+Fengauthor=T.+Zanderauthor=L.+E.+MacConaillauthor=J.+C.+Leeauthor=R.+Nicolettiauthor=C.+Hattonauthor=M.+Goyetteauthor=L.+Girardauthor=K.+Majmudarauthor=L.+Ziaugraauthor=K.-K.+Wongauthor=S.+Gabrielauthor=R.+Beroukhimauthor=M.+Peytonauthor=J.+Barretinaauthor=A.+Duttauthor=C.+Emeryauthor=H.+Greulichauthor=K.+Shahauthor=H.+Sasakiauthor=A.+Gazdarauthor=J.+Minnaauthor=S.+A.+Armstrongauthor=I.+K.+Mellinghoffauthor=F.+S.+Hodiauthor=G.+Dranoffauthor=P.+S.+Mischelauthor=T.+F.+Cloughesyauthor=S.+F.+Nelsonauthor=L.+M.+Liauauthor=K.+Mertzauthor=M.+A.+Rubinauthor=H.+Mochauthor=M.+Lodaauthor=W.+Catalonaauthor=J.+Fletcherauthor=S.+Signorettiauthor=F.+Kayeauthor=K.+C.+Andersonauthor=G.+D.+Demetriauthor=R.+Dummerauthor=S.+Wagnerauthor=M.+Herlynauthor=W.+R.+Sellersauthor=M.+Meyersonauthor=L.+A.+Garraway&title=High-throughput+Oncogene+Mutation+Profiling+in+Human+Cancer&doi=10.1038%2Fng1975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput oncogene mutation profiling in human cancer</span></div><div class="casAuthors">Thomas, Roman K.; Baker, Alissa C.; DeBiasi, Ralph M.; Winckler, Wendy; LaFramboise, Thomas; Lin, William M.; Wang, Meng; Feng, Whei; Zander, Thomas; MacConnaill, Laura E.; Lee, Jeffrey C.; Nicoletti, Rick; Hatton, Charlie; Goyette, Mary; Girard, Luc; Majmudar, Kuntal; Ziaugra, Liuda; Wong, Kwok-Kin; Gabriel, Stacey; Beroukhim, Rameen; Peyton, Michael; Barretina, Jordi; Dutt, Amit; Emery, Caroline; Greulich, Heidi; Shah, Kinjal; Sasaki, Hidefumi; Gazdar, Adi; Minna, John; Armstrong, Scott A.; Mellinghoff, Ingo K.; Hodi, F. Stephen; Dranoff, Glenn; Mischel, Paul S.; Cloughesy, Tim F.; Nelson, Stan F.; Liau, Linda M.; Mertz, Kirsten; Rubin, Mark A.; Moch, Holger; Loda, Massimo; Catalona, William; Fletcher, Jonathan; Signoretti, Sabina; Kaye, Frederic; Anderson, Kenneth C.; Demetri, George D.; Dummer, Reinhard; Wagner, Stephan; Herlyn, Meenhard; Sellers, William R.; Meyerson, Matthew; Garraway, Levi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-351</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Systematic efforts are underway to decipher the genetic changes assocd. with tumor initiation and progression.  However, widespread clin. application of this information is hampered by an inability to identify crit. genetic events across the spectrum of human tumors with adequate sensitivity and scalability.  Here, we have adapted high-throughput genotyping to query 238 known oncogene mutations across 1,000 human tumor samples.  This approach established robust mutation distributions spanning 17 cancer types.  Of 17 oncogenes analyzed, we found 14 to be mutated at least once, and 298 (30%) samples carried at least one mutation.  Moreover, we identified previously unrecognized oncogene mutations in several tumor types and obsd. an unexpectedly high no. of co-occurring mutations.  These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQJq3aVM33obVg90H21EOLACvtfcHk0lgpBPnsm0JK7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVOktrs%253D&md5=e27db295fad8db6bd2133b818363ec1a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fng1975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1975%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DR.%2BK%26aulast%3DBaker%26aufirst%3DA.%2BC.%26aulast%3DDeBiasi%26aufirst%3DR.%2BM.%26aulast%3DWinckler%26aufirst%3DW.%26aulast%3DLaFramboise%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DW.%2BM.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DW.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DMacConaill%26aufirst%3DL.%2BE.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DNicoletti%26aufirst%3DR.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DGoyette%26aufirst%3DM.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DMajmudar%26aufirst%3DK.%26aulast%3DZiaugra%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DEmery%26aufirst%3DC.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DGazdar%26aufirst%3DA.%26aulast%3DMinna%26aufirst%3DJ.%26aulast%3DArmstrong%26aufirst%3DS.%2BA.%26aulast%3DMellinghoff%26aufirst%3DI.%2BK.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DDranoff%26aufirst%3DG.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DNelson%26aufirst%3DS.%2BF.%26aulast%3DLiau%26aufirst%3DL.%2BM.%26aulast%3DMertz%26aufirst%3DK.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DCatalona%26aufirst%3DW.%26aulast%3DFletcher%26aufirst%3DJ.%26aulast%3DSignoretti%26aufirst%3DS.%26aulast%3DKaye%26aufirst%3DF.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DHigh-throughput%2520Oncogene%2520Mutation%2520Profiling%2520in%2520Human%2520Cancer%26jtitle%3DNat.%2520Genet.%26date%3D2007%26volume%3D39%26spage%3D347%26epage%3D351%26doi%3D10.1038%2Fng1975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 11 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yifan Li, Kaichen Shu, Ping Liu, <span class="NLM_string-name hlFld-ContribAuthor">Peipei Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Selective C-5 Oxidative Radical Silylation of Imidazopyridines Promoted by Lewis Acid. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (16)
                                     , 6304-6307. <a href="https://doi.org/10.1021/acs.orglett.0c02131" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c02131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c02131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c02131%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSelective%252BC-5%252BOxidative%252BRadical%252BSilylation%252Bof%252BImidazopyridines%252BPromoted%252Bby%252BLewis%252BAcid%26aulast%3DLi%26aufirst%3DYifan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28062020%26date%3D03082020%26volume%3D22%26issue%3D16%26spage%3D6304%26epage%3D6307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Goutam Brahmachari, Nayana Nayek, Indrajit Karmakar, Khondekar Nurjamal, Swapan K. Chandra, <span class="NLM_string-name hlFld-ContribAuthor">Anindita Bhowmick</span>. </span><span class="cited-content_cbyCitation_article-title">Series of Functionalized 5-(2-Arylimidazo[1,2-a]pyridin-3-yl)pyrimidine-2,4(1H,3H)-diones: A Water-Mediated Three-Component Catalyst-Free Protocol Revisited. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (13)
                                     , 8405-8414. <a href="https://doi.org/10.1021/acs.joc.0c00732" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00732</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00732%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSeries%252Bof%252BFunctionalized%252B5-%2525282-Arylimidazo%25255B1%25252C2-a%25255Dpyridin-3-yl%252529pyrimidine-2%25252C4%2525281H%25252C3H%252529-diones%25253A%252BA%252BWater-Mediated%252BThree-Component%252BCatalyst-Free%252BProtocol%252BRevisited%26aulast%3DBrahmachari%26aufirst%3DGoutam%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20032020%26date%3D15062020%26date%3D29052020%26volume%3D85%26issue%3D13%26spage%3D8405%26epage%3D8414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dongmei  Chen</span>, <span class="hlFld-ContribAuthor ">Yumei  Chen</span>, <span class="hlFld-ContribAuthor ">Qingmei  Wu</span>, <span class="hlFld-ContribAuthor ">Xiaohan  Zhang</span>, <span class="hlFld-ContribAuthor ">Weike  Liao</span>, <span class="hlFld-ContribAuthor ">Zhixu  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, crystal structure and vibrational properties of N-(8-(3-(3-(tert-butyl)ureido)phenyl)imidazo[1,2-a]pyridin-6-yl)acetamide. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1245 </em>, 131101. <a href="https://doi.org/10.1016/j.molstruc.2021.131101" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.131101</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.131101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.131101%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DSynthesis%25252C%252Bcrystal%252Bstructure%252Band%252Bvibrational%252Bproperties%252Bof%252BN-%2525288-%2525283-%2525283-%252528tert-butyl%252529ureido%252529phenyl%252529imidazo%25255B1%25252C2-a%25255Dpyridin-6-yl%252529acetamide%26aulast%3DChen%26aufirst%3DDongmei%26date%3D2021%26volume%3D1245%26spage%3D131101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chengbin  Yang</span>, <span class="hlFld-ContribAuthor ">Chenyue  Xu</span>, <span class="hlFld-ContribAuthor ">Zhipeng  Li</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Tianze  Wu</span>, <span class="hlFld-ContribAuthor ">Hui  Hong</span>, <span class="hlFld-ContribAuthor ">Mingzhu  Lu</span>, <span class="hlFld-ContribAuthor ">Yu  Jia</span>, <span class="hlFld-ContribAuthor ">Yongtai  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaofeng  Liu</span>, <span class="hlFld-ContribAuthor ">Mingli  Deng</span>, <span class="hlFld-ContribAuthor ">Zhenxia  Chen</span>, <span class="hlFld-ContribAuthor ">Qingquan  Li</span>, <span class="hlFld-ContribAuthor ">Yun  Ling</span>, <span class="hlFld-ContribAuthor ">Yaming  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>223 </em>, 113661. <a href="https://doi.org/10.1016/j.ejmech.2021.113661" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113661</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113661%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBioisosteric%252Breplacements%252Bof%252Bthe%252Bindole%252Bmoiety%252Bfor%252Bthe%252Bdevelopment%252Bof%252Ba%252Bpotent%252Band%252Bselective%252BPI3K%2525CE%2525B4%252Binhibitor%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DYang%26aufirst%3DChengbin%26date%3D2021%26volume%3D223%26spage%3D113661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giammarco  Tenti</span>, <span class="hlFld-ContribAuthor ">Ángel  Cores</span>, <span class="hlFld-ContribAuthor ">María Teresa  Ramos</span>, <span class="hlFld-ContribAuthor ">J. Carlos  Menéndez</span>. </span><span class="cited-content_cbyCitation_article-title">(E)-3-((2-Fluorophenyl)(hydroxy)methylene)imidazo[1,2-a]pyridin-2(3H)-one. </span><span class="cited-content_cbyCitation_journal-name">Molbank</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (2)
                                     , M1212. <a href="https://doi.org/10.3390/M1212" title="DOI URL">https://doi.org/10.3390/M1212</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/M1212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2FM1212%26sid%3Dliteratum%253Aachs%26jtitle%3DMolbank%26atitle%3D%252528E%252529-3-%252528%2525282-Fluorophenyl%252529%252528hydroxy%252529methylene%252529imidazo%25255B1%25252C2-a%25255Dpyridin-2%2525283H%252529-one%26aulast%3DTenti%26aufirst%3DGiammarco%26date%3D2021%26date%3D2021%26volume%3D2021%26issue%3D2%26spage%3DM1212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Biswajita  Baruah</span>, <span class="hlFld-ContribAuthor ">Mohit L.  Deb</span>. </span><span class="cited-content_cbyCitation_article-title">Catalyst-free and additive-free reactions enabling C–C bond formation: a journey towards a sustainable future. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (6)
                                     , 1191-1229. <a href="https://doi.org/10.1039/D0OB02149K" title="DOI URL">https://doi.org/10.1039/D0OB02149K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB02149K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB02149K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DCatalyst-free%252Band%252Badditive-free%252Breactions%252Benabling%252BC%2525E2%252580%252593C%252Bbond%252Bformation%25253A%252Ba%252Bjourney%252Btowards%252Ba%252Bsustainable%252Bfuture%26aulast%3DBaruah%26aufirst%3DBiswajita%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D6%26spage%3D1191%26epage%3D1229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao-Yue  Xiang</span>, <span class="hlFld-ContribAuthor ">Xiang  Wang</span>, <span class="hlFld-ContribAuthor ">Yan-Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Xi  Zhang</span>, <span class="hlFld-ContribAuthor ">Cun  Tan</span>, <span class="hlFld-ContribAuthor ">Yi  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Zhi-Wei  Gao</span>, <span class="hlFld-ContribAuthor ">Xiao-Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Bing  Xiong</span>, <span class="hlFld-ContribAuthor ">Zhao-Bing  Gao</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Ling-Hua  Meng</span>, <span class="hlFld-ContribAuthor ">Chun-Hao  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112913. <a href="https://doi.org/10.1016/j.ejmech.2020.112913" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112913</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112913%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bmethyl%252B%2525285-%2525286-%252528%2525284-%252528methylsulfonyl%252529piperazin-1-yl%252529methyl%252529-4-morpholinopyrrolo%25255B2%25252C1-f%25255D%25255B1%25252C2%25252C4%25255Dtriazin-2-yl%252529-4-%252528trifluoromethyl%252529pyridin-2-yl%252529carbamate%252B%252528CYH33%252529%252Bas%252Ban%252Borally%252Bbioavailable%25252C%252Bhighly%252Bpotent%25252C%252BPI3K%252Balpha%252Binhibitor%252Bfor%252Bthe%252Btreatment%252Bof%252Badvanced%252Bsolid%252Btumors%26aulast%3DXiang%26aufirst%3DHao-Yue%26date%3D2021%26volume%3D209%26spage%3D112913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuqiao  Han</span>, <span class="hlFld-ContribAuthor ">Ziwei  Ren</span>, <span class="hlFld-ContribAuthor ">Yixin  Wu</span>, <span class="hlFld-ContribAuthor ">Yunzhong  Chen</span>, <span class="hlFld-ContribAuthor ">Zhenmei  Cui</span>, <span class="hlFld-ContribAuthor ">Tong  Zhu</span>, <span class="hlFld-ContribAuthor ">Mingliang  Ma</span>, <span class="hlFld-ContribAuthor ">Yijie  Du</span>, <span class="hlFld-ContribAuthor ">Suzhen  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological activation of the p53 pathway by a new compound CYZ2017 exerts anti-tumor effects. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2020,</strong> <em>533 </em>
                                    (4)
                                     , 1069-1075. <a href="https://doi.org/10.1016/j.bbrc.2020.09.122" title="DOI URL">https://doi.org/10.1016/j.bbrc.2020.09.122</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2020.09.122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2020.09.122%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DPharmacological%252Bactivation%252Bof%252Bthe%252Bp53%252Bpathway%252Bby%252Ba%252Bnew%252Bcompound%252BCYZ2017%252Bexerts%252Banti-tumor%252Beffects%26aulast%3DHan%26aufirst%3DYuqiao%26date%3D2020%26volume%3D533%26issue%3D4%26spage%3D1069%26epage%3D1075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adinarayana  Nandikolla</span>, <span class="hlFld-ContribAuthor ">Singireddi  Srinivasarao</span>, <span class="hlFld-ContribAuthor ">Banoth  Karan Kumar</span>, <span class="hlFld-ContribAuthor ">Sankaranarayanan  Murugesan</span>, <span class="hlFld-ContribAuthor ">Himanshu  Aggarwal</span>, <span class="hlFld-ContribAuthor ">Louise L.  Major</span>, <span class="hlFld-ContribAuthor ">Terry K.  Smith</span>, <span class="hlFld-ContribAuthor ">Kondapalli Venkata Gowri  Chandra Sekhar</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, study of antileishmanial and antitrypanosomal activity of imidazo pyridine fused triazole analogues. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (63)
                                     , 38328-38343. <a href="https://doi.org/10.1039/D0RA07881F" title="DOI URL">https://doi.org/10.1039/D0RA07881F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA07881F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA07881F%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSynthesis%25252C%252Bstudy%252Bof%252Bantileishmanial%252Band%252Bantitrypanosomal%252Bactivity%252Bof%252Bimidazo%252Bpyridine%252Bfused%252Btriazole%252Banalogues%26aulast%3DNandikolla%26aufirst%3DAdinarayana%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D63%26spage%3D38328%26epage%3D38343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mina  Saeedi</span>, <span class="hlFld-ContribAuthor ">Maryam  Raeisi-Nafchi</span>, <span class="hlFld-ContribAuthor ">Sepideh  Sobhani</span>, <span class="hlFld-ContribAuthor ">Seyedeh Sara  Mirfazli</span>, <span class="hlFld-ContribAuthor ">Mahsa  Zardkanlou</span>, <span class="hlFld-ContribAuthor ">Somayeh  Mojtabavi</span>, <span class="hlFld-ContribAuthor ">Mohammad Ali  Faramarzi</span>, <span class="hlFld-ContribAuthor ">Tahmineh  Akbarzadeh</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 4-alkylaminoimidazo[1,2-a]pyridines linked to carbamate moiety as potent α-glucosidase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2020,</strong> <em>28 </em><a href="https://doi.org/10.1007/s11030-020-10137-8" title="DOI URL">https://doi.org/10.1007/s11030-020-10137-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-020-10137-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-020-10137-8%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DSynthesis%252Bof%252B4-alkylaminoimidazo%25255B1%25252C2-a%25255Dpyridines%252Blinked%252Bto%252Bcarbamate%252Bmoiety%252Bas%252Bpotent%252B%2525CE%2525B1-glucosidase%252Binhibitors%26aulast%3DSaeedi%26aufirst%3DMina%26date%3D2020%26date%3D2020%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiajia  Sun</span>, <span class="hlFld-ContribAuthor ">Yifan  Feng</span>, <span class="hlFld-ContribAuthor ">Yuan  Huang</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>. </span><span class="cited-content_cbyCitation_article-title">Research advances on selective phosphatidylinositol 3 kinase δ (PI3Kδ) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (19)
                                     , 127457. <a href="https://doi.org/10.1016/j.bmcl.2020.127457" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127457%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DResearch%252Badvances%252Bon%252Bselective%252Bphosphatidylinositol%252B3%252Bkinase%252B%2525CE%2525B4%252B%252528PI3K%2525CE%2525B4%252529%252Binhibitors%26aulast%3DSun%26aufirst%3DJiajia%26date%3D2020%26volume%3D30%26issue%3D19%26spage%3D127457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of PI3K/mTOR dual inhibitors in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of PI3K inhibitors containing imidazo[1,2-<i>a</i>]pyridine core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design strategy based on <b>1i</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>5a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaOH, ethanol, H<sub>2</sub>O, 80 °C, 0.5 h, then HCl (2 mol/L), 78%; (b) prop-2-yn-1-amine, HATU, DIPEA, THF, 0 °C to rt, 12 h, 91%; (c) 2,4-difluoro-<i>N</i>-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 110 °C, 1.5 h, 80%; (d) N<sub>3</sub>-R<sub>2</sub>, CuTC, THF, rt, 12 h, 50–87%.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0011.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>9a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2,4-difluoro-<i>N</i>-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 110 °C, reflux, 1.5 h, 95%; (b) NIS, CH<sub>3</sub>CN, rt, 18 h, 80%; (c) trimethylsilylacetylene, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, PPh<sub>3</sub>, CuI, Et<sub>3</sub>N, THF, 45 °C, 14 h, 71%; (d) TBAF, THF, rt, 30 min, 66%; (e) N<sub>3</sub>-R<sub>1</sub>, CuTC, THF, rt, 12 h, 60–85%.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0012.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>15a</b>–<b>r</b> and <b>18a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) hydrazine hydrate, ethanol, 100 °C, reflux, 13 h, 86%; (b) acrolein, acetic acid, CHCl<sub>3</sub>, rt, 23 h; (c) IBD, DCM, rt, 14 h, 14–53% over two steps; (d) nucleophiles, DBU, DCM, rt, 12 h, 33–92%; (e) arylboronic ester, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 110 °C, reflux, 1.5 h, 33–87%; (f) methyl 3-formylbenzoate, acetic acid, CHCl<sub>3</sub>, 70 °C, reflux, 3 h; (g) hydrazine hydrate, ethanol, 50 °C, reflux, 13 h, 67%; (h) aldehydes, CHCl<sub>3</sub>, acetic acid, 70 °C, reflux, 12 h.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0013.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>22</b> and <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) hydrazine hydrate, ethanol, 100 °C, reflux, 2 h, 44–87%; (b) acrolein, acetic acid, CHCl<sub>3</sub>, 70 °C, reflux, 3 h; (c) IBD, DCM, rt, 14 h, 27–31% over two steps; (d) nucleophiles, DBU, DCM, rt, 12 h, 34–64%; (e) arylboronic ester, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 110 °C, reflux, 1.5 h, 52–85%.</p></p></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinase-selectivity profiling of compound <b>15a</b> at a concentration of 1 μM (DiscoveRX). (A) TREEspot interaction maps for compound <b>15a</b> against 97 kinases. (B) Only PI3K isoforms were hits (mTOR is not included in the screening). Data for binding interaction are reported as % control, where low values stand for stronger hits. <i>S</i>-score is a quantitative indicator of compound selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0005.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of <b>15a</b> on pAKT, AKT, p-p70S6K, and p70S6K in HCT116 and HT-29 cells. HCT116 cells and HT-29 cells were treated at the indicated concentrations of <b>15a</b> for 24 h. The expression levels of AKT, p70S6K, and their phosphorylated forms were analyzed by Western blotting. GAPDH was used as a loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0006.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Proposed binding modes between compound <b>15a</b> and the PI3Kα (left, PDB code for PI3Kα is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JPS">4JPS</a>) and mTOR (right, PDB code for mTOR is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>) models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0007.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Pharmacokinetic/pharmacodynamic evaluations of <b>15a</b> in SD rats and HCT116 human colorectal cancer xenografts in nude mice. (A) Mean plasma concentration versus time curves after a single intravenous and oral dosing of <b>15a</b> to male SD rats (<i>n</i> = 3). (B) Plasma and tumor concentrations of <b>15a</b> formulated in vehicle containing 5% DMSO, 45% PEG400 following a single po administration of 20 mg/kg (<i>n</i> = 2) in HCT116 xenografts in nude mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0008.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <b>15a</b> inhibited tumor growth of HCT116 xenograft in female BALB/c nude mice. (A) Tumor volume changes following the treatment of <b>15a</b> at a dose of 15 mg/kg (po, daily) and copanlisib (ip, every second day) at a dose of 15 mg/kg beginning on the fifth day after inoculation. (B) Average body weights for <b>15a</b>, copanlisib, and vehicle-treated mice groups. (C) Tumors removed from vehicle, copanlisib, and <b>15a</b>-treated mice groups. (D) Tumor weight of vehicle, copanlisib, and <b>15a</b>-treated mice groups. (E) Immunohistochemical staining of Ki67 and p-AKT(S473) and HE staining in tumor tissues from <b>15a</b>-treated mice and vehicle groups. Results are expressed as the mean ± SEM (<i>n</i> = 6 for each group) and analyzed by one-way ANOVA analysis: ****<i>P</i> < 0.0001 vs vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/medium/jm9b01736_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0009.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <b>15a</b> inhibited tumor growth of HT-29 xenograft in female BALB/c nude mice. (A) Tumor volume changes following the treatment of <b>15a</b> at doses of 10 mg/kg and 20 mg/kg (po, daily) and copanlisib (ip, every second day) at a dose of 15 mg/kg beginning on the eighth day after inoculation. (B) Average body weights for <b>15a</b>, copanlisib, and vehicle-treated mice groups. (C) Tumors removed from vehicle, copanlisib, and <b>15a</b>-treated mice groups. (D) Tumor weight of vehicle, copanlisib, and <b>15a</b>-treated mice groups. Results are expressed as the mean ± SEM (<i>n</i> = 7 for each group) and analyzed by one-way ANOVA analysis: ****<i>P</i> < 0.0001 vs vehicle, ***<i>P</i> < 0.001 vs vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01736/20200323/images/large/jm9b01736_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01736&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i73">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75438" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75438" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 23 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span> <span> </span><span class="NLM_article-title">PI3K and Cancer: Lessons, Challenges and Opportunities</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&author=D.+A.+Frumanauthor=C.+Rommel&title=PI3K+and+Cancer%3A+Lessons%2C+Challenges+and+Opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0lgofGTC5IkqbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520Cancer%253A%2520Lessons%252C%2520Challenges%2520and%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+Regulation+of+Akt%2FPKB+by+the+Rictor-mTOR+Complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0lg0bwqkvl2W-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520Regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520Rictor-mTOR%2520Complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vivanco, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">The Phosphatidylinositol 3-kinase AKT Pathway in Human Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1038/nrc839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+Phosphatidylinositol+3-kinase+AKT+Pathway+in+Human+Cancer&doi=10.1038%2Fnrc839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0lg0bwqkvl2W-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520Phosphatidylinositol%25203-kinase%2520AKT%2520Pathway%2520in%2520Human%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D489%26epage%3D501%26doi%3D10.1038%2Fnrc839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span> <span> </span><span class="NLM_article-title">PI3K-Akt Pathway: Its Functions and Alterations in Human Cancer</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1023/B:APPT.0000045801.15585.dd</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1023%2FB%3AAPPT.0000045801.15585.dd" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=15505410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVKqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=667-676&author=M.+Osakiauthor=M.+Oshimuraauthor=H.+Ito&title=PI3K-Akt+Pathway%3A+Its+Functions+and+Alterations+in+Human+Cancer&doi=10.1023%2FB%3AAPPT.0000045801.15585.dd"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K-Akt pathway: Its functions and alterations in human cancer</span></div><div class="casAuthors">Osaki, M.; Oshimura, M.; Ito, H.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">667-676</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol-3-kinase (PI3K) is a lipid kinase and generates phosphatidylinositol-3,4,5-trisphosphate (PI(3, 4, 5)P3).  PI(3, 4, 5)P3 is a second messenger essential for the translocation of Akt to the plasma membrane where it is phosphorylated and activated by phosphoinositide-dependent kinase (PDK) 1 and PDK2.  Activation of Akt plays a pivotal role in fundamental cellular functions such as cell proliferation and survival by phosphorylating a variety of substrates.  In recent years, it was reported that alterations to the PI3K-Akt signaling pathway are frequent in human cancer.  Constitutive activation of the PI3K-Akt pathway occurs due to amplification of the PIK3C gene encoding PI3K or the Akt gene, or as a result of mutations in components of the pathway, for example PTEN (phosphatase and tensin homolog deleted on chromosome 10), which inhibit the activation of Akt.  Several small mols. designed to specifically target PI3K-Akt were developed, and induced cell cycle arrest or apoptosis in human cancer cells in vitro and in vivo.  Moreover, the combination of an inhibitor with various cytotoxic agents enhances the anti-tumor efficacy.  Therefore, specific inhibition of the activation of Akt may be a valid approach to treating human malignancies and overcoming the resistance of cancer cells to radiation or chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpetriT7oBnUrVg90H21EOLACvtfcHk0lg0bwqkvl2W-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVKqu70%253D&md5=9bb169ad851d289623247a49b3e63ffd</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1023%2FB%3AAPPT.0000045801.15585.dd&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253AAPPT.0000045801.15585.dd%26sid%3Dliteratum%253Aachs%26aulast%3DOsaki%26aufirst%3DM.%26aulast%3DOshimura%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DH.%26atitle%3DPI3K-Akt%2520Pathway%253A%2520Its%2520Functions%2520and%2520Alterations%2520in%2520Human%2520Cancer%26jtitle%3DApoptosis%26date%3D2004%26volume%3D9%26spage%3D667%26epage%3D676%26doi%3D10.1023%2FB%3AAPPT.0000045801.15585.dd" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuzugullu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">PI3K in Cancer: Divergent Roles of Isoforms, Modes of Activation and Therapeutic Targeting</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1038/nrc3860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1038%2Fnrc3860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=25533673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=7-24&author=L.+M.+Thorpeauthor=H.+Yuzugulluauthor=J.+J.+Zhao&title=PI3K+in+Cancer%3A+Divergent+Roles+of+Isoforms%2C+Modes+of+Activation+and+Therapeutic+Targeting&doi=10.1038%2Fnrc3860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting</span></div><div class="casAuthors">Thorpe, Lauren M.; Yuzugullu, Haluk; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-24</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular signalling in response to extracellular stimuli.  Hyperactivation of PI3K signalling cascades is one of the most common events in human cancers.  In this Review, we discuss recent advances in our knowledge of the roles of specific PI3K isoforms in normal and oncogenic signalling, the different ways in which PI3K can be upregulated, and the current state and future potential of targeting this pathway in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxh6fOPe86x7Vg90H21EOLACvtfcHk0ljrXOjsZ44qOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKltb3N&md5=0b609a62c2ec9fcc6efae437d2ed7a24</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc3860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3860%26sid%3Dliteratum%253Aachs%26aulast%3DThorpe%26aufirst%3DL.%2BM.%26aulast%3DYuzugullu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DPI3K%2520in%2520Cancer%253A%2520Divergent%2520Roles%2520of%2520Isoforms%252C%2520Modes%2520of%2520Activation%2520and%2520Therapeutic%2520Targeting%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D7%26epage%3D24%26doi%3D10.1038%2Fnrc3860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucherlapati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadjipanayis, A.</span></span> <span> </span><span class="NLM_article-title">A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">820</span>– <span class="NLM_lpage">832</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2017.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1016%2Fj.ccell.2017.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=28528867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVCntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=820-832&author=Y.+Zhangauthor=K.+S.+Ngauthor=M.+Kucherlapatiauthor=F.+Chenauthor=Y.+Liuauthor=Y.+H.+Tsangauthor=G.+D.+Velascoauthor=J.+J.+Kangauthor=R.+Akbaniauthor=A.+Hadjipanayis&title=A+Pan-Cancer+Proteogenomic+Atlas+of+PI3K%2FAKT%2FmTOR+Pathway+Alterations&doi=10.1016%2Fj.ccell.2017.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations</span></div><div class="casAuthors">Zhang, Yiqun; Kwok-Shing Ng, Patrick; Kucherlapati, Melanie; Chen, Fengju; Liu, Yuexin; Tsang, Yiu Huen; de Velasco, Guillermo; Jeong, Kang Jin; Akbani, Rehan; Hadjipanayis, Angela; Pantazi, Angeliki; Bristow, Christopher A.; Lee, Eunjung; Mahadeshwar, Harshad S.; Tang, Jiabin; Zhang, Jianhua; Yang, Lixing; Seth, Sahil; Lee, Semin; Ren, Xiaojia; Song, Xingzhi; Sun, Huandong; Seidman, Jonathan; Luquette, Lovelace J.; Xi, Ruibin; Chin, Lynda; Protopopov, Alexei; Westbrook, Thomas F.; Shelley, Carl Simon; Choueiri, Toni K.; Ittmann, Michael; Van Waes, Carter; Weinstein, John N.; Liang, Han; Henske, Elizabeth P.; Godwin, Andrew K.; Park, Peter J.; Kucherlapati, Raju; Scott, Kenneth L.; Mills, Gordon B.; Kwiatkowski, David J.; Creighton, Chad J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">820-832.e3</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Mol. alterations involving the PI3K/AKT/mTOR pathway (including mutation, copy no., protein, or RNA) were examd. across 11,219 human cancers representing 32 major types.  Within specific mutated genes, frequency, mutation hotspot residues, in silico predictions, and functional assays were all informative in distinguishing the subset of genetic variants more likely to have functional relevance.  Multiple oncogenic pathways including PI3K/AKT/mTOR converged on similar sets of downstream transcriptional targets.  In addn. to mutation, structural variations and partial copy losses involving PTEN and STK11 showed evidence for having functional relevance.  A substantial fraction of cancers showed high mTOR pathway activity without an assocd. canonical genetic or genomic alteration, including cancers harboring IDH1 or VHL mutations, suggesting multiple mechanisms for pathway activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9-7y_MBe6ErVg90H21EOLACvtfcHk0ljrXOjsZ44qOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVCntLw%253D&md5=9e1d33679611a9ad57a7c3a815901d96</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2017.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2017.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DNg%26aufirst%3DK.%2BS.%26aulast%3DKucherlapati%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTsang%26aufirst%3DY.%2BH.%26aulast%3DVelasco%26aufirst%3DG.%2BD.%26aulast%3DKang%26aufirst%3DJ.%2BJ.%26aulast%3DAkbani%26aufirst%3DR.%26aulast%3DHadjipanayis%26aufirst%3DA.%26atitle%3DA%2520Pan-Cancer%2520Proteogenomic%2520Atlas%2520of%2520PI3K%252FAKT%252FmTOR%2520Pathway%2520Alterations%26jtitle%3DCancer%2520Cell%26date%3D2017%26volume%3D31%26spage%3D820%26epage%3D832%26doi%3D10.1016%2Fj.ccell.2017.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Q.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1500</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1158%2F0008-5472.CAN-05-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=16452206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1500-1508&author=K.+E.+O%E2%80%99Reillyauthor=F.+Rojoauthor=Q.-B.+Sheauthor=D.+Solitauthor=G.+B.+Millsauthor=D.+Smithauthor=H.+Laneauthor=F.+Hofmannauthor=D.+J.+Hicklinauthor=D.+L.+Ludwigauthor=J.+Baselgaauthor=N.+Rosen&title=mTOR+Inhibition+Induces+Upstream+Receptor+Tyrosine+Kinase+Signaling+and+Activates+Akt&doi=10.1158%2F0008-5472.CAN-05-2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span></div><div class="casAuthors">O'Reilly, Kathryn E.; Rojo, Fredi; She, Qing-Bai; Solit, David; Mills, Gordon B.; Smith, Debra; Lane, Heidi; Hofmann, Francesco; Hicklin, Daniel J.; Ludwig, Dale L.; Baselga, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1500-1508</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway.  In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.  Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity.  We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin deriv., RAD001.  IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR.  In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium.  The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation.  Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIDQUdQ-jbi7Vg90H21EOLACvtfcHk0ljrXOjsZ44qOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D&md5=758cd9999dc156bf498edf32174fc2e7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2925%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DK.%2BE.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DShe%26aufirst%3DQ.-B.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DmTOR%2520Inhibition%2520Induces%2520Upstream%2520Receptor%2520Tyrosine%2520Kinase%2520Signaling%2520and%2520Activates%2520Akt%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1500%26epage%3D1508%26doi%3D10.1158%2F0008-5472.CAN-05-2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gulati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, G.</span></span> <span> </span><span class="NLM_article-title">Nutrient Sensing in the mTOR/S6K1 Signalling Pathway</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1042/BST0350236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1042%2FBST0350236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=17371247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1WrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=236-238&author=P.+Gulatiauthor=G.+Thomas&title=Nutrient+Sensing+in+the+mTOR%2FS6K1+Signalling+Pathway&doi=10.1042%2FBST0350236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Nutrient sensing in the mTOR/S6K1 signalling pathway</span></div><div class="casAuthors">Gulati, P.; Thomas, G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-238</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Nutrient overload induces constitutive S6K1 (S6 kinase 1) activation, which leads to insulin resistance by suppressing insulin-induced class I PI3K (phosphoinositide 3-kinase) signaling.  This finding gave rise to the question of the mechanism by which nutrients, such as AAs (amino acids), enter the mTOR (mammalian target of rapamycin)/S6K1 signaling pathway.  Counter to the prevailing view, our recent studies have shown that the AA input into the mTOR/S6K1 signaling pathway is not mediated by the tumor suppressor TSC1 (tuberous sclerosis complex 1)/TSC2 or its target, the proto-oncogene Rheb (Ras homolog enriched in brain).  Instead, we found that the AA input was mediated by class 3 PI3K, or hVps34 (human vacuolar protein sorting 34).  In brief, ectopic expression of hVps34 drives S6K1 activation, but only in the presence of AAs, and this effect is blocked by small interfering RNAs directed against hVps34.  Moreover, stimulation of cells with AAs increases hVps34 activity, as indicated by the prodn. of PI3P (phosphatidylinositol 3-phosphate).  PI3P mediates the recruitment of proteins contg. FYVE (Fab1p, YOTB, Vac1p, and EEA1) or PX (Phox homol.) domains to endosomal membranes, with PI3P-rich micro-domains acting as signaling platforms.  Addnl. evidence indicating hVps34 as the mediator of AA input to S6K1 came from expts. in which S6K1 activation was attenuated by ectopic expression of a cDNA contg. 2 FYVE domains, which bind to PI3P, preventing binding of proteins contg. either FYVE or PX domains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3zjUVa7vmuLVg90H21EOLACvtfcHk0ljrXOjsZ44qOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1WrsLk%253D&md5=153eb4e66bcc0d6047d8a63c3602ff11</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1042%2FBST0350236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0350236%26sid%3Dliteratum%253Aachs%26aulast%3DGulati%26aufirst%3DP.%26aulast%3DThomas%26aufirst%3DG.%26atitle%3DNutrient%2520Sensing%2520in%2520the%2520mTOR%252FS6K1%2520Signalling%2520Pathway%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2007%26volume%3D35%26spage%3D236%26epage%3D238%26doi%3D10.1042%2FBST0350236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">M Nicole, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipovsky, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Feedback Inhibition of Akt Signaling Limits the Growth of Tumors Lacking Tsc2</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1773</span>– <span class="NLM_lpage">1778</span>, <span class="refDoi"> DOI: 10.1101/gad.1314605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1101%2Fgad.1314605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=16027169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD2MXotFahtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1773-1778&author=B.+D.+Manningauthor=L.+M+Nicoleauthor=A.+I.+Lipovskyauthor=A.+Derekauthor=D.+J.+Kwiatkowskiauthor=L.+C.+Cantley&title=Feedback+Inhibition+of+Akt+Signaling+Limits+the+Growth+of+Tumors+Lacking+Tsc2&doi=10.1101%2Fgad.1314605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2</span></div><div class="casAuthors">Manning, Brendan D.; Logsdon, M. Nicole; Lipovsky, Alex I.; Abbott, Derek; Kwiatkowski, David J.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1773-1778</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The PTEN and TSC2 tumor suppressors inhibit mammalian target of rapamycin (mTOR) signaling and are defective in distinct hamartoma syndromes.  Using mouse genetics, we find that Pten and Tsc2 act synergistically to suppress the severity of a subset of tumors specific to loss of each of these genes.  Interestingly, we find that the slow-growing tumors specific to Tsc2+/- mice exhibit defects in signaling downstream of Akt.  However, Pten haploinsufficiency restores Akt signaling in these tumors and dramatically enhances their severity.  This study demonstrates that attenuation of the PI3K-Akt pathway in tumors lacking TSC2 contributes to their benign nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKGLsPscfT7Vg90H21EOLACvtfcHk0liAAPQ5IhfRTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXotFahtrk%253D&md5=a6715a7e1831d6c0d63b6d3fefc192b9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1101%2Fgad.1314605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1314605%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DM%2BNicole%26aufirst%3DL.%26aulast%3DLipovsky%26aufirst%3DA.%2BI.%26aulast%3DDerek%26aufirst%3DA.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DFeedback%2520Inhibition%2520of%2520Akt%2520Signaling%2520Limits%2520the%2520Growth%2520of%2520Tumors%2520Lacking%2520Tsc2%26jtitle%3DGenes%2520Dev.%26date%3D2005%26volume%3D19%26spage%3D1773%26epage%3D1778%26doi%3D10.1101%2Fgad.1314605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mericbernstam, F.</span></span> <span> </span><span class="NLM_article-title">Targeting the PI3K Pathway in Cancer: Are We Making Headway?</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2018.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1038%2Fnrclinonc.2018.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=29508857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVyjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=273-291&author=F.+Jankuauthor=T.+A.+Yapauthor=F.+Mericbernstam&title=Targeting+the+PI3K+Pathway+in+Cancer%3A+Are+We+Making+Headway%3F&doi=10.1038%2Fnrclinonc.2018.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the PI3K pathway in cancer: are we making headway?</span></div><div class="casAuthors">Janku, Filip; Yap, Timothy A.; Meric-Bernstam, Funda</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">273-291</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The PI3K-AKT-mTOR pathway is one of the most frequently dysregulated pathways in cancer and, consequently, more than 40 compds. that target key components of this signalling network have been tested in clin. trials involving patients with a range of different cancers.  The clin. development of many of these agents, however, has not advanced to late-phase randomized trials, and the antitumor activity of those that have been evaluated in comparative prospective studies has typically been limited, or toxicities were found to be prohibitive.  Nevertheless, the mTOR inhibitors temsirolimus and everolimus and the PI3K inhibitors idelalisib and copanlisib have been approved by the FDA for clin. use in the treatment of a no. of different cancers.  Novel compds. with greater potency and selectivity, as well as improved therapeutic indexes owing to reduced risks of toxicity, are clearly required.  In addn., biomarkers that are predictive of a response, such as PIK3CA mutations for inhibitors of the PI3K catalytic subunit α isoform, must be identified and anal. and clin. validated.  Finally, considering that oncogenic activation of the PI3K-AKT-mTOR pathway often occurs alongside pro-tumorigenic aberrations in other signalling networks, rational combinations are also needed to optimize the effectiveness of treatment.  Herein, we review the current experience with anticancer therapies that target the PI3K-AKT-mTOR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbPxYBT6FMIbVg90H21EOLACvtfcHk0liAAPQ5IhfRTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVyjsLY%253D&md5=73e00e3137c598e3a88ecf6a3d180b8c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2018.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2018.28%26sid%3Dliteratum%253Aachs%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DMericbernstam%26aufirst%3DF.%26atitle%3DTargeting%2520the%2520PI3K%2520Pathway%2520in%2520Cancer%253A%2520Are%2520We%2520Making%2520Headway%253F%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26spage%3D273%26epage%3D291%26doi%3D10.1038%2Fnrclinonc.2018.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faia, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brophy, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lussier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillotson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDougall, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutok, J. L.</span></span> <span> </span><span class="NLM_article-title">PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1364</span>– <span class="NLM_lpage">1374</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1016%2Fj.chembiol.2013.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=24211136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslClsrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1364-1374&author=D.+G.+Winklerauthor=K.+L.+Faiaauthor=J.+P.+DiNittoauthor=J.+A.+Aliauthor=K.+F.+Whiteauthor=E.+E.+Brophyauthor=M.+M.+Pinkauthor=J.+L.+Proctorauthor=J.+Lussierauthor=C.+M.+Martinauthor=J.+G.+Hoytauthor=B.+Tillotsonauthor=E.+L.+Murphyauthor=A.+R.+Limauthor=B.+D.+Thomasauthor=J.+R.+MacDougallauthor=P.+Renauthor=Y.+Liuauthor=L.-S.+Liauthor=K.+A.+Jessenauthor=C.+C.+Fritzauthor=J.+L.+Dunbarauthor=J.+R.+Porterauthor=C.+Rommelauthor=V.+J.+Palombellaauthor=P.+S.+Changelianauthor=J.+L.+Kutok&title=PI3K-%CE%B4+and+PI3K-%CE%B3+Inhibition+by+IPI-145+Abrogates+Immune+Responses+and+Suppresses+Activity+in+Autoimmune+and+Inflammatory+Disease+Models&doi=10.1016%2Fj.chembiol.2013.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models</span></div><div class="casAuthors">Winkler, David G.; Faia, Kerrie L.; DiNitto, Jonathan P.; Ali, Janid A.; White, Kerry F.; Brophy, Erin E.; Pink, Melissa M.; Proctor, Jennifer L.; Lussier, Jennifer; Martin, Christian M.; Hoyt, Jennifer G.; Tillotson, Bonnie; Murphy, Erin L.; Lim, Alice R.; Thomas, Brian D.; MacDougall, John R.; Ren, Pingda; Liu, Yi; Li, Lian-Sheng; Jessen, Katti A.; Fritz, Christian C.; Dunbar, Joi L.; Porter, James R.; Rommel, Christian; Palombella, Vito J.; Changelian, Paul S.; Kutok, Jeffery L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1364-1374</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Phosphoinositide-3 kinase (PI3K)-δ and PI3K-γ are preferentially expressed in immune cells, and inhibitors targeting these isoforms are hypothesized to have anti-inflammatory activity by affecting the adaptive and innate immune response.  We report on a potent oral PI3K-δ and PI3K-γ inhibitor (IPI-145) and characterize this compd. in biochem., cellular, and in vivo assays.  These studies demonstrate that IPI-145 exerts profound effects on adaptive and innate immunity by inhibiting B and T cell proliferation, blocking neutrophil migration, and inhibiting basophil activation.  We explored the therapeutic value of combined PI3K-δ and PI3K-γ blockade, and IPI-145 showed potent activity in collagen-induced arthritis, ovalbumin-induced asthma, and systemic lupus erythematosus rodent models.  These findings support the hypothesis that inhibition of immune function can be achieved through PI3K-δ and PI3K-γ blockade, potentially leading to significant therapeutic effects in multiple inflammatory, autoimmune, and hematol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHLymau7LdZrVg90H21EOLACvtfcHk0liAAPQ5IhfRTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslClsrvN&md5=b9fdfd9444ac255430ff6c8a0fb71ab9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DWinkler%26aufirst%3DD.%2BG.%26aulast%3DFaia%26aufirst%3DK.%2BL.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DWhite%26aufirst%3DK.%2BF.%26aulast%3DBrophy%26aufirst%3DE.%2BE.%26aulast%3DPink%26aufirst%3DM.%2BM.%26aulast%3DProctor%26aufirst%3DJ.%2BL.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DC.%2BM.%26aulast%3DHoyt%26aufirst%3DJ.%2BG.%26aulast%3DTillotson%26aufirst%3DB.%26aulast%3DMurphy%26aufirst%3DE.%2BL.%26aulast%3DLim%26aufirst%3DA.%2BR.%26aulast%3DThomas%26aufirst%3DB.%2BD.%26aulast%3DMacDougall%26aufirst%3DJ.%2BR.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DFritz%26aufirst%3DC.%2BC.%26aulast%3DDunbar%26aufirst%3DJ.%2BL.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DKutok%26aufirst%3DJ.%2BL.%26atitle%3DPI3K-%25CE%25B4%2520and%2520PI3K-%25CE%25B3%2520Inhibition%2520by%2520IPI-145%2520Abrogates%2520Immune%2520Responses%2520and%2520Suppresses%2520Activity%2520in%2520Autoimmune%2520and%2520Inflammatory%2520Disease%2520Models%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1364%26epage%3D1374%26doi%3D10.1016%2Fj.chembiol.2013.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garces, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span> <span> </span><span class="NLM_article-title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: a Medicinal Chemistry Perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4815</span>– <span class="NLM_lpage">4850</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01492</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01492" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFOku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4815-4850&author=A.+E.+Garcesauthor=M.+J.+Stocks&title=Class+1+PI3K+Clinical+Candidates+and+Recent+Inhibitor+Design+Strategies%3A+a+Medicinal+Chemistry+Perspective&doi=10.1021%2Facs.jmedchem.8b01492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Garces, Aimie E.; Stocks, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4815-4850</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate the 3-OH of the inositol ring of phosphoinositides, and deregulation of this pathway has implications in many diseases.  The search for novel PI3K inhibitors has been at the forefront of academic and industrial medicinal chem. with over 600 medicinal chem.-based publications and patents appearing to date, leading to 38 clin. candidates and the launch of two drugs, idelalisib in 2014 and copanlisib in 2017.  This Perspective will discuss medicinal chem. design approaches to novel isoform-selective inhibitors through consideration of brief case histories of compds. that have progressed into clin. development or that have revealed new structural motifs in this highly competitive area of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUu2mgndklHbVg90H21EOLACvtfcHk0lhs1cEaDIzgzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFOku7bK&md5=907395a39ed6fb683464ee92c6a2537f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26aulast%3DGarces%26aufirst%3DA.%2BE.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26atitle%3DClass%25201%2520PI3K%2520Clinical%2520Candidates%2520and%2520Recent%2520Inhibitor%2520Design%2520Strategies%253A%2520a%2520Medicinal%2520Chemistry%2520Perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4815%26epage%3D4850%26doi%3D10.1021%2Facs.jmedchem.8b01492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhari, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donatelli, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newlander, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridgers, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarpong, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aller, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garver, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gontarek, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kershner, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherk, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegrzyn, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1021/ml900028r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml900028r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvF2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=39-43&author=S.+D.+Knightauthor=N.+D.+Adamsauthor=J.+L.+Burgessauthor=A.+M.+Chaudhariauthor=M.+G.+Darcyauthor=C.+A.+Donatelliauthor=J.+I.+Luengoauthor=K.+A.+Newlanderauthor=C.+A.+Parrishauthor=L.+H.+Ridgersauthor=M.+A.+Sarpongauthor=S.+J.+Schmidtauthor=G.+S.+Van+Allerauthor=J.+D.+Carsonauthor=M.+A.+Diamondauthor=P.+A.+Elkinsauthor=C.+M.+Gardinerauthor=E.+Garverauthor=S.+A.+Gilbertauthor=R.+R.+Gontarekauthor=J.+R.+Jacksonauthor=K.+L.+Kershnerauthor=L.+Luoauthor=K.+Rahaauthor=C.+S.+Sherkauthor=C.-M.+Sungauthor=D.+Suttonauthor=P.+J.+Tumminoauthor=R.+J.+Wegrzynauthor=K.+R.+Augerauthor=D.+Dhanak&title=Discovery+of+GSK2126458%2C+a+Highly+Potent+Inhibitor+of+PI3K+and+the+Mammalian+Target+of+Rapamycin&doi=10.1021%2Fml900028r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin</span></div><div class="casAuthors">Knight, Steven D.; Adams, Nicholas D.; Burgess, Joelle L.; Chaudhari, Amita M.; Darcy, Michael G.; Donatelli, Carla A.; Luengo, Juan I.; Newlander, Ken A.; Parrish, Cynthia A.; Ridgers, Lance H.; Sarpong, Martha A.; Schmidt, Stanley J.; Van Aller, Glenn S.; Carson, Jeffrey D.; Diamond, Melody A.; Elkins, Patricia A.; Gardiner, Christine M.; Garver, Eric; Gilbert, Seth A.; Gontarek, Richard R.; Jackson, Jeffrey R.; Kershner, Kevin L.; Luo, Lusong; Raha, Kaushik; Sherk, Christian S.; Sung, Chiu-Mei; Sutton, David; Tummino, Peter J.; Wegrzyn, Ronald J.; Auger, Kurt R.; Dhanak, Dashyant</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-43</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase α (PI3Kα) is a crit. regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers.  The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition. 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458, 1 (I)) has been identified as a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.  Compd. 1 is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBH6_ywCnjCrVg90H21EOLACvtfcHk0lhs1cEaDIzgzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvF2qtw%253D%253D&md5=72fcca85702dba95529ac03281e0bdbc</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fml900028r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml900028r%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DS.%2BD.%26aulast%3DAdams%26aufirst%3DN.%2BD.%26aulast%3DBurgess%26aufirst%3DJ.%2BL.%26aulast%3DChaudhari%26aufirst%3DA.%2BM.%26aulast%3DDarcy%26aufirst%3DM.%2BG.%26aulast%3DDonatelli%26aufirst%3DC.%2BA.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26aulast%3DNewlander%26aufirst%3DK.%2BA.%26aulast%3DParrish%26aufirst%3DC.%2BA.%26aulast%3DRidgers%26aufirst%3DL.%2BH.%26aulast%3DSarpong%26aufirst%3DM.%2BA.%26aulast%3DSchmidt%26aufirst%3DS.%2BJ.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DCarson%26aufirst%3DJ.%2BD.%26aulast%3DDiamond%26aufirst%3DM.%2BA.%26aulast%3DElkins%26aufirst%3DP.%2BA.%26aulast%3DGardiner%26aufirst%3DC.%2BM.%26aulast%3DGarver%26aufirst%3DE.%26aulast%3DGilbert%26aufirst%3DS.%2BA.%26aulast%3DGontarek%26aufirst%3DR.%2BR.%26aulast%3DJackson%26aufirst%3DJ.%2BR.%26aulast%3DKershner%26aufirst%3DK.%2BL.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DRaha%26aufirst%3DK.%26aulast%3DSherk%26aufirst%3DC.%2BS.%26aulast%3DSung%26aufirst%3DC.-M.%26aulast%3DSutton%26aufirst%3DD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DWegrzyn%26aufirst%3DR.%2BJ.%26aulast%3DAuger%26aufirst%3DK.%2BR.%26aulast%3DDhanak%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520GSK2126458%252C%2520a%2520Highly%2520Potent%2520Inhibitor%2520of%2520PI3K%2520and%2520the%2520Mammalian%2520Target%2520of%2520Rapamycin%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D39%26epage%3D43%26doi%3D10.1021%2Fml900028r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melendez Cuero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutvoet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anak, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Oral Phosphatidylinositol-3-kinase and mTOR Inhibitor BGT226 in Patients with Advanced Solid Tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2399</span>– <span class="NLM_lpage">2408</span>, <span class="refDoi"> DOI: 10.1093/annonc/mds011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1093%2Fannonc%2Fmds011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=22357447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A280%3ADC%252BC38vjvFemsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=2399-2408&author=B.+Markmanauthor=J.+Taberneroauthor=I.+Kropauthor=G.+I.+Shapiroauthor=L.+Siuauthor=L.+C.+Chenauthor=M.+Mitaauthor=M.+Melendez+Cueroauthor=S.+Stutvoetauthor=D.+Birleauthor=O.+Anakauthor=W.+Hacklauthor=J.+Baselga&title=Phase+I+Safety%2C+Pharmacokinetic%2C+and+Pharmacodynamic+Study+of+the+Oral+Phosphatidylinositol-3-kinase+and+mTOR+Inhibitor+BGT226+in+Patients+with+Advanced+Solid+Tumors&doi=10.1093%2Fannonc%2Fmds011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors</span></div><div class="casAuthors">Markman B; Tabernero J; Krop I; Shapiro G I; Siu L; Chen L C; Mita M; Melendez Cuero M; Stutvoet S; Birle D; Anak O; Hackl W; Baselga J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2399-408</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This phase I dose-escalation study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics (PDs), and preliminary antitumor activity of BGT226, a potent, oral dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin inhibitor.  PATIENTS AND METHODS:  Fifty-seven patients with advanced solid tumors received BGT226 2.5-125 mg/day three times weekly (TIW).  Dose escalation was guided by an adaptive Bayesian logistic regression model with overdose control.  Assessments included response per RECIST, [18F]-fluorodeoxyglucose uptake, and phosphorylated-S6 in skin and paired tumor samples.  RESULTS:  Three patients (125 mg cohort) had dose-limiting toxic effects (grade 3 nausea/vomiting, diarrhea).  BGT226-related adverse events included nausea (68%), diarrhea (61%), vomiting (49%), and fatigue (19%).  BGT226 demonstrated rapid absorption, variable systemic exposure, and a median half-life of 6-9 h.  Seventeen patients (30%) had stable disease (SD) as best response.  Nine patients had SD for ≥16 weeks.  Thirty patients (53%) achieved stable metabolic disease as assessed by [18F]-fluorodeoxyglucose-positron emission tomography; however, no correlation between metabolic response and tumor shrinkage according to computed tomography was observed.  PD changes suggested PI3K pathway inhibition but were inconsistent.  CONCLUSIONS:  The MTD of BGT226 was 125 mg/day TIW, and the clinically recommended dose was 100 mg/day TIW.  Limited preliminary antitumor activity and inconsistent target inhibition were observed, potentially due to low systemic exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHz9m4_rnszwpJitSxOdIlfW6udTcc2eYyJFq31zEiGbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vjvFemsQ%253D%253D&md5=c9bab106af9fb7fea93049bc77587b9a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds011%26sid%3Dliteratum%253Aachs%26aulast%3DMarkman%26aufirst%3DB.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DKrop%26aufirst%3DI.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DSiu%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DMelendez%2BCuero%26aufirst%3DM.%26aulast%3DStutvoet%26aufirst%3DS.%26aulast%3DBirle%26aufirst%3DD.%26aulast%3DAnak%26aufirst%3DO.%26aulast%3DHackl%26aufirst%3DW.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520Safety%252C%2520Pharmacokinetic%252C%2520and%2520Pharmacodynamic%2520Study%2520of%2520the%2520Oral%2520Phosphatidylinositol-3-kinase%2520and%2520mTOR%2520Inhibitor%2520BGT226%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3D2399%26epage%3D2408%26doi%3D10.1093%2Fannonc%2Fmds011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gravis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machiels, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellado, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csonka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravartty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fizazi, K.</span></span> <span> </span><span class="NLM_article-title">Phase Ib Dose-finding Study of Abiraterone Acetate Plus Buparlisib (BKM120) or Dactolisib (BEZ235) in Patients with Castration-resistant Prostate Cancer</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2017.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1016%2Fj.ejca.2017.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=28282611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtFeltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=36-44&author=C.+Massardauthor=K.+N.+Chiauthor=D.+Castellanoauthor=J.+de+Bonoauthor=G.+Gravisauthor=L.+Dirixauthor=J.-P.+Machielsauthor=A.+Mitaauthor=B.+Melladoauthor=S.+Turriauthor=J.+Maierauthor=D.+Csonkaauthor=A.+Chakravarttyauthor=K.+Fizazi&title=Phase+Ib+Dose-finding+Study+of+Abiraterone+Acetate+Plus+Buparlisib+%28BKM120%29+or+Dactolisib+%28BEZ235%29+in+Patients+with+Castration-resistant+Prostate+Cancer&doi=10.1016%2Fj.ejca.2017.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer</span></div><div class="casAuthors">Massard, Christophe; Chi, Kim Nguyen; Castellano, Daniel; de Bono, Johann; Gravis, Gwenaelle; Dirix, Luc; Machiels, Jean-Pascal; Mita, Alain; Gonzalez, Begona Mellado; Turri, Sabine; Maier, Joan; Csonka, Denes; Chakravartty, Arunava; Fizazi, Karim</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) signalling axis and androgen receptor (AR) pathways exhibit reciprocal feedback regulation in phosphatase and tensin homolog (PTEN)-deficient metastatic castration-resistant prostate cancer (CRPC) in preclin. models.  This phase Ib study evaluated the pan-PI3K inhibitor buparlisib (BKM120) and the dual pan-PI3K/ mammalian target of rapamycin (mTOR) inhibitor dactolisib (BEZ235) in combination with abiraterone acetate (AA) in patients with CRPC.  Patients with CRPC who had progressed on AA therapy received escalating doses of either buparlisib or dactolisib, along with fixed doses of AA (1000 mg once daily (qd)) and prednisone (5 mg twice daily (bid)).  The primary objective was to define the max. tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of either buparlisib or dactolisib in combination with AA.  Secondary objectives included safety, antitumor activity (Prostate Cancer Working Group 2 (PCWG2) criteria; 30% of prostate-specific antigen (PSA) decline at ≥week 12) and pharmacokinetic (PK) profile.  In buparlisib + AA arm, 25 patients received buparlisib + AA (median age, 67 years; Eastern Cooperative Oncol. Group performance status (ECOG PS) of 0/1/2 for 7/17/1 patients, resp.).  At 100 mg qd; two patients experienced dose-limiting toxicities (DLTs) (grade 3 hyperglycemia; grade 2 asthenia), and this was the max. buparlisib dose explored.  Buparlisib + AA showed a 26% lower median area under the curve from time zero to 24°h (AUC0-24) and 48% lower median max. serum concn. (Cmax) vs. the single-agent buparlisib assessed in first-in-human study.  No objective response and few PSA decreases were reported.  In dactolisib + AA arm, 18 patients (median age, 71 years; ECOG PS of 0/1 for 6/12 patients, resp.) received dactolisib + AA at the first dose level (200 mg bid).  Five patients had 9 DLTs (grades 2&3 stomatitis; grade 3 hyperglycemia; grades 2& 3 diarrhea; grades 1& 2 pyrexia, grade 2 vomiting, and grade 2 chills).Based on the assessment of available pharmacokinetics, safety, and efficacy data, no further study is planned for either buparlisib or dactolisib in combination with AA in CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5ivzHQTJ0i7Vg90H21EOLACvtfcHk0lgtMpDmWOoOng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtFeltrY%253D&md5=4a92c856180ca246e3a44ae8dab0ac94</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2017.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2017.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DMassard%26aufirst%3DC.%26aulast%3DChi%26aufirst%3DK.%2BN.%26aulast%3DCastellano%26aufirst%3DD.%26aulast%3Dde%2BBono%26aufirst%3DJ.%26aulast%3DGravis%26aufirst%3DG.%26aulast%3DDirix%26aufirst%3DL.%26aulast%3DMachiels%26aufirst%3DJ.-P.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DMellado%26aufirst%3DB.%26aulast%3DTurri%26aufirst%3DS.%26aulast%3DMaier%26aufirst%3DJ.%26aulast%3DCsonka%26aufirst%3DD.%26aulast%3DChakravartty%26aufirst%3DA.%26aulast%3DFizazi%26aufirst%3DK.%26atitle%3DPhase%2520Ib%2520Dose-finding%2520Study%2520of%2520Abiraterone%2520Acetate%2520Plus%2520Buparlisib%2520%2528BKM120%2529%2520or%2520Dactolisib%2520%2528BEZ235%2529%2520in%2520Patients%2520with%2520Castration-resistant%2520Prostate%2520Cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2017%26volume%3D76%26spage%3D36%26epage%3D44%26doi%3D10.1016%2Fj.ejca.2017.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Britten, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houk, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P. M.</span></span> <span> </span><span class="NLM_article-title">Phase I Study of PF-04691502, a Small-molecule, Oral, Dual Inhibitor of PI3K and mTOR, in Patients with Advanced Cancer</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.1007/s10637-013-0062-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1007%2Fs10637-013-0062-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=24395457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVant70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=510-517&author=C.+D.+Brittenauthor=A.+A.+Adjeiauthor=R.+Millhamauthor=B.+E.+Houkauthor=G.+Borzilloauthor=K.+Pierceauthor=Z.+A.+Wainbergauthor=P.+M.+LoRusso&title=Phase+I+Study+of+PF-04691502%2C+a+Small-molecule%2C+Oral%2C+Dual+Inhibitor+of+PI3K+and+mTOR%2C+in+Patients+with+Advanced+Cancer&doi=10.1007%2Fs10637-013-0062-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer</span></div><div class="casAuthors">Britten, Carolyn D.; Adjei, Alex A.; Millham, Robert; Houk, Brett E.; Borzillo, Gary; Pierce, Kristen; Wainberg, Zev A.; LoRusso, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">510-517</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose To det. the max. tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, and preliminary evidence of antitumor activity of the PI3K/mTOR inhibitor PF-04691502, administered orally once daily.  Methods Escalating doses of PF-04691502 were administered to 23 patients with advanced solid tumors in sequential cohorts across the following dose levels: 2 mg, 4 mg, 8 mg, and 11 mg. 14 addnl. patients were enrolled in an expansion cohort at the MTD to ensure at least five matched pre- and post-treatment biopsies for biomarkers of PI3K activity.  Results The MTD of PF-04691502 was 8 mg orally once daily.  There were three dose-limiting toxicities: one grade 3 fatigue at 8 mg, one grade 3 rash at 11 mg, and one intolerable grade 2 fatigue at 11 mg.  Among 37 patients enrolled, treatment-related adverse events included fatigue, decreased appetite, nausea, hyperglycemia, rash, and vomiting.  Across all dose levels, av. steady-state plasma PF-04691502 concns. approximated or exceeded the target concn. of 16.2 ng/mL required for ≥75 % tumor growth inhibition in preclin. models.  PF-04691502 resulted in increased mean fasting serum glucose, insulin, and c-peptide levels, and produced partial blockade of PI3K signalling in five paired tumor biopsies, as demonstrated by redns. in phosphorylated Akt, FKHR/FKHRL1, and STAT3.  No objective anti-tumor responses were obsd.  Conclusions Daily oral administration of PF-04691502 was tolerable at 8 mg orally once daily, with a safety profile similar to other PI3K/mTOR inhibitors.  PF-04691502 demonstrated PI3K pathway inhibition by changing glucose homeostasis, and by decreasing phosphorylation of downstream mols. in tumor tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-Gyl-ccubnrVg90H21EOLACvtfcHk0lgtMpDmWOoOng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVant70%253D&md5=dbf09eb4421930dccf1dbeb0360d032f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs10637-013-0062-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-013-0062-5%26sid%3Dliteratum%253Aachs%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DMillham%26aufirst%3DR.%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DBorzillo%26aufirst%3DG.%26aulast%3DPierce%26aufirst%3DK.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DPhase%2520I%2520Study%2520of%2520PF-04691502%252C%2520a%2520Small-molecule%252C%2520Oral%252C%2520Dual%2520Inhibitor%2520of%2520PI3K%2520and%2520mTOR%252C%2520in%2520Patients%2520with%2520Advanced%2520Cancer%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2014%26volume%3D32%26spage%3D510%26epage%3D517%26doi%3D10.1007%2Fs10637-013-0062-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koizumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Sulfonylhydrazone-substituted Imidazo[1,2-a]pyridines as Novel PI3 Kinase p110α Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5837</span>– <span class="NLM_lpage">5844</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.05.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1016%2Fj.bmc.2007.05.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=17601739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=5837-5844&author=M.+Hayakawaauthor=K.+I.+Kawaguchiauthor=H.+Kaizawaauthor=T.+Koizumiauthor=T.+Ohishiauthor=M.+Yamanoauthor=M.+Okadaauthor=M.+Ohtaauthor=S.+I.+Tsukamotoauthor=F.+I.+Raynaud&title=Synthesis+and+Biological+Evaluation+of+Sulfonylhydrazone-substituted+Imidazo%5B1%2C2-a%5Dpyridines+as+Novel+PI3+Kinase+p110%CE%B1+Inhibitors&doi=10.1016%2Fj.bmc.2007.05.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110α inhibitors</span></div><div class="casAuthors">Hayakawa, Masahiko; Kawaguchi, Ken-ichi; Kaizawa, Hiroyuki; Koizumi, Tomonobu; Ohishi, Takahide; Yamano, Mayumi; Okada, Minoru; Ohta, Mitsuaki; Tsukamoto, Shin-ichi; Raynaud, Florence I.; Parker, Peter; Workman, Paul; Waterfield, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5837-5844</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The authors have previously reported the imidazo[1,2-a]pyridine deriv. 4 as a novel p110α inhibitor; however, although 4 is a potent inhibitor of p110α enzymic activity and tumor cell proliferation in vitro, it is unstable in soln. and ineffective in vivo.  To increase stability the pyrazole of 4 was replaced with a hydrazone and a moderately potent p110α inhibitor 7a was obtained.  Subsequent optimization of 7a afforded exceptionally potent p110α inhibitors, including compds. (I and II), with IC50 values of 0.30 nM and 0.26 nM.  Compd. I was also stable in soln. and exhibited significant antitumor effectiveness in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLaUeSvcQQULVg90H21EOLACvtfcHk0lgKGcC218UXdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWjsbg%253D&md5=e24268693f0022fd955d2d06ceb151ba</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.05.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.05.070%26sid%3Dliteratum%253Aachs%26aulast%3DHayakawa%26aufirst%3DM.%26aulast%3DKawaguchi%26aufirst%3DK.%2BI.%26aulast%3DKaizawa%26aufirst%3DH.%26aulast%3DKoizumi%26aufirst%3DT.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DYamano%26aufirst%3DM.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DTsukamoto%26aufirst%3DS.%2BI.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Sulfonylhydrazone-substituted%2520Imidazo%255B1%252C2-a%255Dpyridines%2520as%2520Novel%2520PI3%2520Kinase%2520p110%25CE%25B1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D5837%26epage%3D5844%26doi%3D10.1016%2Fj.bmc.2007.05.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Imidazopyridine Analogues as Inhibitors of Phosphoinositide 3-Kinase Signaling and Angiogenesis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2455</span>– <span class="NLM_lpage">2466</span>, <span class="refDoi"> DOI: 10.1021/jm101582z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101582z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivFyjt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2455-2466&author=O.+Kimauthor=Y.+Jeongauthor=H.+Leeauthor=S.-S.+Hongauthor=S.+Hong&title=Design+and+Synthesis+of+Imidazopyridine+Analogues+as+Inhibitors+of+Phosphoinositide+3-Kinase+Signaling+and+Angiogenesis&doi=10.1021%2Fjm101582z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Imidazopyridine Analogues as Inhibitors of Phosphoinositide 3-Kinase Signaling and Angiogenesis</span></div><div class="casAuthors">Kim, Okseon; Jeong, Yujeong; Lee, Hyunseung; Hong, Sun-Sun; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2455-2466</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinase α (PI3Kα) is an important regulator of intracellular signaling pathways, controlling remarkably diverse arrays of physiol. processes.  Because the PI3K pathway is frequently up-regulated in human cancers, the inhibition of PI3Kα can be a promising approach to cancer therapy.  In this study, we have designed and synthesized a new series of imidazo[1,2-a]pyridine derivs. as PI3Kα inhibitors through the fragment-growing strategy.  By varying groups at the 3- and 6-positions of imidazo[1,2-a]pyridines, we studied the SAR profiles and identified a series of potent PI3Kα inhibitors.  Representative derivs. showed good activity in cellular proliferation and apoptosis assays.  Moreover, these inhibitors exhibited noteworthy antiangiogenic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTcM2h9dxy2LVg90H21EOLACvtfcHk0lgKGcC218UXdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivFyjt70%253D&md5=f95faefaa020858642e959f424aeaba1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm101582z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101582z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DO.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DHong%26aufirst%3DS.-S.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Imidazopyridine%2520Analogues%2520as%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520Signaling%2520and%2520Angiogenesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2455%26epage%3D2466%26doi%3D10.1021%2Fjm101582z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. W.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Novel 3-Substituted Imidazo[1,2-a]pyridine and Quinazolin-4(3H)-one Derivatives as PI3Kα Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1016%2Fj.ejmech.2017.07.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=28800461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSls7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=95-106&author=Y.+H.+Fanauthor=W.+Liauthor=D.+D.+Liuauthor=M.+X.+Baiauthor=H.+R.+Songauthor=Y.+N.+Xuauthor=S.+K.+Leeauthor=Z.+P.+Zhouauthor=J.+Wangauthor=H.+W.+Ding&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Novel+3-Substituted+Imidazo%5B1%2C2-a%5Dpyridine+and+Quinazolin-4%283H%29-one+Derivatives+as+PI3K%CE%B1+Inhibitors&doi=10.1016%2Fj.ejmech.2017.07.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors</span></div><div class="casAuthors">Fan, Yan-Hua; Li, Wei; Liu, Dan-Dan; Bai, Meng-Xuan; Song, Hong-Rui; Xu, Yong-Nan; Lee, SangKook; Zhou, Zhi-Peng; Wang, Jian; Ding, Huai-Wei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95-106</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinase (PI3K) is a pivotal regulator of intracellular signaling pathways and considered as a promising target in the development of a therapeutic treatment of cancer.  Among the different PI3K subtypes, the PIK3CA gene encoding PI3K p110α is frequently mutated and overexpressed in majority of human cancers.  Therefore, the inhibition of PI3Kα has been considered to be an efficient approach for the treatment of cancer.  In this study, two series compds. contg. hydrophilic group in imidazo[1,2-a]pyridine and quinazolin-4(3H)-one were synthesized and their antiproliferative activities against five cancer cell lines, including HCT-116, SK-HEP-1, MDA-MB-231, SNU638 and A549, were evaluated.  Compd. I with most potent antiproliferative activity was selected for further biol. evaluation.  PI3K kinase assay showed that I has selectivity for PI3Kα distinguished from other isoforms.  The western blot assay indicated that I is more effective than HS-173, an imidazopyridine-based PI3Ka inhibitor, in reducing the levels of phospho-Akt.  All these results suggested that I is a potent PI3Kα inhibitor and could be considered as a potential candidate for the development of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolVgFNIFP22LVg90H21EOLACvtfcHk0lgKGcC218UXdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSls7fI&md5=948df88b378b90d43ee4c71988dd4d16</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.074%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DY.%2BH.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DD.%2BD.%26aulast%3DBai%26aufirst%3DM.%2BX.%26aulast%3DSong%26aufirst%3DH.%2BR.%26aulast%3DXu%26aufirst%3DY.%2BN.%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DZhou%26aufirst%3DZ.%2BP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DH.%2BW.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Novel%25203-Substituted%2520Imidazo%255B1%252C2-a%255Dpyridine%2520and%2520Quinazolin-4%25283H%2529-one%2520Derivatives%2520as%2520PI3K%25CE%25B1%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D95%26epage%3D106%26doi%3D10.1016%2Fj.ejmech.2017.07.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-kinase Inhibitors for Cancer Treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6087</span>– <span class="NLM_lpage">6109</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00416</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00416" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyjs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6087-6109&author=S.+Linauthor=C.+Wangauthor=M.+Jiauthor=D.+Wuauthor=Y.+Lvauthor=K.+Zhangauthor=Y.+Dongauthor=J.+Jinauthor=J.+Chenauthor=J.+Zhangauthor=L.+Shengauthor=Y.+Liauthor=X.+Chenauthor=H.+Xu&title=Discovery+and+Optimization+of+2-Amino-4-methylquinazoline+Derivatives+as+Highly+Potent+Phosphatidylinositol+3-kinase+Inhibitors+for+Cancer+Treatment&doi=10.1021%2Facs.jmedchem.8b00416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment</span></div><div class="casAuthors">Lin, Songwen; Wang, Chunyang; Ji, Ming; Wu, Deyu; Lv, Yuanhao; Zhang, Kehui; Dong, Yi; Jin, Jing; Chen, Jiajing; Zhang, Jingbo; Sheng, Li; Li, Yan; Chen, Xiaoguang; Xu, Heng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6087-6109</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Increased phosphatidylinositol 3-kinase (PI3K) signaling is among the most common alterations in cancer, spurring intensive efforts to develop new cancer therapeutics that target this pathway.  In this work, we discovered a series of novel 2-amino-4-methylquinazoline derivs. through a hybridization and subsequent scaffold hopping approach that were highly potent class I PI3K inhibitors.  Lead optimization resulted in several promising compds. (e.g., 19, 20, 37, and 43) with nanomolar PI3K potencies, prominent antiproliferative activities, favorable PK profiles, and robust in vivo antitumor efficacies.  More interestingly, compared with 19 and 20, 37 and 43 demonstrated improved brain penetration and in vivo efficacy in an orthotopic glioblastoma xenograft model.  Furthermore, preliminary safety assessments including hERG channel inhibition, AMES, CYP450 inhibition, and single-dose toxicity were performed to characterize their toxicol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_AIT1xHicq7Vg90H21EOLACvtfcHk0ligivscUibMlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyjs7bF&md5=3d9e6f2f1d8028cad66b3c14f8be353d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00416%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DLv%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%25202-Amino-4-methylquinazoline%2520Derivatives%2520as%2520Highly%2520Potent%2520Phosphatidylinositol%25203-kinase%2520Inhibitors%2520for%2520Cancer%2520Treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6087%26epage%3D6109%26doi%3D10.1021%2Facs.jmedchem.8b00416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulloora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabaraya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, A. V.</span></span> <span> </span><span class="NLM_article-title">New 6-Bromoimidazo[1,2-a]pyridine-2-carbohydrazide Derivatives: Synthesis and Anticonvulsant Studies</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3019</span>– <span class="NLM_lpage">3028</span>, <span class="refDoi"> DOI: 10.1007/s00044-013-0887-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1007%2Fs00044-013-0887-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeksrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=3019-3028&author=S.+Ullooraauthor=R.+Shabarayaauthor=A.+V.+Adhikari&title=New+6-Bromoimidazo%5B1%2C2-a%5Dpyridine-2-carbohydrazide+Derivatives%3A+Synthesis+and+Anticonvulsant+Studies&doi=10.1007%2Fs00044-013-0887-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">New 6-bromoimidazo[1,2-a]pyridine-2-carbohydrazide derivatives: synthesis and anticonvulsant studies</span></div><div class="casAuthors">Ulloora, Shrikanth; Shabaraya, Ramakrishna; Adhikari, Airody Vasudeva</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3019-3028</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Boston</span>)
        </div><div class="casAbstract">The facile synthesis and anticonvulsant study of new imidazo[1,2-a]pyridines carrying biol. active hydrazone functionality and suitably substituted 1,2,4-triazole moieties were reported.  The in-vivo anticonvulsant activity of the target compds. studied using maximal electroshock seizure and s.c. pentylenetetrazole, while their toxicity study was detd. by rotarod at 20, 40, and 100 mg/kg.  Most of the new compds. displayed remarkable anticonvulsant properties at these doses.  Particularly, hydrazide I and triazole II carrying H-bond donor groups, viz. OH and amine moieties, resp., exhibited complete protection against seizure comparable to std. diazepam.  All the compds. are non-toxic ≤100 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjDqOpZ0Ao_LVg90H21EOLACvtfcHk0ligivscUibMlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeksrvM&md5=05d2ce5f998d86810fda347d338c2da1</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs00044-013-0887-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-013-0887-7%26sid%3Dliteratum%253Aachs%26aulast%3DUlloora%26aufirst%3DS.%26aulast%3DShabaraya%26aufirst%3DR.%26aulast%3DAdhikari%26aufirst%3DA.%2BV.%26atitle%3DNew%25206-Bromoimidazo%255B1%252C2-a%255Dpyridine-2-carbohydrazide%2520Derivatives%253A%2520Synthesis%2520and%2520Anticonvulsant%2520Studies%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2014%26volume%3D23%26spage%3D3019%26epage%3D3028%26doi%3D10.1007%2Fs00044-013-0887-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haegebarth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fracasso, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkie, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">BAY 80-6946 is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2319</span>– <span class="NLM_lpage">2330</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0993-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1158%2F1535-7163.MCT-12-0993-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=24170767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=2319-2330&author=N.+Liuauthor=B.+R.+Rowleyauthor=C.+O.+Bullauthor=C.+Schneiderauthor=A.+Haegebarthauthor=C.+A.+Schatzauthor=P.+R.+Fracassoauthor=D.+P.+Wilkieauthor=M.+Hentemannauthor=S.+M.+Wilhelmauthor=W.+J.+Scottauthor=D.+Mumbergauthor=K.+Ziegelbauer&title=BAY+80-6946+is+a+Highly+Selective+Intravenous+PI3K+Inhibitor+with+Potent+p110%CE%B1+and+p110%CE%B4+Activities+in+Tumor+Cell+Lines+and+Xenograft+Models&doi=10.1158%2F1535-7163.MCT-12-0993-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models</span></div><div class="casAuthors">Liu, Ningshu; Rowley, Bruce R.; Bull, Cathy O.; Schneider, Claudia; Haegebarth, Andrea; Schatz, Christoph A.; Fracasso, Paul R.; Wilkie, Dean P.; Hentemann, Martin; Wilhelm, Scott M.; Scott, William J.; Mumberg, Dominik; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2319-2330</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Because of the complexity derived from the existence of various phosphoinositide 3-kinase (PI3K) isoforms and their differential roles in cancers, development of PI3K inhibitors with differential pharmacol. and pharmacokinetic profiles would allow best exploration in different indications, combinations, and dosing regimens.  Here, we report BAY 80-6946, a highly selective and potent pan-class I PI3K inhibitor with sub-nanomolar IC50s against PI3Kα and PI3Kδ.  BAY 80-6946 exhibited preferential inhibition (about 10-fold) of AKT phosphorylation by PI3Kα compared with PI3Kβ in cells.  BAY 80-6946 showed superior antitumor activity (>40-fold) in PIK3CA mutant and/or HER2 overexpression as compared with HER2-neg. and wild-type PIK3CA breast cancer cell lines.  In addn., BAY 80-6946 revealed potent activity to induce apoptosis in a subset of tumor cells with aberrant activation of PI3K as a single agent.  In vivo, single i.v. administration of BAY 80-6946 exhibited higher exposure and prolonged inhibition of pAKT levels in tumors vs. plasma.  BAY 80-6946 is efficacious in tumors with activated PI3K when dosed either continuously or intermittently.  Thus, BAY 80-6946 induced 100% complete tumor regression when dosed as a single agent every second day in rats bearing HER2-amplified and PIK3CA-mutated KPL4 breast tumors.  In combination with paclitaxel, weekly dosing of BAY 80-6946 is sufficient to reach sustained response in all animals bearing patient-derived non-small cell lung cancer xenografts, despite a short plasma elimination half-life (1 h) in mice.  Thus, BAY 80-6946 is a promising agent with differential pharmacol. and pharmacokinetic properties for the treatment of PI3K-dependent human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxfdGLDML1MrVg90H21EOLACvtfcHk0ligivscUibMlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarsrrM&md5=344a497d4e4638f3b37900a417054510</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0993-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0993-T%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DRowley%26aufirst%3DB.%2BR.%26aulast%3DBull%26aufirst%3DC.%2BO.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DHaegebarth%26aufirst%3DA.%26aulast%3DSchatz%26aufirst%3DC.%2BA.%26aulast%3DFracasso%26aufirst%3DP.%2BR.%26aulast%3DWilkie%26aufirst%3DD.%2BP.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DScott%26aufirst%3DW.%2BJ.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DBAY%252080-6946%2520is%2520a%2520Highly%2520Selective%2520Intravenous%2520PI3K%2520Inhibitor%2520with%2520Potent%2520p110%25CE%25B1%2520and%2520p110%25CE%25B4%2520Activities%2520in%2520Tumor%2520Cell%2520Lines%2520and%2520Xenograft%2520Models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D2319%26epage%3D2330%26doi%3D10.1158%2F1535-7163.MCT-12-0993-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBiasi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winckler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFramboise, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zander, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacConaill, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoletti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majmudar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziaugra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beroukhim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barretina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emery, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellinghoff, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischel, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloughesy, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liau, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalona, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signoretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span> <span> </span><span class="NLM_article-title">High-throughput Oncogene Mutation Profiling in Human Cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1038/ng1975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=10.1038%2Fng1975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=17293865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVOktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2007&pages=347-351&author=R.+K+Thomasauthor=A.+C.+Bakerauthor=R.+M.+DeBiasiauthor=W.+Wincklerauthor=T.+LaFramboiseauthor=W.+M.+Linauthor=M.+Wangauthor=W.+Fengauthor=T.+Zanderauthor=L.+E.+MacConaillauthor=J.+C.+Leeauthor=R.+Nicolettiauthor=C.+Hattonauthor=M.+Goyetteauthor=L.+Girardauthor=K.+Majmudarauthor=L.+Ziaugraauthor=K.-K.+Wongauthor=S.+Gabrielauthor=R.+Beroukhimauthor=M.+Peytonauthor=J.+Barretinaauthor=A.+Duttauthor=C.+Emeryauthor=H.+Greulichauthor=K.+Shahauthor=H.+Sasakiauthor=A.+Gazdarauthor=J.+Minnaauthor=S.+A.+Armstrongauthor=I.+K.+Mellinghoffauthor=F.+S.+Hodiauthor=G.+Dranoffauthor=P.+S.+Mischelauthor=T.+F.+Cloughesyauthor=S.+F.+Nelsonauthor=L.+M.+Liauauthor=K.+Mertzauthor=M.+A.+Rubinauthor=H.+Mochauthor=M.+Lodaauthor=W.+Catalonaauthor=J.+Fletcherauthor=S.+Signorettiauthor=F.+Kayeauthor=K.+C.+Andersonauthor=G.+D.+Demetriauthor=R.+Dummerauthor=S.+Wagnerauthor=M.+Herlynauthor=W.+R.+Sellersauthor=M.+Meyersonauthor=L.+A.+Garraway&title=High-throughput+Oncogene+Mutation+Profiling+in+Human+Cancer&doi=10.1038%2Fng1975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput oncogene mutation profiling in human cancer</span></div><div class="casAuthors">Thomas, Roman K.; Baker, Alissa C.; DeBiasi, Ralph M.; Winckler, Wendy; LaFramboise, Thomas; Lin, William M.; Wang, Meng; Feng, Whei; Zander, Thomas; MacConnaill, Laura E.; Lee, Jeffrey C.; Nicoletti, Rick; Hatton, Charlie; Goyette, Mary; Girard, Luc; Majmudar, Kuntal; Ziaugra, Liuda; Wong, Kwok-Kin; Gabriel, Stacey; Beroukhim, Rameen; Peyton, Michael; Barretina, Jordi; Dutt, Amit; Emery, Caroline; Greulich, Heidi; Shah, Kinjal; Sasaki, Hidefumi; Gazdar, Adi; Minna, John; Armstrong, Scott A.; Mellinghoff, Ingo K.; Hodi, F. Stephen; Dranoff, Glenn; Mischel, Paul S.; Cloughesy, Tim F.; Nelson, Stan F.; Liau, Linda M.; Mertz, Kirsten; Rubin, Mark A.; Moch, Holger; Loda, Massimo; Catalona, William; Fletcher, Jonathan; Signoretti, Sabina; Kaye, Frederic; Anderson, Kenneth C.; Demetri, George D.; Dummer, Reinhard; Wagner, Stephan; Herlyn, Meenhard; Sellers, William R.; Meyerson, Matthew; Garraway, Levi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-351</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Systematic efforts are underway to decipher the genetic changes assocd. with tumor initiation and progression.  However, widespread clin. application of this information is hampered by an inability to identify crit. genetic events across the spectrum of human tumors with adequate sensitivity and scalability.  Here, we have adapted high-throughput genotyping to query 238 known oncogene mutations across 1,000 human tumor samples.  This approach established robust mutation distributions spanning 17 cancer types.  Of 17 oncogenes analyzed, we found 14 to be mutated at least once, and 298 (30%) samples carried at least one mutation.  Moreover, we identified previously unrecognized oncogene mutations in several tumor types and obsd. an unexpectedly high no. of co-occurring mutations.  These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQJq3aVM33obVg90H21EOLACvtfcHk0lhDMpQFqTPsnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVOktrs%253D&md5=e27db295fad8db6bd2133b818363ec1a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fng1975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1975%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DR.%2BK%26aulast%3DBaker%26aufirst%3DA.%2BC.%26aulast%3DDeBiasi%26aufirst%3DR.%2BM.%26aulast%3DWinckler%26aufirst%3DW.%26aulast%3DLaFramboise%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DW.%2BM.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DW.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DMacConaill%26aufirst%3DL.%2BE.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DNicoletti%26aufirst%3DR.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DGoyette%26aufirst%3DM.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DMajmudar%26aufirst%3DK.%26aulast%3DZiaugra%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DEmery%26aufirst%3DC.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DGazdar%26aufirst%3DA.%26aulast%3DMinna%26aufirst%3DJ.%26aulast%3DArmstrong%26aufirst%3DS.%2BA.%26aulast%3DMellinghoff%26aufirst%3DI.%2BK.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DDranoff%26aufirst%3DG.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DNelson%26aufirst%3DS.%2BF.%26aulast%3DLiau%26aufirst%3DL.%2BM.%26aulast%3DMertz%26aufirst%3DK.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DCatalona%26aufirst%3DW.%26aulast%3DFletcher%26aufirst%3DJ.%26aulast%3DSignoretti%26aufirst%3DS.%26aulast%3DKaye%26aufirst%3DF.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DHigh-throughput%2520Oncogene%2520Mutation%2520Profiling%2520in%2520Human%2520Cancer%26jtitle%3DNat.%2520Genet.%26date%3D2007%26volume%3D39%26spage%3D347%26epage%3D351%26doi%3D10.1038%2Fng1975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JPS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JPS','PDB','4JPS'); return false;">PDB: 4JPS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6','PDB','4JT6'); return false;">PDB: 4JT6</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i68"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01736">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_11208"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01736?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01736</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Specific data of kinase profiling of compound <b>15a</b> (Tables S1 and S2); liver injury in animal studies (Figure S1); NMR spectra and HPLC chromatograms of synthesized compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01736/suppl_file/jm9b01736_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01736/suppl_file/jm9b01736_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01736/suppl_file/jm9b01736_si_001.pdf">jm9b01736_si_001.pdf (7.86 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01736/suppl_file/jm9b01736_si_002.csv">jm9b01736_si_002.csv (4.54 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">We will release the atomic coordinates for <b>15a</b>/PI3Kα and <b>15a</b>/mTOR and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01736&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01736%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-6" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01736" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a97b5c9562440","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
